Regulating the expression of eEF1A to decipher its non canonical functions in eukaryotic cells by Hallbrook, Kerry
  
Some pages of this thesis may have been removed for copyright restrictions. 
If you have discovered material in Aston Research Explorer which is unlawful e.g. breaches 
copyright, (either yours or that of a third party) or any other law, including but not limited to 
those relating to patent, trademark, confidentiality, data protection, obscenity, defamation, 
libel, then please read our Takedown policy and contact the service immediately 
(openaccess@aston.ac.uk) 
Page | 1  
 
 
Regulating the Expression of eEF1A to 
Decipher its Non Canonical Functions in 
Eukaryotic Cells  
 
Kerry Ann Hallbrook 




© Kerry Ann Hallbrook, 2015 
Kerry Ann Hallbrook asserts her moral right to be identified as the author 
of this thesis 
This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and that no quotation from 
the thesis and no information derived from it may be published without appropriate 
permission or acknowledgement. 
Page | 2  
 
 Regulating the Expression of eEF1A to Decipher its Non 
Canonical Functions in Eukaryotic Cells 
Kerry Hallbrook 
A thesis submitted for the degree of Doctor of Philosophy 
2015 
Abstract 
The canonical function of eEF1A is delivery of the aminoacylated tRNA to the A site of the 
ribosome during protein translation, however, it is also known to be an actin binding protein.  
As well as this actin binding function, eEF1A has been shown to be involved in other cellular 
processes such as cell proliferation and apoptosis.  It has long been thought that the actin 
cytoskeleton and protein synthesis are linked and eEF1A has been suggested to be a candidate 
protein to form this link, though very little is understood about the relationship between its 
two functions.  Overexpression of eEF1A has also been shown to be implicated in many 
different types of cancers, especially cancers that are metastatic, therefore it is important to 
further understand how eEF1A can affect both translation and the organisation of the actin 
cytoskeleton.  To this end, we aimed to determine the effects of reduced expression of eEF1A 
on both translation and its non canonical functions in CHO cells. We have shown that reduced 
expression of eEF1A in this cell system results in no change in protein synthesis, however 
results in an increased number of actin stress fibres and other proteins associated with these 
fibres such as myosin IIA, paxillin and vinculin.  Cell motility and attachment are also affected 
by this reduction in eEF1A protein expression.  The organisational and motility phenotypes 
were found to be specific to eEF1A by transforming the cells with plasmids containing either 
human eEF1A1 or eEF1A2.  Though the mechanisms by which these effects are regulated have 
not yet been established, this data provides evidence to show that the translation and actin 
binding functions of eEF1A are independent of each other as well as being suggestive of a role 
for eEF1A in cell motility as supported by the observation that overexpression of eEF1A 
protein tends to be associated with the cancer cells that are metastatic.  
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1.1 Protein Translation and eEF1A 
 
Protein translation is an essential process to synthesise new proteins for growth and repair.  It 
occurs in three stages that are carefully controlled by numerous proteins throughout each 
stage.  Initiation is the first and is thought to be the most rate limiting step. It is during this 
phase that the correct positioning of the ribosome on the mRNA, at the initiation codon AUG 
is regulated to enable the accurate recognition of the open reading frame and therefore the 
correct synthesis of the amino acid sequence as shown in figure 1.1.1.   
The ribosome is made up of the 40S and 60S subunits which come together to make up the 
complete 80S ribosome.  In the first stages of initiation, the 40S subunit of the ribosome is 
bound by both eukaryotic initiation factor (eIF) eIF1A and eIF3 (Pain, 1995), and the 60S 
subunit possibly bound by eIF6 (Gingras et al., 1999). These steps are necessary to prevent the 
reassociation of the 40S and 60S subunits. In the early phases of the activation of the 40S 
ribosomal subunits, two different processes take place.  First, the eIF2 in complex with 
guanine triphosphate (GTP) binds to initiator or methionine tRNA which results in the delivery 
of the met-tRNA-eIF2-GTP complex to the 40S subunit to form the preinitiation complex.  This 
preinitiation complex then binds to the 5’ cap of the mRNA through the activity of eIF4s, after 
which the complex migrates to the initiation AUG codon.  The eIF4F complex is made up of 
eIF4E, which has the ability to bind the 5’ cap of the mRNA, eIF4A, which is an RNA helicase, 
and eIF4G which is the backbone of the complex and can bind eIF4E, eIF4A and eIF3, which can 
bind to the 40S ribosomal subunit (Gingras et al., 1999).  This means that eIF4F can interact 
with both the mRNA cap and the ribosomal subunit as well as providing a way to unravel the 
mRNA such that the ribosome can scan along the mRNA to find the initiation codon.   
Once the preinitiation complex is positioned at the initiation codon, the GTPase accelerating 
protein activity (GAP) of eIF5 results in inactivation of eIF2 through the hydrolysis of the GTP 
to guanine diphosphate (GDP), which causes the release of the initiation factors from the 
complex, allowing the 60S subunit to associate to form the 80S ribosome ready for the 
elongation stage.  The hydrolysed GDP complexed with eIF2 is then prevented from release by 
the guanine dissociation inhibition activity of eIF5 until the GDP is recycled back to GTP by the 
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guanine nucleotide exchange factor (GEF) eIF2B (Jennings et al., 2013).  Most initiation events 
are reinitiation events, which occur on mRNA that are already associated with translating 
ribosomes resulting in polysomes associated with the mRNA. 
Reunification of the two ribosomal subunits, along with the release of the different initiation 
factors and the recognition of the AUG codon ultimately lead to the completion of the 
initiation step.  Following from this, the elongation phase will begin where the bulk of the 
amino acid incorporation takes place and where, in essence, the proteins are being 
synthesised, as shown in figure 1.1.2.  In this phase, the peptide chain is elongated by delivery 
of the aminoacylated tRNA to the ribosome so that a codon anti codon match can be made 
and the correct amino acid added to the peptide chain.  This step is performed by the 
eukaryotic elongation factor 1A (eEF1A).   
The eukaryotic elongation factor 1A (eEF1A) is the guanine nucleotide binding protein 
responsible for transporting the aminoacylated tRNA to the A site of the ribosome.  eEF1A 
binds to aminoacylated tRNA, and delivers them to the exposed A site of the ribosome.  
Matching of the mRNA codon with the proper tRNA triggers GTPase activity converting GTP 
back to GDP and causing eEF1A to dissociate from the ribosome (Riis et al., 1990).  Binding of 
eEF1A to the γ subunit of the guanine nucleotide exchange factor (GEF) eEF1β allows GDP to 
be replaced by GTP, reactivating eEF1A in the process so that it can bind to another aminoacyl 
tRNA.  eEF1A in its GDP bound form has also been shown to interact with deacylated tRNA, 
which can cause localisation of the eEF1A to aminoacyl tRNA synthetase (Petrushenko et al., 
2002, Petrushenko et al., 1997).    
Once the correct aminoacylated tRNA has been integrated in the A site of the ribosome, 
translocation occurs which transfers the deacylated tRNA to the E site of the ribosome and the 
peptidyl tRNA to the P site resulting in an empty A site for a new aminoacylated tRNA to enter 
(Merrick, 1992).  When the next aminoacylated tRNA binds to the A site of the ribosome, the 
deacylated tRNA at the E site is released and the process continues until an in frame stop 
codon is reached at the end of the mRNA sequence. 
Translocation of the ribosome on the mRNA is assisted by eEF2, a G protein which utilises the 
independence of the two different ribosomal subunits to move the ribosome one codon along 
the mRNA.  When bound to GTP, eEF2 can bind to the 40S ribosomal subunit causing a 
rotation which moves the tRNAs from the A and P sites in the ribosome to the P and E sites.  
Hydrolysis of the GTP to GDP causes the release of eEF2 - GDP from the ribosome, with the 
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rotation of the ribosome returning, resulting in the repositioning of the tRNAs as well as the 
movement of the ribosome to the next codon, ready for the delivery of the next 
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Figure 1.1.1 – Schematic representation of protein translation initiation.  The 40 and 60S 
ribosomal subunits dissociate from the mRNA.  The 40S subunit is bound by eIF3 and eIF1A, 
whilst the 60S subunit is bound by eIF6.  eIF2 binds methionine tRNA allowing the delivery of 
this complex to the 40S complex to form the preinitiation complex.  The preinitiation complex 
can then bind to the 5’ cap of the mRNA through eIF4s, and the complex migrates along the 
mRNA to the start codon.  eIF5 causes the inactivation of eIF2 by causing the hydrolysis of 
GTP-GDP which results in release of initiation factors allowing the 60S subunit to associate to 
form the assembled 80S ribosome on the mRNA ready for elongation.  
 













Figure 1.1.2 – Schematic representation of protein translation elongation.  eEF1A-GTP delivers the aminoacylated tRNA to the A site of the ribosome.  Upon 
the match of codon to anti-codon, the GTP is hydrolysed to GDP and eEF1A is released.  A peptide bond is formed between the two amino acids, and when 
eEF2 binds to the 40S subunit, a rotation occurs which causes translocation which moves the tRNAs one space to the left, so that the two tRNAs are now 
occupying the E and P sites.  The tRNA in the P site is then released and the next tRNA can enter the A site of the ribosome. 
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Protein synthesis is stopped by binding of a protein release factor (RF), which allows the fully 
translated protein to be released from the mRNA, and the ribosome to dissociate into its 40S 
and 60S subunits in the final stage of translation, termination, as described in figure 1.1.3.  
When one of the termination codons is reached, UAA, UGA or UAG, the polypeptide chain is 
released in a GTP dependent manner (Goldstein et al., 1970, Beaudet and Caskey, 1971).  
eRF1, which has a ribosome binding site, a termination codon recognition site, a peptidyl tRNA 
interaction site and an eRF3 binding site, recognises the termination codon, and binds to the 
ribosome (Kisselev et al., 2003).  eRF3, a G protein, binds in its GDP bound state to the 
ribosome only when eRF1 is bound, after which the GDP dissociates leading to a complex of 
guanine free eRF3 with eRF1 bound to the ribosome.  After hydrolysis of the ester bond in 
peptidyl tRNA, GTP can bind to eRF3 bound to the ribosome resulting in a conformational 
change which leads to the release of eRF1 from the complex.  The hydrolysis of GTP to GDP 
results in a low affinity of eRF3 for the ribosome without eRF1 resulting in the dissociation of 
eRF3 from the ribosome ready for the next round of termination (Kisselev et al., 2003).  
 












Figure 1.1.3 – Schematic representation of protein translation termination.  When the stop codon is reached, eRF1 can bind to the ribosome, and when 
eRF1 is bound, eRF3-GDP can also bind to the ribosome, after which the GDP dissociates.  After hydrolysis of the ester bond between the amino acid and 
the tRNA, GTP can then bind to eRF3 causing a conformational change leading to release of eRF1.  Hydrolysis of GTP to GDP then results in a lower affinity 
of eRF3, leading to its release and dissociation of the ribosomal complex from the mRNA. 
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1.2 Structure of eEF1A 
 
The eEF1A protein has been demonstrated to be composed of three structural domains.  
Domain I is responsible for GTP binding, domain II for tRNA binding and domain III for actin 
binding (Moore and Cyr, 2000).  The guanine nucleotide exchange factor (GEF), eEF1β, 
interacts with both domain I and II of eEF1A (Andersen et al., 2001).  The elucidation of the 
molecular structure of eEF1A in complex with eEF1β allowed further understanding of the way 
in which eEF1A works.  eEF1β consists of two subunits, eEF1βα and eEF1βγ.  The eEF1βα 
subunit is responsible for the catalysis of the GDP – GTP exchange.  This subunit interacts with 
domain II of eEF1A at the same binding site as that of the aminoacylated tRNA, therefore 
competing for its binding (Andersen et al., 2001). 
 
1.3 Isoforms of eEF1A 
 
In mammalian cells, there are two isoforms of eEF1A, eEF1A1 and eEF1A2 which have 75% 
similarity at the nucleotide level and 98% similarity at the protein level  (Knudsen et al., 1993, 
Panasyuka et al., 2008) and demonstrate mutually exclusive expression. eEF1A1 is ubiquitously 
expressed in all tissues except in specific tissues such as in neurons, differentiated skeletal 
muscle, terminally differentiated heart and brain cells and human pancreatic islets, where 
eEF1A2 is expressed,  (Knudsen et al., 1993, Kahns et al., 1998, Ahmed et al., 2005), comprising 
cells with specific architectures and generally of slow growth.  Both isoforms have been shown 
to be present in brain and aorta tissue (Knudsen et al., 1993, Kahns et al., 1998, Kristensen et 
al., 1998, Ahmed et al., 2005).  In rapidly proliferating cells, including tumours, the level of 
mRNA of eEF1A is greatly increased which suggests that eEF1A may have a role in cell 
proliferation (Condeelis, 1995).  
It has further been suggested that eEF1A1 is the predominant form in these terminally 
differentiated tissues such as heart, brain and skeletal cells, until they are fully differentiated, 
during which time the level of eEF1A2 mRNA accumulates, and the level of eEF1A1 mRNA 
reduces until undetectable (Lee et al., 1995).  This switch in eEF1A isoform expression has also 
been well characterised in mice in neuronal tissue with Pan et al, 2004, showing that eEF1A1 
was the predominant form of eEF1A in neurons after 1 day, and then slowly declines until at 
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14 days, eEF1A1 expression was barely detectable and from 20 days onwards is undetectable.  
Conversely, eEF1A2 expression is only detectable after 14 days, slowly increasing until it is the 
dominant form after 20 days (Pan et al., 2004).  This isoform switch has also been shown to be 
conserved in Xenopus, though the reduced level of eEF1A1 protein is controlled in a post 
transcriptional manner with eEF1A1 mRNA levels remaining at similar levels to eEF1A2 mRNA 
(Newbery et al., 2011).  Interestingly, Khalyfa et al, 1999, showed that after skeletal tissue 
injury by Marcaine injection, the ratio of eEF1A1 to eEF1A2 switches back to that seen in the 
developmental stages, and after recovery from that injury the ratio reverts back to that of 
normal developed skeletal tissue.  The reason for this is unknown but it has been suggested to 
be due to potential different secondary functions of eEF1A1 and eEF1A2 outside of its primary 
function in protein translation (Khalyfa et al., 1999).  This is supported by the high level of 
conservation seen between the two isoforms across species, and the tightly regulated control 
of expression.   
The translational activity of both isoforms has been shown to be very similar, though the 
affinity for GDP and GTP was found to be different, with eEF1A1 shown to bind GDP and GTP 
with similar  affinity and eEF1A2 having a stronger relative affinity for GDP, most likely due to 
the difference in amino acid residue at position 197 which is very close to the known binding 
position of the guanine nucleotide (Kahns et al., 1998).  This could be of interest as GTP 
binding has been shown to inhibit binding of eEF1A to G-actin (Dharmawardhane et al., 1991), 
therefore the higher affinity of eEF1A to GDP could potentially affect the likelihood of this 
isoform to be able to participate in cytoskeletal remodelling.  The rate of GTP hydrolysis was 
found to be the same for both isoforms which was unsurprising as the amino acids proposed 
to be involved in GTP hydrolysis are conserved between the two isoforms (Kahns et al., 1998).   
It has also been noted that eEF1A2 tends to be associated with tumour development in tissues 
that would normally only express eEF1A1 (Anand, 2002, Amiri et al., 2007) which supports the 
theory of the two different isoforms performing the same canonical function in protein 
translation, as shown by Kahns et al, 1998,  but different non-canonical functions.  Examples of 
these non canonical functions and the differing effects of the two isoforms will be discussed in 
detail in section 1.4. 
Seven post translational modifications have been shown for eEF1A1 (Dever et al., 1989), at 
least 3 of which are conserved in eEF1A2, however the lysine residues at amino acids 55 and 
165 were found to be trimethylated in eEF1A2 but only dimethylated in the eEF1A1 isoform 
(Kahns et al., 1998).   
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1.4 Non Canonical Functions of eEF1A  
 
The non-canonical roles of eEF1A are extensive and include roles in quality surveillance of 
newly synthesised proteins (Hotokezaka, 2002), ubiquitin dependent degradation (Chuang et 
al., 2005, Gonen et al., 1994), viral functions (Kinzy and Goldman, 2000), facilitating apoptosis 
(Duttaroy et al., 1998, Chen et al., 2000, Lamberti et al., 2004), interactions with the 
cytoskeleton from yeast through to mammals (Edmonds et al., 1996, Gross and Kinzy, 2005, 
Suda et al., 1999, Munshi et al., 2000), and microtubule binding, bundling and severing (Moore 
et al., 1998, Moore and Cyr, 2000, Ueno et al., 2003).  
 
1.4.1 eEF1A and the Cytoskeleton 
 
Translation has been shown to be dependent upon an intact cytoskeleton (Negrutskii and 
Deutscher, 1991, Gross and Kinzy, 2007), and mRNA has specifically been shown to localise to 
actin fibres (Bassell et al., 1994, Bassell and Singer, 1997), therefore eEF1A has been suggested 
to be a regulator of both translation and the actin cytoskeleton, mainly highlighted by the fact 
that eEF1A is the second most abundant protein after actin, making up between 1-10% of total 
cellular protein in normally growing cells (Liu et al., 1996b, Merrick, 1992), and studies have 
shown that there is a 17-35 fold molar excess of eEF1A when compared to ribosomes (Slobin, 
1980).  Based on this large excess in comparison to the other components of the translational 
machinery, it has been suggested that there may be ‘pools’ of eEF1A present for different 
functions where translational functions would be prioritised over others, including its 
regulatory properties on the actin remodelling.   




The actin cytoskeleton has three main functions, to maintain spatial organisation of the cell 
contents, to allow the cell to connect to the extracellular matrix and to create coordinated 
forces to ensure maintenance of cell shape and motility (Fletcher and Mullins, 2010).   
Actin is found in the cell as globular actin (G-actin) and fibrous actin (F-actin), usually observed 
as cortical actin which surrounds the cell or as stress fibres which are located throughout the 
cell.  The polymerisation of monomeric G actin into filamentous F actin and vice versa is a 
tightly regulated process as maintenance of the actin cytoskeleton is essential for normal 
cellular functions.  Actin filaments are polymerised by nucleation, where the addition of single 
G actin monomers occurs over time to form a structure containing 3-4 units.  The addition of G 
actin monomers usually occurs at the fast growing/barbed end or the plus end of the fibre, 
with the removal of monomers from the pointed or minus end of the fibre (Dominguez, 2009).  
Polymerisation can be inhibited by the binding and sequestering of monomers by actin binding 
proteins such as thymosin.  Another actin monomer binding protein is profilin, which 
completes with thymosin to bind the actin monomer resulting in prevention of addition of the 
monomer from the minus end, but allows addition to the plus end of the actin fibre (Remedios 
et al., 2002).  Once the monomer-profilin complex is bound, a conformational change in the 
actin monomer occurs which reduces the affinity of profilin for actin, therefore releasing 
profilin and making the actin fibre one monomer longer (Remedios et al., 2002).   
The main regulator of actin nucleation is the Arp2/3 complex, which when working together 
with the WASP/WAVE family of proteins, recruits actin and activates nucleation (Dominguez, 
2009).  The Rho GTPase Cdc42 has been shown to indirectly activate the Arp2/3 complex  
using the WASP family of proteins as adaptor proteins (Machesky and Insall, 1998), and it has 
been suggested that the Arp2/3 complex is likely to be the effector for Rac induced actin 
polymerisation using the SCAR/WAVE family of proteins as the adaptor (Welch, 1999).  The 
WASP proteins have been shown to bind to actin monomers with the potential function of 
delivering the monomers to the plus end of the actin filament for polymerisation (Winder and 
Ayscough, 2005).   
It has been suggested that, as in yeast, while the Arp2/3 complex is involved in the nucleation 
of short branched actin filaments, formins may be involved in the formation of longer 
unbranched actin filaments (Winder and Ayscough, 2005).  Formins have been shown to bind 
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to barbed ends (Higgs, 2005) and interact with profilin, the actin monomer binding protein 
resulting in delivery of the monomer to the plus end of the actin filament (Evangelista, 2003).  
The FH2 domain of the formin Bni1p has been shown to bind to eEF1A, an actin 
binding/bundling protein (Umikawa et al., 1998), which could link the nucleation and 
polymerisation of actin with the organisation of the actin filaments. 
 
1.4.1.2 Actin binding proteins 
  
There are many different actin binding proteins (ABPs), at least 162 known, that regulate the 
binding and bundling of actin fibres into the cortical actin and stress fibres observed in the cell, 
as well as playing a role in regulating the ratio of G actin to F actin (Remedios et al., 2002).  The 
different actin binding proteins can be categorised dependent on whether the protein binds to 
G actin or F actin, as well as where the protein binds to on the F actin fibre.  These are 
summarised in figure 1.4.1.2. 
Already discussed are the monomer binding proteins such as thymosin and profilin which 
compete to prevent the unregulated association of G actin into F actin filaments.  Actin cap 
binding proteins also help to prevent both addition and removal of actin monomers to either 
the plus or minus end of the actin fibre by binding to the ends of the fibre.  The Arp2/3 
complex, as well as being involved in nucleation of the actin fibre, is also a capping protein.  It 
binds to the minus end of the fibre with a high affinity, therefore capping the fibre so that 
monomer addition or removal cannot occur from that end of the fibre (Cooper and Schafer, 
2000).  CapZ is another capping protein but unlike Arp2/3, it binds to the plus end of the actin 
fibre (Cooper and Schafer, 2000).  Both the blocking of the actin fibres by capping proteins 
such as these, as well as the regulation of the free pool of G actin monomer by the actin 
monomer binding proteins, ensures tight regulation of the polymerisation of the actin fibres 
such that when polymerisation is required, capping proteins can be removed and more G actin 
monomers can be made available.  
Another group of actin binding proteins are the side filament binding proteins which include 
both tropomyosin and the ADF/cofilin family.  Tropomyosin binds to the side of the actin 
filament, spanning 6-7 subunits giving strength and stability.  The binding of tropomyosin 
protects the fibre from depolymerisation by DNase I and severing by the ADF/cofilin family, as 
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well as regulating the access of some other actin binding proteins (Cooper, 2002) and myosin 
Ib (Tang and Ostap, 2001).  Tropomyosin has also been shown to inhibit the nucleation of actin 
fibres by Arp2/3 by preventing the binding of the complex, therefore tropomyosin can also 
affect polymerisation indirectly (Blanchoin et al., 2001). 
The ADF/cofilin family are side binding proteins that shorten actin filaments, by both severing 
and increasing the rate of loss of monomers from filament ends (Cooper and Schafer, 2000).  
Cofilin can bind to the actin fibre in an ADP dependent manner, inducing the fibre to twist by 
reducing the number of contacts between the monomers and making the fibre more brittle 
and more susceptible to severing (Cooper and Schafer, 2000).  This binding to actin filaments 
associated with ADP helps to differentiate between old and new actin filaments as newer 
filaments are associated with ATP, and older filaments with ADP.   
The change in structure of the fibre induced by binding cofilin could also result in dissociation 
of other actin binding proteins such as the Arp2/3 complex from the ends of the filament 
resulting in increased actin depolymerisation (Cooper and Schafer, 2000).  Binding of cofilin 
has also been shown to increase the rate of actin polymerisation by severing the filament 
providing more free filament ends for polymerisation to occur, possibly regulated by the 
nucleating activity of the Arp2/3 complex (Cooper and Schafer, 2000).  This provides a view in 
which the ADF/cofilin family of proteins could potentially play a role in actin polymerisation 
and depolymerisation under differing circumstances.  The binding of ADF/cofilin and 
tropomyosin has been shown to be mutually exclusive, therefore this competitive binding can 
also regulate the polymerisation and depolymerisation of actin filaments (Cooper, 2002). 
In order for the actin cytoskeleton to exert any effect on the extracellular matrix, the 
cytoskeleton must connect to the ECM via membrane associated actin binding proteins.  These 
can link the actin cytoskeleton to the plasma membrane, such as annexins or to the 
extracellular matrix, for example talin and vinculin (Winder and Ayscough, 2005).  Both have 
the ability to bind to actin and link the cytoskeleton to integrins in the ECM therefore 
anchoring the cell to the matrix (Winder and Ayscough, 2005).  These actin binding proteins 
will be further described in the section explaining focal adhesions (Section 1.4.1.7). 
Lastly, the final group of actin binding proteins are the bundling or cross-linking proteins.  
These provide the structure to the actin filament by bundling into fibres and/or cross-linking 
into the required structure.  Cross-linking proteins usually contain either multiple actin binding 
domains which are separated by a long flexible spacer domain α-actinin, or contain one actin 
Page | 38  
 
binding site, and therefore first need to dimerise to form a homodimer offering two actin 
binding sites separated by a spacer domain (Winder and Ayscough, 2005).  An example of the 
latter class is filamin whose dimerisation results in the perpendicular formation of actin 
filaments in relation to each other with the filamin acting as a bracket for the filaments 
(Popowicz et al., 2006).  The long spacer domain of filamin also acts as a scaffold for 
membrane receptor associated signalling proteins, suggesting further functions coinciding 
with its role as an actin cross-linker (Popowicz et al., 2006). 
α – actinin also bundles actin filaments via the formation of homodimers.  In this instance, the 
coupling of the two proteins is done in an antiparallel manner with a resultant helical spacer 
domain in between the two actin binding sites, causing an increased space between the two 
actin filaments and looser bundles, such as those seen in actin stress fibres (Winder and 
Ayscough, 2005).  It has also been shown to cross-link actin into a disordered square lattice to 
create a rigid actin meshwork (Pelletier et al., 2003). 
As well as having actin nucleating activity and being a capping protein, the Arp2/3 complex can 
also cross-link actin filaments by capping/binding to the end of one protein and 
simultaneously binding to the side of another filament forming a branched actin network 
(Welch, 1999). 
Actin bundling proteins can be further sub grouped depending on whether they form loose or 
tightly associated actin filaments, as well as their orientations. Such properties, as explained 
earlier, can be determined by the number of actin binding sites, the size of the spacer domain 
and the angle at which they bind filaments.  Fimbrin for example packs fibres into tight 
bundles, such as those found in microvilli, as its two actin binding sites are in close proximity 
to each other (Winder and Ayscough, 2005).  The filaments within the actin bundles can also 
be organised into parallel or anti parallel arrangements depending on the bundling protein 
involved, for example, fascin only bundles filaments into a parallel orientation, a cross-linker 
such as α – actinin can bind actin fibres at many different angles (Courson and Rock, 2010), 
and eEF1A has been shown to be an anti parallel actin bundling protein (Owen et al., 1992).  
The actin binding proteins all bind with differing affinity to actin.  Binding affinity is measured 
by Kd, the dissociation constant, defined as the concentration at which 50% of the binding 
sites are occupied by the protein ligand.  Actin capping proteins for example only require one 
molecule to cap one actin filament which contains many actin monomers, therefore small 
changes in the concentration of actin capping proteins can cause significant changes to actin 
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polymerisation and depolymerisation rates, resulting in a low Kd value, usually around 1nM.  A 
side binding protein such as tropomyosin binds to the filament and spans only 6 to 7 actin 
monomers, therefore a higher concentration is required to have a significant protective effect 
on the actin filament, resulting in a higher Kd value usually between 0.1-1µM.   
The consequence of the differences in affinity of the ABPs determines which ABP is more likely 
to bind, for example, if two proteins were present at the same concentration, the protein with 
the higher affinity or the lowest Kd would be more likely to occupy more binding sites than the 
protein with the lower affinity or the higher Kd.  The monomer binding protein thymosin has a 
Kd of approximately 0.7µM, compared to the Kd of profilin, 0.1µM, which means that profilin 
can bind the actin more tightly than thymosin, hence why the binding of profilin to actin is 
preferential to that of thymosin to help regulate actin polymerisation (Pollard et al., 2007), 
however, not only does the binding depend on the affinity of the protein but also on many 
other factors such as concentration of the proteins involved and competitive binding. 
The actin bundling protein eEF1A has been shown to bundle actin filaments in such as way as 
to exclude other actin binding proteins (Owen et al., 1992), and has a Kd of between 0.1-
10µM, compared to other filament binding proteins such as filamin with a Kd of 0.5µM and α – 
actinin with a Kd of between 1-5µM (Pollard et al., 2007).  This means that eEF1A, depending 
on the conditions, could have the ability to bind actin with a higher affinity than the other 
filament binding proteins, making it most likely to be bound, and providing further evidence to 
support the exclusion of other ABPs, and therefore potentially one of the main regulators of 
the organisation of the actin cytoskeleton. 
 




Figure 1.4.1.2 – A schematic representation of the different types of actin binding proteins, with examples, adapted from Winder and Ayscough, 2005.
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1.4.1.3 eEF1A and Actin Binding/Bundling 
 
eEF1A was first identified as an actin binding and bundling protein in 1990 from Dictyostelium 
discoideum, initially termed ABP-50 by Demma et al, 1990, through the isolation of a 50,000 
dalton protein capable of actin filament bundling.  ABP-50 was found to cross-link F-actin to 
form actin bundles in two different configurations, tightly packed, more ordered bundles and 
loosely packed less ordered bundles, as determined by electron microscopy (Demma et al., 
1990).  Further work showed that eEF1A can bundle actin in such a way that the actin 
filaments are rotated at 90o relative to each other and are thought to have the ability to 
exclude other actin binding proteins (Owen et al., 1992).  Immunofluorescence studies also 
showed that ABP-50/eEF1A was localised within the cell cortex, where actin bundles are 
known to reside.  This ability of ABP-50 to bundle actin filaments was found to be unaffected 
by calcium (Ca2+) and ATP.  The same ABP-50 protein was subsequently identified as eEF1A by 
functional analysis and sequence comparison, resulting in the first direct connection between 
the actin cytoskeleton and the translational machinery (Yang et al., 1990).  
 
1.4.1.3.1 Regulation of eEF1A Binding to Actin by pH and Ionic Strength 
 
Changes in the cellular pH of Dictyostelium have been shown to affect the association of 
eEF1A with actin.  At a low physiological pH, eEF1A was found to be mainly associated with 
actin, whereas with increasing pH, both the bundling and binding activities of eEF1A were 
diminished with different severity. Bundling loss was the first to occur followed by the loss of 
actin binding activity (Edmonds et al., 1995).  This implies that eEF1A binding to actin filaments 
is less sensitive to changes in pH than actin bundling by eEF1A, and that actin binding and 
bundling by eEF1A are independent events, which was suggested to indicate multiple binding 
sites within the eEF1A protein.  The interaction between eEF1A and actin was also found to be 
affected by the total ionic strength, suggesting that the interaction could be charge dependent 
(Edmonds et al., 1995), which is supported by the evidence that eEF1A is a basic protein, and 
actin is an acidic protein (Liu et al., 1996a).   
It has been suggested that the change in pH could in effect mediate translational activity of 
eEF1A.  Low pH conditions would favour the association of eEF1A with actin filaments, 
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reducing its interactions with other components of the translational machinery.  As pH 
increases within the physiological range, eEF1A actin bundling activity is lost freeing the 
protein to associate with other components of the translational machinery (Edmonds et al., 
1995).  This was found to be likely as at a lower pH eEF1A binding to F-actin is favoured over 
eEF1A binding to aa-tRNA, whereas at higher pH, the opposite was true (Liu et al., 1996b).  The 
binding affinity of eEF1A for aa-tRNA was found to be fairly constant over the range of pHs, 
whereas the binding affinity of eEF1A to actin was found to change (Liu et al., 1996b).   
In the same study, both domains I and III of eEF1A showed actin binding activity, and although 
changes in pH affected both actin binding sites, the site in domain I was more sensitive than 
the site in domain III.  This fits in with the finding that as pH is increased, actin bundling is 
decreased, as the binding site in domain I could be released leaving the single actin binding 
site in domain III to bind to actin filaments.  As pH increases further, the actin binding site in 
domain III is also affected, and therefore both binding sites are released from the actin 
filament, leaving unbound eEF1A.  The authors suggested that, as binding of eEF1A to actin or 
aa-tRNA seem to be independent, and binding of eEF1A to aa-tRNA blocks eEF1A actin 
binding, the binding sites for actin and aa-tRNA on the eEF1A protein are likely to be located 
on the same part of the protein, and that the sequences may even overlap.   
 
1.4.1.3.2 Regulation of eEF1A Binding to Actin by Calcium and Calmodulin 
 
Previous studies have shown that eEF1A can bind to calmodulin (Kaur and Ruben, 1994) and 
that whilst actin bundling is inhibited by the presence of Ca2+/calmodulin, actin binding was 
unaffected, though eEF1A has been shown to be insensitive to Ca2+ in the absence of 
calmodulin (Kurasawa et al., 1996b).   
This led the authors to hypothesise that two possibilities existed, either eEF1A has two 
separate actin binding sites, only one of which is affected by Ca2+/calmodulin, or eEF1A has 
only one actin binding site and dimers are formed allowing cross-linking of the actin filaments 
and therefore actin bundle formation.  The authors seem to favour the dimer formation 
theory, as the molar ratio of eEF1A to actin observed was 1:1, whereas if eEF1A contained two 
binding sites, the expected molar ratio would be 2:1 (Kurasawa et al., 1996b).  There is 
currently evidence to support both of these theories. 
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Previous studies have shown that eEF1A can form dimers, and that whilst eEF1A monomers 
and dimers are both capable of binding actin, only eEF1A dimers have the ability to bundle 
actin in Tetrahymena, supporting the dimer theory of actin bundling (Bunai et al., 2006).  
Furthermore it was shown that dimer formation was regulated by Ca2+/calmodulin, such that 
in the presence of Ca2+/calmodulin, dimers are separated into monomers, and when Ca2+ is 
chelated, dimers are formed, which supports the work of Kurasawa et al., 1996b.  The authors 
suggested that in the absence of Ca2+, calmodulin cannot bind to eEF1A, leaving it free to bind 
to another eEF1A molecule to form the dimer.  In the presence of Ca2+, the Ca2+/calmodulin 
complex binds to eEF1A, preventing another eEF1A molecule from binding, inhibiting 
dimerisation.  The binding of Ca2+/calmodulin to eEF1A also reduces the affinity of eEF1A for F-
actin leading to dissociation of the eEF1A/Ca2+/calmodulin complex from the F-actin filament.  
This monomer would then be free to participate in translation, therefore Ca2+/calmodulin 
could be a controlling link between the actin binding/bundling activity and the translational 
activity of eEF1A. 
Continuing on with the work on eEF1A dimer formation it was found that domain III was 
responsible for dimer formation as well as F-actin binding, and that all three domains have the 
ability to bind calmodulin, though to varying degrees dependent on the concentration of 
calcium (Morita et al., 2008).  At a Ca2+ concentration of 1mM all three domains demonstrated 
the ability to bind calmodulin, however at a concentration of 1µM only domains I and III could 
bind to calmodulin, and at a concentration of 100nM only domain I showed calmodulin 
binding with domain III showing very slight calmodulin binding activity (Morita et al., 2008).  In 
line with this, at a Ca2+ concentration of 100nM F-actin bundles were unaffected, between 
500nM - 1µM bundles were loosened, and at a concentration of between 100µM – 1mM the 
bundles were disassembled, suggesting a model in which Ca2+ concentrations of below 100nM 
result in the binding of domain I to calmodulin, domain III to both another eEF1A molecule to 
form a dimer resulting in actin bundling, whereas when the concentration of Ca2+ increases to 
1µM, calmodulin binds to domain III of eEF1A causing the eEF1A dimers to split into 
monomers, therefore loosening the actin bundles and reducing the binding of eEF1A to actin 
filaments (Figure 1.4.1.3.1)      
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Figure 1.4.1.3.2 – The model of regulation of eEF1A actin binding by calcium and calmodulin 
based on eEF1A dimerisation adapted from Morita et al, 2008.  In the presence of low 
concentrations of calcium, eEF1A can form dimers and therefore bundle actin, however at 
higher concentration of calcium, calcium can bind to domains I and III of eEF1A leading to the 
separation of dimers into monomers and the release of eEF1A from the actin fibre resulting in 
loosening and then loss of the actin bundles with an increasing calcium concentration.  
 
1.4.1.3.3 Which eEF1A Domains are Important for Actin Binding/Bundling? 
 
As explained so far, the direct mechanisms to explain how eEF1A promotes its actin bundling 
properties have remained elusive as evidence for both dimerisation of single actin binding 
domain units or a single protein containing multiple binding sites have been reported.  The 
regulation of actin binding and bundling by pH favoured the monomer actin binding theory, as 
both domains I and III of eEF1A were found to bind to actin (Liu et al., 1996b), however the 
regulation by Ca2+/calmodulin favours the dimer theory as only domain III was shown to bind 
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to F actin, as well as binding to other eEF1A molecules (Kurasawa et al., 1996b), with Bunai et 
al, 2006, clearly demonstrating dimer formation. 
In contrast to the dimer theory, a review by Liu et al., 1996a, favours the theory that eEF1A 
has two actin binding sites.  The formation of the tightly packed bundles created by the 
bundling activity of eEF1A, would indicate that the cross-linking of actin filaments by eEF1A is 
restricted in space which supports the theory of the two different actin binding sites of eEF1A 
rather than dimer formation (Liu et al., 1996a). 
Based on the strong evidence for both theories, it could be possible that eEF1A is capable of 
bundling actin by both monomer binding and dimerisation, as demonstrated in figure 
1.4.1.3.3, but under different conditions. 
The first study to experimentally try to identify specific regions within domain III of eEF1A that 
can bind to actin using mutagenesis and by creation of truncations, found that amino acids 
414-427 of eEF1A, and mutations F422A, N305S and N329S  are important, and that the 
mutants in which actin binding were affected, had no change in translational activity (Gross 
and Kinzy, 2005).   
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Figure 1.4.1.3.3 – Schematic representation of the two different actin binding theories for 
eEF1A.  On the left, the monomer binding theory is shown.  Domain III has been shown to have 
two actin binding sites, therefore it is possible that domain III is solely responsible for the 
bundling activity of eEF1A.  On the right shows the dimer binding theory.  Domain III has been 
shown to have the ability to bind to both itself and actin, therefore two eEF1A molecules could 
come together in order to bundle actin.  Evidence has been shown for both theories. 
 
1.4.1.4 eEF1A and Actin Polymerisation 
 
Not only has eEF1A been shown to bind and bundle actin, it has also been found to affect the 
rate of polymerisation from both the barbed, fast growing end, as well as the pointed end of 
the actin filament, and this effect has been shown to be dependent on the actin bundling 
activity of eEF1A (Murray et al., 1996).  It is thought that the bundling of actin by eEF1A causes 
the ends of the actin filaments to be unavailable for polymerisation to occur.  eEF1A also 
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affects actin polymerisation in a concentration dependent manner so that at higher eEF1A 
levels, depolymerisation is inhibited. 
 
1.4.1.5 eEF1A and G Actin 
 
It was observed that eEF1A can bind to G-actin in the cytosol, and that GTP can inhibit this 
binding, though binding of F-actin by eEF1A is thought to be unaffected by both GDP and GTP 
(Dharmawardhane et al., 1991).  It has also been shown that binding of eEF1A to G-actin can 
inhibit its translational activity (Bektaş et al., 2004). 
 
1.4.1.6 Actin stress fibre subtypes 
 
Actin stress fibres (SFs) are divided into four different types, the actin cap, transverse arcs, 
dorsal SFs and ventral SFs which can be differentiated based on their position within the cell, 
the proteins that localise to them and their connection to the extracellular matrix (ECM), as 
demonstrated in figure 1.4.1.6.  The actin cap consists of stress fibres located above the 
nucleus, which provide it with structural support, especially during interphase (Tojkander et 
al., 2012).  Myosin IIA is known to localise to the actin cap SFs.  They attach to the extracellular 
matrix through focal adhesions at both ends of the fibre, and could therefore behave as 
mechanotransducers to allow force from the ECM to be relayed to the nucleus (Tojkander et 
al., 2012).   
Transverse arcs are curved bundles of actin that can flow from the leading edge of the cell to 
the rear of the cell during migration (Pellegrin and Mellor, 2007, Tojkander et al., 2012).  They 
alone do not associate with focal adhesion proteins, at either end of the fibre, however, they 
can connect with dorsal stress fibres (Tojkander et al., 2012).  Dorsal stress fibres attach to the 
ECM via focal adhesion proteins at their distal end, with the other end usually connecting to 
the transverse arc.  Unusually, myosin IIA does not localise to dorsal SFs, meaning that 
contractility from these fibres can only occur through their connection with transverse arcs. 
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Ventral stress fibres are the most common SF structures, with localisation of myosin IIA along 
the fibre, and focal adhesion proteins to both ends.  This localisation of myosin IIA and the 
ability to attach to the ECM makes ventral stress fibres the main contractile machinery in some 
cells, and they have also been shown to affect directional cell migration by detaching from the 
rear of the cell and reattaching to adhesions at the front of the cell, with the new direction of 
motion aligning perpendicular to the direction of the newly attached fibre (Rid et al., 2005).  
Dorsal SFs and transverse arcs have been shown to merge to form ventral stress fibres 
(Hotulainen and Lappalainen, 2006). 
The assembly and regulation of stress fibres is known to be promoted by both Rho A and Rac, 
small GTPases involved in the regulation of actin dynamics in the cell (Tojkander et al., 2012).  
mDia is an effector of Rho A and facilitates the polymerisation of actin filaments which are 
important for the formation of dorsal stress fibres, though it is likely that other proteins are 
also involved in the polymerisation of actin from the focal adhesion for this type of stress fibre, 
most likely another member of the formin family of proteins (Hotulainen and Lappalainen, 
2006).  The formation of transverse arcs was shown to be disrupted by siRNA knockdown 
targeted to the Arp2/3 complex, though this did not affect the formation of dorsal stress 
fibres, therefore it is suggested that the two stress fibres are formed by independent 
pathways with formins, specifically mDia involved in dorsal SF formation and the Arp2/3 
complex involved in transverse arc formation (Hotulainen and Lappalainen, 2006).   
Ventral stress fibres were found to be formed by the merging of two dorsal stress fibres with a 
transverse arc, and through contraction of the transverse arc, the fibres are aligned, and 
connect to the ECM through the focal adhesions formed at one end of the dorsal stress fibre 
(Hotulainen and Lappalainen, 2006).  












Figure 1.4.1.6 – A schematic representation of the different types of actin stress fibres 
adapted from Tojkander et al, 2012.  Actin cap fibres which span the nucleus, ventral stress 
fibres which are associated with focal adhesions at either end, dorsal stress fibres which are 
only associated with focal adhesions at one end, and transverse arcs, which are not associated 
with focal adhesions however associate with dorsal stress fibres. 
 
1.4.1.7 Focal adhesions 
 
Focal adhesion complexes allow the actin cytoskeleton to attach to the ECM through 
interaction with integrins, as well as creating a point for signal transduction, with many 
different tyrosine phosphorylated proteins, tyrosine kinases, phosphatases and adapter 
proteins being recruited along with the focal adhesion proteins (Riveline et al., 2001).  They 
are tightly regulated multi protein complexes that are formed when the cell attaches to the 
ECM.  Newly formed focal complexes which mature into focal adhesions can be observed just 
behind the migrating front of the cell which has enabled the order of recruitment under 
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certain conditions to be established.  The earliest focal adhesion proteins to be incorporated 
into hyaluronan mediated focal complexes were paxillin and talin, followed by vinculin, α – 
actinin, VASP and focal adhesion kinase (FAK) (Zaidel-Bar et al., 2004).  Some focal complexes 
then disappear, however others mature into focal adhesions with this transition dependent on 
actomyosin contractility which requires the presence of an active form of RhoA to activate 
both Rho Kinase (ROCK) and mDia, both of which are involved in cytoskeletal dynamics (Zaidel-
Bar et al., 2004).  Some of the main components of focal adhesions are the adapter proteins 
paxillin and vinculin (Zaidel-Bar et al., 2004). 
Paxillin has been shown to bind to vinculin, possibly to help to recruit vinculin to the focal 
adhesion complex (Turner et al., 1990).  Myosin IIA activity has been shown to result in 
phosphorylation of paxillin by focal adhesion kinase (FAK), and that this phosphorylation can 
lead to the recruitment of vinculin to the focal adhesion to encourage focal adhesion 
maturation (Pasapera et al., 2010).  Paxillin has also been shown to be a critical transducer of 
fibronectin signalling (Hagel et al., 2002).  The phosphorylation of paxillin is essential for cell 
migration in some cell types (Huang et al., 2008), and it has been shown to be involved in 
transformation of cells as it is a common target for oncoproteins that contain tyrosine kinases 
(Sattler et al., 2000). 
Whereas paxillin has an important role in the early stages of focal adhesion formation, vinculin 
appears later and has roles involved with cell spreading by coupling to integrins, and focal 
adhesion turnover (Ezzell et al., 1997, Saunders et al., 2006).  Cells lacking vinculin were not 
only found to be deficient in cell spreading but were also not able to form actin stress fibres, 
suggestive of a role of vinculin in the promotion of stress fibre formation as well as reducing 
the amount of paxillin associated with the cytoskeleton (Ezzell et al., 1997).    Complementing 
this link between vinculin and integrins, is the work that shows that vinculin stabilises focal 
adhesions, therefore inhibiting cell migration and that binding of the vinculin tail to inositol 
phospholipids has a role in focal adhesion turn over (Saunders et al., 2006). 
In order for focal adhesions within the cell to make contact with the ECM, the adapter proteins 
such as talin connect to integrins which connect to the ECM.  Integrins are made up of α and β 
subunits, of which there are many different types that can assemble to form different integrin 
receptors which can bind to different proteins of the ECM, for example, α5β1 integrins are 
most commonly associated with binding to fibronectin (Srichai and Zent, 2010).  Binding of the 
ligand within the ECM to the extracellular domain of the integrin results in integrin clustering 
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and recruitment of proteins such as talin and paxillin (Zaidel-Bar et al., 2004), the first stage of 
focal complex formation.   
 
1.4.1.8 Cell Migration  
 
The process of overall cell motility is very complicated at the molecular level, there are 
however four main steps of cells migration that form a cycle; extension, attachment, 
contraction and release, after which the process restarts (Sheetz et al., 1998). 
The first stage of the cycle, extension, involves the development of both filopodia and 
lamellipodium.  Filopodia are spike like structures that are extensions of the cell membrane.  
Filopodia are often described as sensing structures which are extended in order to determine 
whether the surrounding area is suitable for cell adhesion and therefore determines which 
direction the cell migrates in.  Lamellipodia have a different structure to filopodia and are 
often referred to as the leading edge of the cell.  It is just behind the lamellipodium that actin 
polymerisation occurs allowing the cell to move in the appropriate direction and where initial 
focal complexes are formed leading to stable focal adhesions as the complexes mature 
(Schäfer et al., 2009).  Jeganathan et al, 2008, found that increased levels of eEF1A2 can 
increase stimulation of filopodia formation by interacting with PI4kIIIβ, which in turn increases 
the amount of PI4P, which is the precursor for PI(4,5)P2, which is essential for eEF1A2 
mediated filopodia formation. 
Once a favourable environment has been detected, focal adhesions and stress fibres are 
formed which attach the front of the cell to the ECM.  Once the cell has extended using 
filopodia and lamellipodia, and made contact with the ECM through formation of focal 
adhesions, the cell must contract in order to migrate, hence the need for such complex control 
of actin organisation.  Myosin II is thought to be involved in this contraction, by the double 
head of the myosin fibre attaching to two actin filaments and pulling the fibres.  This is also 
thought to cause the focal adhesions at the rear of the cell to pull apart, therefore allowing the 
rear of the cell to move forward (Lauffenburger and Horwitz, 1996).   
What becomes apparent is that the dynamic organisation of the actin cytoskeleton is an 
essential component of successful cell migration therefore any potential disruption of this 
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tightly controlled process would be highly likely to have a significant effect on overall cell 
migration rate.  That being said, proteins such as eEF1A, which is known to have actin binding 
properties, are likely to be very closely monitored during this process and any change in level 
of such proteins could potentially lead to changes in migration phenotypes observed.  This 
particular association between eEF1A, actin and cell migration is not completely understood 
therefore requires further investigation.  The link between cell migration and cancer 
metastasis is well known, and the effect of eEF1A expression and its relation to increased 
cancer metastasis may suggest that by analysing the way in which eEF1A can affect cell 
migration at a molecular level, may result in potential targets for interruption of cancer 
metastasis in the future. 
There are many different proteins that are involved in this migrational process, and Condeelis 
et al, 1992, argue that the process of metastasis is similar to the process of chemotaxis of 
motile cells along the cytokine gradient, therefore molecules identified as being involved in 
the process of chemotaxis, are also likely to be relevant during metastasis of the cancer cells.  
The migration of cells is highly dependent upon the rearrangement of the actin cytoskeleton 
upon cytokine stimulation.  When cytokines bind to their receptors, the intracellular signalling 
cascade stimulates the production of polarised surface projections of newly synthesised actin 
(Devreotes and Zigmond, 1988) which are then stabilised by actin binding proteins.   
 
1.4.1.9 Other Components of the Cytoskeleton 
 
Microtubules are made up of α and β tubulin which form heterodimers that combine to form 
protofilaments.  Thirteen of these protofilaments then bundle to form a hollow cylindrical 
fibre, a microtubule.  Microtubules have a variety of functions, from maintaining the structure 
of the cell, transport of intracellular vesicles and organelles, and also their role in the 
formation of the mitotic spindle in cell mitosis.  They have also been shown to be essential for 
directional cell migration in some cell types and have been shown to be stabilised by Rho 
GTPases and in turn microtubules can also affect the activities of the Rho GTPases (Watanabe 
et al., 2005).   
The interaction between eEF1A and microtubules was first reported in higher plant cells by 
isolating and identifying proteins associated with microtubules (Durso and Cyr, 1994).  This 
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association was found to stabilise the microtubule network in a calcium and calmodulin 
dependent manner (Durso and Cyr, 1994, Moore et al., 1998).  Further studies demonstrated 
that the microtubule binding sites were located on domains I and III of eEF1A.  Further analysis 
indicated that the binding site in domain III was found to bind to microtubules under normal 
cellular conditions, however, domain I was found to bind to the microtubule conditionally 
depending on the local pH, therefore suggestive of the latter domain being the  regulating 
factor (Moore and Cyr, 2000).  In contrast to this, eEF1A has also been shown to sever 
microtubules (Shiina et al., 1994), therefore it is possible that eEF1A has a role in regulating 
microtubules, with different activities based on different conditions. 
Intermediate filaments function to maintain cell shape by enabling the cell to bear tension.  
They are generally made up of keratin or vimentin with lamin providing support for the 
nuclear envelope.  There are six main types of intermediate filaments types I – VI.  In epithelial 
cells, the most important types are I & II which consist of keratins, type III which consist of 
vimentin and type V which consist of nuclear lamins.  The intermediate filaments form a 
complex meshwork of proteins which give the cell structural integrity especially when the cells 
are under stress, however unlike microtubules and actin filaments, they have no role in cell 
migration.  No links between eEF1A and intermediate filaments have so far been established. 
 
1.4.2 eEF1A and Cell Death 
 
The first evidence to suggest a potential role of eEF1A in cell death was the finding that eEF1A 
localises to the nucleus in Trypanosoma cruzi  during apoptosis, as shown by 
immunofluorescence studies (Billaut-Mulot et al., 1996).  Further supporting evidence was 
provided when activation of p53, during the apoptosis process, was shown to upregulate the 
levels of eEF1A proteins (Kato et al., 1997).  Induction of apoptosis through the use of sub 
lethal doses of hydrogen peroxide also resulted in  transiently increased levels of eEF1A and 
that decreasing the level of eEF1A using antisense eEF1A protected the cells from apoptosis, 
and the level of protection, corresponds to the degree of repression of eEF1A expression 
(Chen et al., 2000), however there was no clear ideas whether such properties were due to 
translation of specific proteins involved in the apoptotic process, or other non-canonical 
functions. 
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Conversely to the results obtained by previous studies, a screen on IL-3 dependent cells 
identified eEF1A as a gene contributing to apoptotic resistance, as induced by both serum 
deprivation and by induction of endoplasmic reticulum (ER) stress (Talapatra et al., 2002).  This 
protection from apoptosis was also found to occur in a dose dependent manner, with the 
highest level of eEF1A expression resulting in the greatest level of protection without 
correlating with total cellular protein level, cell size, or the rate of protein synthesis, indicating 
a translation independent role for eEF1A in apoptosis (Talapatra et al., 2002).  No clear 
explanations were provided, however it was suggested that the protective effect of higher 
levels of expression of eEF1A seen in apoptosis could be due to better translational accuracy, 
resulting in fewer amino acid misincorporations, and therefore a reduction in protein 
misfolding leading to a decrease in accumulated misfolded proteins at the ER and reduced ER 
stress. 
To add to the complexity and uncertainties regarding a role of eEF1A in cell viability, the two 
isoforms of eEF1A appear to have opposite roles in regulating apoptosis.  Studies show that 
eEF1A1 seems to have a pro-apoptotic effect, with resistance to apoptosis occurring when 
eEF1A1 is disrupted, whereas eEF1A2 appears to have an anti-apoptotic effect, resulting in 
reduced cell death where expression of eEF1A2 is increased (Ruest, 2002, Chen et al., 2000, 
Borradaile et al., 2005).  Duttaroy et al, 1998, suggested that eEF1A1 may be an essential 
regulator of apoptosis by showing that an increase in the expression of eEF1A resulted in an 
increased rate of apoptosis, whereas a decreased level of expression of eEF1A resulted in a 
decreased rate of apoptosis upon apoptotic stimuli.  This potential role of both isoforms of 
eEF1A, in particular the anti-apoptotic potential of eEF1A2, may partially explain the 
oncogenic potential of the eEF1A2 isoform since eEF1A2 protected differentiated myotubes 
from caspase 3 mediated apoptosis, when the cells were deprived of serum (Ruest, 2002).  
This opposing effect of eEF1A1 and eEF1A2 in the process of apoptosis may allow eEF1A to 
have an important role in regulating apoptosis in cells, and as eEF1A2 is usually expressed in 
terminally differentiated cells, this finding that eEF1A2 could protect the cells from apoptotic 
cell death, could be physiologically important.  The authors suggested that eEF1A2 may favour 
the translation of pro-survival genes or repress the translation of pro-apoptotic genes, with 
eEF1A1 working in the opposite way (Ruest, 2002).   
Further studies into the effect of eEF1A on apoptosis found that only the eEF1A2 isoform 
interacts with peroxiredoxin-1 (Prdx-1), and that this interaction helps to protect cells against 
apoptotic cell death induced by hydrogen peroxide (Chang and Wang, 2007).  Prdx-1 has been 
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shown to protect cells against oxidative stress by reducing reactive oxygen species (ROS), and 
transfection studies on Prdx-1 and eEF1A2 showed that alone, both genes had a protective 
effect against apoptosis, however, double transfections, with both genes, resulted in increased 
resistance, when compared to single transfections.  The increase in eEF1A2 and Prdx-1 also 
correlates to an increase in the level of Akt, a survival factor, which previous studies have 
already shown to be affected by eEF1A2, as well as having a role in actin remodelling, and 
regulating migration, invasion and proliferation (Amiri et al., 2007, Pecorari et al., 2009).  The 
findings from Li et al, 2010, that eEF1A2 knockdown in plasmacytomas increases apoptosis, 
also supports the idea that eEF1A2 has a protective effect against apoptotic cell death (Li et 
al., 2010). 
eEF1A has also shown to be involved in anoikis, apoptosis caused by loss of cell anchorage 
(Itagaki et al., 2012).  It has been suggested that, during serum starvation, NIH3T3 cells that 
adhere to fibronectin undergo anoikis caused by matrix metalloproteinase 2 (MMP-2) 
excretion which contributes to exposure of a cryptic anti-adhesive site within the fibronectin 
molecule.  eEF1A then has the ability to mediate the anti-adhesive effect of the site, resulting 
in loss of cell anchorage and therefore death by anoikis.  siRNA disruption of eEF1A expression 
resulted in resistance to anoikis, indicating the importance of eEF1A in this method of cell 
death. 
A novel form of cell death was found to be induced by downregulation of eEF1A1 in 
tetraploids, cells in which the chromosomes did not segregate properly during mitosis, 
resulting in cells with four chromosomes rather than the usual two, which can facilitate 
tumour formation (Kobayashi and Yonehara, 2009).  This cell death correlated with a decrease 
in eEF1A1 expression at both the mRNA and protein level, and transfection of the cells with an 
eEF1A1 plasmid resulted in reduction of cell death, suggesting that the downregulation of 
eEF1A1 induces the observed cell death.  This increase in eEF1A1, and the corresponding 
decrease in this method of cell death resulted in an increased number of spontaneous 
binucleations, indicating that the novel form of cell death observed in this study contributes to 
the elimination of these naturally arising cells within a normal cell population (Kobayashi and 
Yonehara, 2009).  The authors suggested that, as eEF1A2 was found to have a similar effect on 
this form of cell death when compared to eEF1A1, the tumorigenicity of eEF1A2 when 
overexpressed could be related to diminishing the cell death that would normally be induced 
by the reduction of expression of eEF1A1.  It was found that the 5’ untranslated region (UTR) 
from eEF1A1 is important to this downregulation of eEF1A1 expression. 
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Together all of this evidence suggests that overall expression of eEF1A1 may have a 
proapoptotic role, whereas eEF1A2 may have the reverse role, indicating an apparent 
difference in the non-canonical roles of the two isoforms.  Suggestions were made by many 
authors regarding the mechanism by which eEF1A regulates apoptosis, with some indicating 
differences in translation of specific proteins essential for apoptotic cell death, with others 
suggesting the non-canonical function of eEF1A in actin binding and microtubule severing, and 
therefore overall cytoskeletal reorganisation as the mechanism for this regulation.  So far 
there is little evidence to confirm or refute these theories.  
 
1.4.3 eEF1A and Cell Cycle and Ageing 
 
eEF1A has been thought to be associated with cell proliferation and ageing due to its 
involvement in different types of cancers when overexpressed and also due to the difference 
between expression of the different isoforms.  The two isoforms are specifically expressed in 
cells with very different rates of cell proliferation, with eEF1A1 being expressed in rapidly 
dividing cells, and eEF1A2 in terminally differentiated cells, therefore providing the possibility 
that the isoform present could affect the rate of cell proliferation which may suggest that 
eEF1A could perform a regulatory role.  In 1989, a study showed that an additional copy of the 
eEF1A gene lead to a longer life span in fruit flies, and Cavallius et al, 1989, showed that the 
activity of eEF1A decreased towards the end of the lifespan of human fibroblasts (Cavallius et 
al., 1986a).  A more recent study identified eEF1A as an age related protein in human colonic 
epithelial cells, with the expression of eEF1A reduced in senescent cells (Yi et al., 2010).  eEF1A 
expression was also found to be down regulated in different cancer cell lines that were 
undergoing  induced cellular senescence in response to various stimuli, such as ionising 
radiation and hydrogen peroxide treatment, providing further evidence of the involvement of 
eEF1A, and potentially identifying eEF1A as a marker of cellular senescence and a potential 
therapeutic target for cancer treatment (Byun et al., 2009). 
Reduced expression of eEF1A has been shown to reduce the proliferation rate of cells, and two 
independent studies on different cells have shown that reducing the expression of eEF1A 
results in a longer G1 phase resulting in the slower proliferation rate (Janse et al., 2003, 
Pecorari et al., 2009). 
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1.4.4 Other Secondary Functions 
 
eEF1A has been implicated in the export of both tRNAs and proteins from the nucleus.  
Interruption by siRNA or mutation of the binding of eEF1A to the transcription dependent 
nuclear export motif of the protein resulted in defective nuclear export, with the suggestion 
that eEF1A stimulates nuclear export without entering the nucleus (Khacho et al., 2008).  
When protein translation occurs, the synthesised protein undergoes quality surveillance to 
ensure there is no damage to the protein.  How this is regulated is poorly understood, 
however eEF1A has been suggested to be involved by several studies, such as Hotokezaka et 
al, 2002, who showed that eEF1A associated with newly synthesised proteins that were not 
folded correctly, but not to proteins that were correctly folded (Hotokezaka, 2002), and 
Chuang et al, 2005, who found that the degradation of damaged proteins by the proteasome 
involved eEF1A by interaction with ubiquitinated proteins and the proteasome (Chuang et al., 
2005).  Further to this, eEF1A was also found to interact with the proteasome in Xenopus 
oocytes (Tokumoto et al., 2003).  eEF1A has also been shown to bind to defective proteins 
which are released from the ribosomes which can then trigger aggresome formation (Meriin et 
al., 2012).  eEF1A has also been shown to be required for the ubiquitin dependent degradation 
of certain proteins, including actin, though the mechanism by which this occurs is not 
understood (Gonen et al., 1994). 
eEF1A has been shown to have a chaperone like function to allow renaturation of aminoacyl 
tRNA synthetases and other proteins which has been suggested to be important for 
maintaining enzyme activity and protecting the cells from stress (Lukash et al., 2004, Caldas et 
al., 1998). 
All of the secondary functions mentioned show eEF1A to be a multi functional protein with 
many different roles, however, what is not certain is whether these functions are independent 
of its role in translation, for example if eEF1A protein expression is reduced, cell proliferation 
rate is decreased, but is this because protein translation is slower and therefore cell division is 
slowed down, or does eEF1A have an independent regulatory function in cell proliferation?  
The work by Gross and Kinzy, 2005, showed changes in actin binding while not affecting 
translation suggesting that the actin binding and translation functions of eEF1A are 
Page | 58  
 
independent.  Further understanding is required to be able to identify if this is true for the 
other proposed secondary functions of eEF1A to determine which are true secondary 
functions and understand to how it is able to participate in so many different roles and have 
the ability to regulate such complex processes. 
 
1.4.5 eEF1A Interactions 
 
eEF1A has been shown to interact with a number of different molecules including 
phosphotidylinositol-4 kinase and calmodulin (Yang et al., 1993, Kaur and Ruben, 1994, Durso 
and Cyr, 1994, Shiina et al., 1994), phospholipase C-gamma 1 (Chang et al., 2002, Kim et al., 
1999), non-receptor tyrosine kinase Txk of the Tec family (Maruyama et al., 2007), and Akt2 
rho associated kinase (Lau et al., 2006).  The molecules that eEF1A can interact with is also 
dependent on the isoform that is present as in some cases, eEF1A1 cannot bind to the same 
molecules as eEF1A2, for example, eEF1A2 has been shown to be able to interact with the SH2 
domain of Shc and the SH3 domain of Crk, whereas eEF1A1 cannot (Panasyuka et al., 2008).  In 
fact, by using the SH2 and SH3 domains of various different signalling molecules, Panasyuka et 
al, 2008, hypothesised that the difference in non-canonical functions between the two 
isoforms may be due to the difference in potential to participate in phosphotyrosine-mediated 
signalling.  eEF1A2 appears to have greater potential when compared to eEF1A1 as eEF1A2 
was demonstrated to have the ability to interact with more domains of signalling proteins, 
such as the SH2 domains of Grb2, rasGAP, and Shc, as well as the SH3 domains of Crk, Fgr and 
Fyn, whereas no such ability was found for eEF1A1.  They also suggested that the increased 
oncogenicity of eEF1A2 compared to eEF1A1 may also be due to the difference in 
phosphotyrosine-mediated signalling. 
 
1.5 eEF1A in Infection and Disease 
 
eEF1A has been implicated in many different infections and/or diseases including the ‘wasted’ 
mouse, autoimmune diseases, viral infections and many different cancers albeit  for different 
reasons.   The role of eEF1A in these different diseases is summarised below: 
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The ‘wasted’ mouse is a mouse model characterised by weight loss, progressive paralysis, 
tremors and ataxia after 21 days.  By 28 days, the mice have died due to muscle wasting and 
neuronal degeneration.  It was found that these mice have a homozygous mutation in which 
the promoter region and the first non coding exon of the eEF1A2 gene is deleted therefore 
there gene cannot be transcribed (Chambers et al., 1998).  The time of development of this 
disease correlates to the isoform switch in mice which sees the expression of the eEF1A1 
isoform replaced with the eEF1A2 isoform in skeletal muscle and neurons (Lee et al., 1993, 
Khalyfa, 2001), therefore in ‘wasted’ mice, as the eEF1A2 gene is not functional, when the 
level of eEF1A1 expression decreases, there is no isoform to replace this decrease, leading to 
cells deficient of eEF1A.  This lack of eEF1A would mean that the cell could not synthesise new 
proteins, and would potentially affect the actin cytoskeleton leading to the wasting and 
degeneration of the tissue.   
The ‘wasted’ mouse is used as a model for amyotrophic lateral sclerosis (ALS) (Newbery and 
Abbott, 2001), and a link between eEF1A and neuronal degeneration has been tentatively 
suggested due to the ability of eEF1A to form a complex with the zinc finger protein 1 (ZPR1) 
and alter the localisation of both proteins (Gangwani et al., 1998).  A mutation of the survival 
motor neuron protein (SMN) has been linked to an early onset form of motor neuron disease 
(Monani, 2005), and ZPR1 has been shown to form a complex with SMN which has been 
shown to be essential for the correct localisation of SMN in neurons.  Alongside this a protein 
of the same size as eEF1A co-purifies with the ZPR1/SMN complex suggesting that eEF1A may 
play a role in this complex, and potentially neuronal degeneration (Matera and Herbert, 2001).  
Interestingly the neuronal degeneration observed in the ‘wasted’ mouse was accompanied by 
the reduced expression of ZPR1 protein, which may add further credence to this theory 
(Murray et al., 2008).  Reduced expression of eEF1A has also been noted to result in reduced 
protein translation in Myotonic Dystrophy 2, caused by a reduced expression of zinc finger 
factor 9 (ZNF9), which was shown to bind to eEF1A mRNA in myoblasts, suggesting that in 
normal myoblasts, ZNF9 may play some part in regulating the translation of eEF1A mRNA such 
that when it is reduced the level of eEF1A is also reduced leading to a decrease in total protein 
synthesis (Huichalaf et al., 2009).  
eEF1A has been linked to Felty’s syndrome with Ditzel et al, 2000 finding that 66% of patients 
with this syndrome had anti-eEF1A1 antibodies in their serum, however the reason and 
significance for the presence of the autoantibodies in these patients is currently unknown 
(Ditzel et al., 2000). 
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Viruses require the host cell to provide the translational machinery in order to translate the 
viral genes needed for production of viral proteins and formation of further viral particles 
(Walsh and Mohr, 2011), it is therefore unsurprising that eEF1A, as a main component of the 
translational machinery, has been implicated in many different viral infections including the 
tombusvirus, HIV-1, human papillomavirus (HPV), hepatitis B and C, West Nile virus (WNV) and 
mosaic viruses (Li et al., 2009, Gamarnik et al., 2010, Warren et al., 2012, Yue et al., 2011, Lin 
et al., 2012, Kou et al., 2006, Davis et al., 2007, Yamaji et al., 2006, Thivierge et al., 2008, 
Yamaji et al., 2009).  Unsurprisingly eEF1A can bind to viral RNA, as well as interact with viral 
polymerases and other proteins.  It has also been shown to facilitate viral particle assembly (Li 
et al., 2013).  Along with its translational function, the actin binding function of eEF1A has 
been shown to be utilised by viruses.  The X protein from the hepatitis B virus (HBV) has been 
shown to bind to eEF1A and prevent its dimerisation and alter its actin bundling activity (Lin et 
al., 2012).   
Viral infection can sometimes lead to the development of cancer such as with the HPV virus, 
which after persistent infection can lead to cervical cancer (Chen et al., 2011).  Some of the 
HPV viruses have been shown to induce cellular immortalisation and transformation through 
expression of two oncoproteins, E6 and E7 (Ghittoni et al., 2009), the latter of which has been 
shown to associate with domain III of eEF1A, resulting in decreased actin binding by eEF1A and 
therefore disruption of the actin cytoskeleton (Yue et al., 2011).   
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1.6 eEF1A and Cancer 
 
Aberrant expression of eEF1A has been associated with many different types of cancer 
including breast, lung, ovarian and prostate cancer (Kulkarni et al., 2006, Li et al., 2006, Anand 
et al., 2002, Scaggiante et al., 2011), however, what is more interesting is that it has been 
shown to be associated with the metastatic process (Edmonds et al., 1996, Pencil et al., 1993).  
Based on the role of eEF1A in the organisation of the cytoskeleton, as well as its role in protein 
translation, it is perhaps unsurprising that changes in the level of eEF1A could lead to such 
phenotypes, though how this occurs is currently unknown.  Determining the function of eEF1A 
in cell attachment and cell migration would therefore be of interest to help to understand this 
link.  It has also been shown that the two different isoforms of eEF1A can both affect cancer 
progression and formation, particularly where expression of eEF1A2 is observed in tissues that 
would normally only express the eEF1A1 isoform (Anand et al., 2002, Amiri et al., 2007). 
 
1.6.1 Prostate Cancer 
 
Increased expression of both eEF1A1 and eEF1A2 has been observed in prostate cancer cells 
when compared to normal controls, in particular in metastatic tumour cell lines (Zhu et al., 
2009, Scaggiante et al., 2011, Rehman et al., 2012).  Furthermore reducing the eEF1A 
expression by siRNA resulted in decreased proliferation, invasion and migration, indicating 
that eEF1A could be a good therapeutic target for prostate cancer, as well as a good marker 
for tumour progression, however the specific isoform of eEF1A involved was not determined 
(Zhu et al., 2009).  Further to this, an assay used to determine serum biomarkers for 
metastatic progression of human prostate cancer found that eEF1A1 protein expression was 
significantly increased in non progressing cancer compared to the normal control group, and a 
further significant increase in the progressing cancer, further confirming that the expression of 
eEF1A could be used as a biomarker for the progression of prostate cancer (Rehman et al., 
2012).  In contrast to these results, a study by Scaggiante et al, 2011, showed that eEF1A1 
mRNA and protein levels were unchanged in the prostate cancer cell lines used, however, 
eEF1A2 levels were significantly increased in all the cancer cell lines used, with the highest 
expression observed in the least aggressive form of cancer (Scaggiante et al., 2011).  
Interestingly, prostate tumour inducing gene 1 (PTI-1), a truncated mutated form of eEF1A 
Page | 62  
 
(Mansilla et al., 2005), is also differentially expressed in metastatic prostate carcinomas in 
comparison to their normal and benign counterparts (Sun et al., 1997). 
 
1.6.2 Ovarian Cancer 
 
Amplification of the 20q13 locus is commonly observed in ovarian cancers (Sonoda et al., 
1997).  As this is the location of the eEF1A2 gene (Lund et al., 1996), it was an interesting 
target to determine any correlation with the incidence of ovarian cancer.  eEF1A2 has been 
determined as an oncogene in ovarian cancer with eEF1A2 gene expression found to be 
overexpressed in 30% of ovarian cancers (Anand et al., 2002, Pinke et al., 2007), increased 
eEF1A2 protein expression in 75% of ovarian clear cell carcinomas (Tomlinson et al., 2007) and 
increased eEF1A2 gene expression coinciding with an increased likelihood of recurrence of 
epithelial ovarian cancer (Sharma et al., 2007).  Similarly, a study by Sun et al, 2008, showed 
that an increase in eEF1A2 protein expression by lentiviral transfection resulted in apoptosis 
resistance, serum independence, and anchorage independence which could be reversed by 
siRNA interference (Sun et al., 2008).  In contrast to these studies, serous tumours with a 
higher expression of eEF1A2 resulted in a better probability of survival than those with a lower 
expression suggesting that, as in the case of prostate cancer, an increased expression of 
eEF1A2 leads to a more favourable outcome (Pinke et al., 2007).  
 
1.6.3 Breast Cancer 
 
Amplification of chromosome 20 is commonly observed in breast cancer, in particular 20q12-
13, the region in which eEF1A2 is found (Lund et al., 1996), which is amplified in 40% of breast 
cancer cell lines (Hodgson et al., 2003).  eEF1A has been shown to be upregulated in breast 
cancer tissue (Chen, 2005), and has been suggested to be a potential diagnostic marker for 
breast cancer development (Hamrita et al., 2011).  Both eEF1A and eEF1β were found to be 
upregulated in cancerous tissue when compared to normal breast tissue (Al-Maghrebi et al., 
2005).  Specifically eEF1A2 has been shown to be overexpressed in two thirds of breast 
tumours, and is suggested to be an oncogene in breast cancer, as well as a potential diagnostic 
marker and therapeutic target (Tomlinson et al., 2005).  It was determined that patients with 
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tumours showing a high expression of eEF1A2 have an increased probability of 20 year survival 
when compared to those with tumours that show a low eEF1A2 expression (Kulkarni et al., 
2006).   
A study by Edmonds et al, 1996, showed that eEF1A protein expression is increased in 
metastatic rat mammary adenocarcinoma, and that its actin binding activity is reduced 
compared to non metastatic tumours resulting in potential reorganisation of the cytoskeleton 
and changes to the translation of specific mRNAs that are associated (Edmonds et al., 1996).  It 
has been shown that as well as binding to actin, eEF1A can interact with pAkt-1, which is 
involved in regulating cell proliferation motility and angiogenesis (Pecorari et al., 2009).  
Downregulation of eEF1A by siRNA resulted in reduced expression of pAkt-1 leading to 
reduced proliferation, migration and invasion suggesting that eEF1A may regulate pAkt 
(Pecorari et al., 2009).  Akt/PKB is a serine/threonine kinase that regulates many different 
cellular processes, in particular those involved in cancer such as proliferation, motility and 
survival (Liu et al., 2007), and activation of this can result in more aggressive tumour behaviour 
and decreased survival (Bellacosa et al., 2005).  Pecorari et al, 2009, showed that decreased 
expression of eEF1A resulted in decreased pAkt, and inhibited cell proliferation, invasion and 
promoted apoptosis of HCC1937 cells, indicating that eEF1A is a regulator of pAkt activity, and 
agreeing with previous studies that show that eEF1A promotes tumourigenesis and indicate 
that eEF1A expression is required for many breast cancer cell properties via both pAkt 
dependent and Akt independent mechanisms.  eEF1A2 has also been shown to stimulate cell 
migration in a PI3K and Akt dependent way in BT549 cells, suggesting that eEF1A2 regulates 
oncogenesis through these pathways by cytoskeletal remodelling (Amiri et al., 2007).   
 
1.6.4 Lung Cancer 
 
Two different studies have implicated the overexpression of eEF1A2 in lung cancer and have 
suggested it to be an oncogene, possibly acting as a biomarker for diagnosis and therapy (Li et 
al., 2006, Zhu et al., 2007).  Indeed inhibition of eEF1A2 expression by siRNA was shown to 
reduce cell proliferation as well as increasing the rate of apoptosis in all four lung cancer cell 
lines that were tested (Li et al., 2006).  Interestingly PRDX1, a protein which protects cells from 
oxidative stress by reducing reactive oxygen species, was also found to be increased in lung 
cancer cells and the cells adjacent to the cancer cells (Li et al., 2006).  eEF1A, specifically 
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eEF1A2, has been shown to interact with PRDX1 to protect cells against apoptosis induced by 
oxidative cell stress (Chang and Wang, 2007), therefore the increased expression of both of 
these proteins in lung cancer cells could provide a mechanism for apoptotic resistance.  
Furthermore eEF1A2 has been shown to be increased in lung cancer cells, not by an increase in 
expression, but by a decrease in the degradation of eEF1A2 after phosphorylation by C-Raf, 
and that this increase appeared to have an anti-apoptotic effect on the cancer cells (Lamberti 
et al., 2007). 
 
1.6.5 Other Cancers 
 
As well as those cancers already mentioned, eEF1A has also been associated with other types 
of cancer which have not been studied as extensively.  eEF1A2 has been shown to be a 
potential marker for patient outcome in gastric adenocarcinoma, with reduced expression of 
eEF1A2 being associated with poor survival (Xu et al., 2011).  In cancer of the liver, eEF1A1 
mRNA levels were found to be increased in both cancer cell lines analysed, and eEF1A2 in only 
one when compared to normal controls (Grassi et al., 2007).  Wit et al, 2002, showed that 
eEF1A2 was downregulated in human melanoma cell lines (Wit et al., 2002).  eEF1A2 has also 
been shown to promote cell growth and inhibit apoptosis in mouse plasmacytomas and some 
human multiple myelomas, potentially through regulation of the JAK/STAT or Akt signalling 
pathways (Li et al., 2010).  A study on the expression of eEF1A2 in pancreatic cancer found 
that eEF1A2 was overexpressed in 83% of the pancreatic cancers studied, and that this 
overexpression resulted in increased cell growth, survival and invasion (Cao et al., 2009).  
Overexpression of eEF1A2 in NIH3T3 cells resulted in increased cell growth rate as well as 
making cells more tumourigenic by enhancing focus formation and allowing anchorage 
dependent growth (Anand et al., 2002).   
 
1.6.6 Targeting of eEF1A in Cancer Therapy 
 
eEF1A has been shown to be a candidate marker for the diagnosis and prognosis of different 
types of cancer, and its overexpression has been demonstrated to affect cell proliferation, 
migration and invasion as well as apoptosis, the main attributes for a cancer to become 
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metastatic.  For this reason eEF1A, especially eEF1A2 has been suggested to be a good 
therapeutic target despite its essential function in translation, and could potentially explain 
why tumour cells that grow rapidly may be more sensitive to any potential interference (Lee, 
2003).   
Inhibition of PTI-1, the truncated mutated form of eEF1A with antisense PTI-1 resulted in 
reversal of the transformed cells into a more normal morphological phenotype suppressing 
anchorage independent growth (Su et al., 1998).  Some success has also been achieved in 
increasing the survival of mice with metastatic melanomas by targeting eEF1A with 
narciclasine which reduces cancer cell proliferation with little effect on normal non cancerous 
cell lines (Van Goietsenoven et al., 2010).  eEF1A2 has also been suggested to be a potential 
target of resveratrol which has been shown have the ability to reduce the proliferation rate of 
ovarian cancer cells (Lee et al., 2009). 
eEF1A has been shown to be the binding target of cytotoxic GT oligomers that can have 
antiproliferative and cytotoxic effects on lymphoblasts (Dapas et al., 2003), haematopoietic 
human cancer cells (Scaggiante et al., 2006) and prostate cancer cells (Scaggiante et al., 2014).  
These are promising results using eEF1A as a target to combat cancers, and further support 
the idea that eEF1A is one of the main oncogenes, overexpression of which can significantly 
contribute to the cancerous phenotypes of increased cell proliferation, migration, invasion and 
decreased rates of apoptosis, making the mechanism by which eEF1A exerts this effect 
important to establish.  eEF1A has also been shown to be upregulated in cells with acquired 
cisplatin resistance (Johnsson et al., 2000), therefore adding increased difficulty to treatments 
already used. 
Early stage research has shown that targeting eEF1A in prostate cancer cells using an aptamer 
called GT75, a nucleic acid which has been shown to be able to bind to eEF1A, resulted in a 
decrease in cell proliferation and migration in cancer cells with little effect on the non 
tumourigenic control, as well as increasing the effect of conventional drugs (Scaggiante et al., 
2014).  This further confirms eEF1A as a causative agent of the increased growth and migration 
rates of progressive prostate cancers and highlights the importance of understanding the 
mechanism by which eEF1A causes this change to enable specific targeting of these processes 
with few side effects. 
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1.7 Aims and Objectives 
 
Most, if not all of the work so far, has focused on the aberrantly regulated effects of eEF1A 
expression, most notably eEF1A overexpression.  Very little attention has been focused on 
trying to determine the physiological consequences of eEF1A expression in normal cells, due 
to direct implications related to the canonical function of these proteins, at least in 
mammalian cells. Through different strategies, cells constitutively expressing differential levels 
of eEF1A, including eEF1A1 and eEF1A2, were obtained. The aim of this work was to establish, 
both at the cellular and molecular levels, the implications of low expression of these proteins 
on protein synthesis and other reported non canonical functions of the factors.  Using 
immunofluorescence and motility studies, changes in cytoskeletal organisation and cell 
migration were analysed to determine whether any differences could be observed when the 
level of eEF1A protein expression was reduced.  Our main objectives were; 
 To determine whether the reduced expression of eEF1A protein would affect its role in 
protein translation 
 To determine whether the reduced expression of eEF1A proteins was sufficient to 
affect its role in actin binding and bundling 
 To determine whether any of the above differences would affect the motility of the 
cells 
 To prove that any changes observed were eEF1A dependent 
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2.0 Materials and Methods 
2.1 Materials for Mammalian Cell Work 
2.1.1 Antibodies Used 
 
Table 2.1.1.1 Antibodies Used for Immunofluorescence Staining 
 
Name of Antibody Secondary Antibody 
Used 
Source Dilution 
Immunofluorescence Staining – Primary Antibodies 
Phalloidin (Actin) Mouse Invitrogen 1 in 100 
eEF1A Mouse Millipore 1 in 100 
Paxillin Mouse Invitrogen 1 in 100 
Vinculin Mouse Sigma Aldrich 1 in 200 
VASP Rabbit Abcam 1 in 200 
Tubulin Mouse Sigma Aldrich 1 in 100 
Vimentin - Sigma Aldrich 1 in 200 
Myosin IIA Rabbit Covance 1 in 2,000 
Arp3 Mouse Abcam 1 in 500 
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β-1 Integrin Mouse Millipore 1 in 500 
Immunofluorescence Staining – Secondary Antibodies 
Anti- Mouse FITC - Dako 1 in 100 
Anti- Rabbit FITC - Dako 1 in 100 
 
Table 2.1.1.1 – The primary and secondary antibody dilutions used for all immunofluorescence 
studies described in chapters 3 and 4, including the company purchased from, as well as the 
secondary antibody used where applicable. 
 
Table 2.1.1.2 Antibodies Used for Western Blotting 
 
Name of Antibody Secondary Antibody 
Used 
Source Dilution 
Western Blotting – Primary Antibodies 
eEF1A1 Rabbit Gene Tex 1 in 1,000 
eEF1A2 Rabbit Gene Tex 1 in 1,000 
eEF1A Mouse Millipore 1 in 5,000 
α-Adaptin Mouse Santa Cruz 1 in 1,000 
Paxillin Mouse Invitrogen 1 in 1,000 
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Vinculin Mouse Sigma Aldrich 1 in 2,000 
VASP Rabbit Abcam 1 in 2,000 
Tubulin Mouse Sigma Aldrich 1 in 5,000 
Vimentin Mouse Gene Tex 1 in 1,000 
Myosin IIA Rabbit Covance 1 in 20,000 
Arp3 Mouse Abcam 1 in 1,000 
β-1 Integrin Mouse Millipore 1 in 1,000 
Actin Rabbit Sigma Aldrich 1 in 1,000 
Actin (From Kit) Rabbit Cytoskeleton 1 in 500 
Western Blotting – Secondary Antibodies 
Anti- Mouse HRP - Sigma Aldrich 1 in 5,000 
Anti- Rabbit HRP - Sigma Aldrich 1 in 5,000 
 
Table 2.1.1.2 – The primary and secondary antibody dilutions used for all Western blotting 
studies described in chapters 3 and 4, including the company purchased from, as well as the 
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Table 2.1.1.3 Antibodies Used for ELISA 
 
Name of Antibody Secondary Antibody 
Used 
Source Dilution 
 ELISA – Primary Antibodies 
eEF1A Mouse Millipore 1 in 1,000 
Tubulin Mouse Sigma Aldrich 1 in 1,000 
ELISA – Secondary Antibodies 
Anti- Mouse HRP - Sigma Aldrich 1 in 2,000  
 
Table 2.1.1.3 - The primary and secondary antibody dilutions used for all ELISA studies 
described in chapters 3 and 4, including the company purchased from, as well as the 
secondary antibody used where applicable. 
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2.1.2 Primers Used for Mammalian Cell Work 
 
Primer Name Primer Sequence 5’-3’ Digestion Enzyme 
eEF1A1 Forward CGGAATTCGCCACCATGGGAAAGGAAAAGACT EcoRI 
eEF1A1 Reverse TGCTCTAGATCATTTAGCCTTCTGAGC XbaI 
eEF1A2 Forward CGGAATTCGCCACCATGGGCAAGGAGAAGACC EcoRI 
eEF1A2 Reverse TGCTCTAGATCACTTGCCCGCCTTCTG XbaI 
 
Table 2.1.2 – List of primers used for plasmid construction including sequences and digestion 
enzymes used. 
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2.1.3 Plasmids Used for Mammalian Cell Work 
 







Ampicillin and Zeocin 
resistance 




Cloning vector, Ampicillin 
and Kanamycin 
resistance 
To create plasmid 
with PCR product 




eEF1A1 in pGEM-T easy 
vector, Ampicillin 
resistance 
Plasmid used as 




eEF1A2 in pcDNA3.0, 
Ampicillin and G418 
resistance 
Plasmid used as 
PCR template for 
eEF1A2 insert 
- 
eEF1A1 in Cloning 
Vector 
eEF1A1 in pstBLUE-1 
Cloning Vector, 
Ampicillin and Kanamycin 
resistance 
Plasmid created 
with eEF1A1 PCR 
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eEF1A2 in Cloning 
Vector 
eEF1A2 in pstBLUE-1 
Cloning Vector, 
Ampicillin and Kanamycin 
resistance 
Plasmid created 
with eEF1A2 PCR 





eEF1A1 in pcDNA3.1 Zeo, 








eEF1A2 in pcDNA3.1 Zeo, 








Table 2.1.3 – Plasmids used throughout chapter 4, including names, description and usage. 
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2.2 Methods Used for Mammalian Cell Work 
 
2.2.1 Cell Lines Used 
 
Chinese hamster ovary cells (CHO cells) were used as a control cell line.  CHO cells with a 
reduced expression of eEF1A were kindly donated by Borradaile et al, 2005, referred to from 
this point on as 2E2 cells.  The 2E2 cells had been created by Borradaile in the process of 
studying resistance of CHO cells to lipotoxic cell death.  They were generated using a vesicular 
stomatitis virus G protein (VSV-G) pseudotyped murine retrovirus, which encoded the 
ROSAβgeo retroviral promoter trap (Friedrich and Soriano, 1991).  This virus was used to 
transduce the CHO-K1 cells such that there was only one integration per 10 genomes, to 
attempt to ensure that there was no more than one integration per cell.  The mutated cells 
were then selected using 500µg/ml G418 in high glucose (4.5 mg/ml) DMEM and Ham’s F-12 
nutrient mixture (1:1), with 5% (v/v) fetal bovine serum (FBS), 2 mM l-glutamine, 50 U/ml 
penicillin G sodium, 50 U/ml streptomycin sulfate, and 1 mM sodium pyruvate for 8 days, after 
which 500µM palmitate was added to the media, sufficient to result in death of wild type CHO 
cells that had not acquired resistance.   
Clones of cells that survived were then isolated, and 5’ rapid amplification of cDNA ends 
(RACE) was used to identify the gene that had been disrupted by the integration, which was 
found to be eEF1A.  Northern blotting, using a probe created from full length eEF1A1, and 
Western blotting using an eEF1A antibody that recognises both isoforms of eEF1A were 
performed and only a feint residual band was detected in the mutated cells when compared to 
the control CHO cells.  PCR using primers specific to either eEF1A1, eEF1A2, or ROSAβgeo, 
showed that only the eEF1A1 gene was interrupted in the mutated cells, which led the authors 
to conclude that expression of eEF1A1 was completely knocked out, and that the residual 
band observed on the Northern and Western blots were due to the lack of specificity of the 
probes as the sequences of eEF1A1 and eEF1A2 are so similar at the amino acid level, resulting 
in a cell line that only expressed very small amounts of eEF1A2 and no eEF1A1.  The selection 
used for the 2E2 cell line was the G418 antibiotic, and, in order to enable the control cell line 
to be grown in the same media, CHO cells were transfected with an empty plasmid containing 
the G418 resistance gene, neo, and selected using 500 µg/ml G418 containing medium.  These 
CHO cells transfected with the empty G418 resistance plasmid are referred to as CHO G418 
cells.  2E2 cells were also transfected with the pcDNA3.1 zeocin plasmid containing eEF1A1 or 
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eEF1A2 and both 2E2 and CHO G418 cells were transfected with the empty pcDNA3.1 zeocin 
plasmid as controls.  These cells are referred to as 2E2 eEF1A1, 2E2 eEF1A2, 2E2 zeo and CHO 
G418 zeo respectively from this point forward.   
 
2.2.2 Cell Culture 
 
The control CHO cell line used was grown in DMEM.  The 2E2 and CHO G418 cell lines were 
grown in DMEM media (Table 2.2.2) with 500 µg/ml G418.  Transfected 2E2 cells and CHO 
G418 zeo cells were grown in DMEM with 500μg/ml G418 and 200μg/ml zeocin.  All cell lines 
were incubated at 37oC in a humidified atmosphere with 5% (v/v) CO2 and 95% (v/v) air. 
 
Table 2.2.2 Composition of DMEM 
Name of Solution/Buffer Composition of Buffer 
DMEM DMEM 
4500mg/L Glucose 
< 1% (w/v) Sodium Pyruvate 
< 0.37% (w/v) Sodium Bicarbonate 
0.02% (w/v) L- Glutamine 
10% (v/v) Foetal Bovine Serum (FBS) 




Table 2.2.2 – Composition of basic DMEM used for cell culture.  
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2.2.3 Passaging of cells 
 
In order to maintain a healthy supply of cells, the cell lines were grown in the above conditions 
until a confluency of around 70-80% was reached.  The media was removed from the flask and 
the cells washed with an appropriate amount of serum free medium.  1x Trypsin with 2mM 
ethylenediaminetetraacetic Acid (EDTA) at pH 7.4, was then added to cover the bottom of the 
flask and the cells were incubated at 37oC for a few minutes until the cells detached from the 
flask.  Serum containing medium was then added to deactivate the trypsin, and the cells 
transferred into a 15ml centrifuge tube, before pelleting by centrifugation at 250g for 5 
minutes at room temperature.  The supernatant was then poured off leaving the pellet at the 
bottom, and the cells were resuspended with fresh complete medium ready for counting or 
replenishing growing stock.  Cell counting was done by adding an appropriate amount of 
medium depending on the size of the pellet observed, then resuspending the cells and adding 
10µl to both sides of a haemocytometer.  A cell counter was then used to count the number of 
cells in the grid, allowing the number of cells to be seeded to be calculated. 
 
2.2.4 Cell Freezing 
 
The above method for passaging was followed until the cells were pelleted at the bottom of 
the tube.  The cells were then resuspended in the freezing mixture made up of 90% (v/v) FBS 
and 10% (v/v) dimethyl sulphoxide (DMSO), using 1-1.5mls for each vial to be frozen.  The 
mixture was then transferred to a cryovial and placed into the -20oC freezer for 1 hour before 
being transferred into the -80oC freezer.  For longer term storage, cells were transferred to a 
liquid nitrogen tank. 
 
2.2.5 Cell Thawing 
 
Cells to be thawed were removed from the liquid nitrogen stock or -80oC freezer and quickly 
thawed using a 37oC water bath.  The content of the vial was then gently transferred to a 
25cm2 flask and pre-warmed complete media was added very slowly to the flask whilst gently 
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mixing the solutions together.  The cells were then incubated for 4-6 hours or until the cells 
attached, the media removed and fresh media was added.  The cells were then placed back 
into the incubator. 
 
2.2.6 Cell Homogenisation for SDS PAGE Analysis 
 
500,000 cells or 1,000,000 cells were seeded into a 6cm or 10cm tissue culture dish, and left to 
grow for 2 days, or until confluent.  If cells were treated with triton before harvesting, the 
media was removed, the cells washed with 1x PBS, then 1ml of 10% (v/v) triton added and 
incubated at room temperature for 2 minutes. The triton wash was then collected.  Cells were 
washed with 1x PBS again, before scraping cells into 100μl homogenising buffer (Table 2.2.6) 
using a cell scraper sterilised using 75% (v/v) IMS and 25% (v/v) distilled water and transferred 
using a pipette into a 1.5ml eppendorf tube.  The cells were then sonicated on ice at 6-8 Amps 
for 10 seconds, three times with a 30 second break in between.  20µl of sample was removed 
for the purposes of protein quantification and the remaining 80µl was kept on ice and 5x 
protein dye added ready to run on the gel for the Western blot.  Cells that were not washed 
with triton were harvested by removing media, and washing cells with ice cold PBS 3 times, 
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Table 2.2.6 Composition of Homogenising Buffer 
Name of Solution/Buffer Composition of Buffer 
Homogenising Buffer 0.25M Sucrose 
5mM Tris-HCl pH 7.4 
2mM EDTA 
200mM Phenylmethylsulfonyl Fluoride 
(PMSF) 
 
Table 2.2.6 – Composition of homogenising buffer used to prepare cell lysate for Western 
blotting. 
 
2.2.7 Protein Quantification 
 
To determine the amount of total protein in the sample, 5µl was added to a 96 well plate in 
triplicate, 25μl Biorad protein assay reagent A added and 200μl Biorad protein assay reagent B 
added then pipetted up and down to mix whilst avoiding the production of bubbles.  Alongside 
this, 5µl of standards containing different levels, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 and 10.0 mg/ml, of 
bovine serum albumin (BSA) were added to the 96 well plate to use as a standard curve.  The 
absorbance at 750nm was then measured and recoded using a plate reader and a straight line 
graph created using the values obtained from the standards.  The standard curve was then 
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2.2.8 SDS Gel Electrophoresis 
 
Table 2.2.8.1 Composition of Acrylamide Gels 
Running Gel (8%) Running Gel (10%) Stacking Gel (3%) 
4.94 ml dH20 4.4 ml dH20 1.725 ml dH20 
1.7 ml 1.5M Tris pH8.8 1.7 ml 1.5M Tris pH8.8 1.7 ml 1.5M Tris pH8.8 
1.1 ml 60% Sucrose 1.1 ml 60% Sucrose 33 µl 10% SDS 
67 µl 10% SDS 67 µl 10% SDS 0.375 ml acrylamide (40%) 
2.16 ml acrylamide (40%) 2.7 ml acrylamide (40%) 20 µl 10% APS 
50 µl 10% APS 50 µl 10% APS 3.3 µl TEMED 
3.3 µl TEMED 3.3 µl TEMED  
 
Table 2.2.8.1 – Both 10% (v/v) and 8% (v/v) running gels were used for Western blotting 
depending on the size of the protein that is being detected, prepared with the chemicals as 
shown.  For proteins between 25-200 kDa, such as vinculin, the 8% (v/v) gel was used, though 
for smaller proteins, between 15-100 kDa, such as eEF1A and paxillin, the 10% (v/v) gel was 
used.  The stacking gel stayed the same regardless of which running gel was used. 
 
The running gel was made and mixed as shown in table 2.2.8.1 then pipetted into the gel cast 
leaving a gap of around 1-2cm at the top.  The stacking gel was then made and mixed as 
shown by the table and pipetted into the gel cast until the cast was full.  A 10 well comb was 
then placed into the gel cast using laboratory tissue to catch the overflow of extra gel.  The gel 
was then left, either in the incubator at 37oC or on the bench, to set.  The gel was taken out of 
the setting cast and placed into the running cast and the tank filled with 1x running buffer 
(Table 2.2.8.2).  An appropriate amount of sample, usually between 10-50µg protein, was then 
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loaded and the gel run at 60V to introduce the samples, and then increased to 120V until the 
sample reached the end of the gel. 
Table 2.2.8.2 Composition of All Buffers Used to Run Acrylamide Gels 
Name of Solution/Buffer Composition of Buffer 
5x Loading Dye 250mM Tris pH 6.8 
40% (v/v) Glycerol 
4% (w/v) Sodium Dodecyl Sulphate (SDS) 
4% (v/v) 2-Mercaptoethanol 
Bromophenol Blue to add Colour  
10x Running Buffer 30g Tris 
144g Glycine 
10g SDS 
Made up to 1 Litre with Distilled Water 
1x Running Buffer 100mls 10x running buffer 
Made up to 1 Litre with Distilled Water 
 
Table 2.2.8.2 – Composition of all buffers used to run the acrylamide gels for separation of 
proteins ready for Western blotting 
 
2.2.9 Western Blotting 
 
The gel obtained from the gel electrophoresis was placed onto nitrocellulose and sandwiched 
between filter paper and foam then placed into a cassette.  The cassette was placed into the 
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Western blot kit, along with an ice block, and the chamber filled with ice cold 1x electroblot 
(Table 2.2.9).    The chamber was then surrounded by ice and the sample transferred onto the 
nitrocellulose at 200mA for 2 hours.  The transfer was checked using ponceau stain (Table 
2.2.9) and washed with TBS tween (Table 2.2.9), until all stain was removed.  The membrane 
was then blocked for 30 minutes in TBS tween (Table 2.2.9) containing 5% (w/v) milk, before 
exchanging this for TBS tween with 5% (w/v) milk containing the primary antibody at the 
appropriate dilution as shown by table 2.1.2, and leaving overnight at 4oC on the shaker.  The 
primary antibody was then washed off using TBS tween and blocked for 30 minutes using TBS 
tween with 5% (w/v) milk.  The secondary antibody was then added at the appropriate dilution 
as shown by table 2.1.2, and left on the shaker at room temperature for 2 hours.  This was 
followed by washing again with TBS tween before adding ECL detection reagent (Table 2.2.9), 
and developing the Western blot using Kodak film and developer and fixer made as per 
manufacturer’s instructions in the dark room.  The bands observed were then quantified by 
densitometry using ImageJ. 
 
Table 2.2.9 Composition of Buffers Used for Western Blotting 
Name of Solution/Buffer Composition of Buffer 
10x Electroblot 30.25g Tris 
144g Glycine 
Made up to 1 Litre with Distilled Water and pH 
to 8.3 with HCl 
1x Electroblot 100mls 10x Electroblot 
200mls Methanol 
700mls Distilled Water 
Ponceau Stain 0.1% (w/v) Ponceau S 
5% (v/v) Acetic Acid 
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10x TBS 0.1mM Tris 
1.5mM Sodium Chloride 
pH to 8.0 with HCl 
TBS Tween 100mls 10x TBS 
0.5mls Tween 20 
Made up to 1 Litre with Distilled Water 
ECL 1ml of 1M Tris pH 8.5 
9ml distilled water 
20µl 90mM Coumaric acid 
50µl 250mM Luminol 
3µl 37% H2O2 
 
Table 2.2.9 – Composition of all buffers used for each different stage of Western blotting. 
 
2.2.10 Cell Growth Determination 
 
The MTT assay was performed by seeding 10,000 cells into each well on a 24 well plate in a 
total of 0.4mls complete medium.  After a set period of time; 4 hours, 24 hours, 48 hours, 72 
hours or 96 hours, 40µl of 5mg/ml (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) in phosphate buffered saline (PBS) was added, and incubated at 37oC for 30 
minutes.  The media was then removed and 0.4mls of DMSO was added and incubated at 37oC 
for 10 minutes.  100µl of each sample was then transferred to a 96 well plate and the 
absorbance at 550nm was read using a plate reader and recorded.  Any sample that had a 
reading of above 1.1 was diluted appropriately with DMSO in order to maintain accuracy. 
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The cell counting assay was carried out by seeding 10,000 cells into each well of a 24 well plate 
in a total of 0.4mls complete medium, and placed in the incubator at 37oC for a set period of 
time, either 4 hours, 24 hours, 48 hours, 72 hours or 96 hours.  The cells were then washed 
with serum free medium to remove all traces of serum, and 100µl trypsin was used to remove 
the cells from the well.  10µl of the trypsin containing the cells was then mounted onto a 
haemocytometer and counted.  If the cell density was too high, 1x PBS was added to dilute the 
cells in order to maintain accuracy whist counting, with this dilution taken into account when 
working out the total number of cells.  
 
2.2.11 Scratch Assay 
 
500,000 cells were seeded into each well of a 6 well plate with 5mls of complete medium, or 
50,000 cells into each well of a 24 well plate with 0.4mls media.  The cells were left to grow to 
confluency, usually overnight, and a scratch was made through the cells using a 100µl pipette 
tip.  Media was then removed, the cells gently washed to remove any loose cells and fresh 
medium added.  The cells were then observed using the Cell IQ machine, which consistently 
images the same point on each scratch of each well over a predetermined period of time.  The 
software then allows the threshold of the scratch to be determined in order to quantify the 
width of the scratch as well as the area, from which the percentage closure over time can be 
determined.  As with this method of creating the scratch, the size of the scratch is not always 
consistent, the percentage closure seemed to be the most reproducible measurement.  
Triplicate points on each scratch were selected and each well was repeated in triplicate, 
allowing for 9 repeated measurements, which were compiled into graphs showing the 
percentage closure curves of the individual points as well as an average percentage closure 
curve. 
 
2.2.12 Immunofluorescence Staining 
 
Round glass coverslips, measuring 13mm in diameter were placed into the wells of a 24 well 
plate.  The lid of the 24 well plate containing the coverslips was removed and exposed to UV 
light for 10 minutes in order to sterilise.  The coverslips were then coated with fibronectin, 2µg 
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per well dissolved in sterile 1x PBS, incubated for 30 minutes at 37oC, and washed twice with 
PBS.  10,000 cells per well were then seeded in 0.4mls medium and left in the incubator at 
37oC to grow for 48 hours.  The cells were washed with 1x cytoskeletal buffer (CB buffer) 
(Table 2.2.12) twice, and fixed in 3.7% (w/v) PFA in 1x CB buffer at 37oC for 20 minutes.  0.4mls 
of 30mM glycine in 1x CB buffer was added for 10 minutes at room temperature before the 
cells were permeabilised with either 5% or 10% (v/v) Triton X-100 in CB buffer for 2 or 10 
minutes at room temperature.  The cells were then washed with 1x CB buffer twice and 
blocked with 10% (v/v) goat serum in 1x CB buffer for 30 minutes at room temperature or left 
in the fridge overnight.  The primary antibody in 1% (v/v) goat serum was added at the 
appropriate dilution as shown by table 2.1.2, and incubated at room temperature for 45 
minutes.  The coverslips were then washed three times in 1% (v/v) goat serum in 1x CB buffer 
before adding the correct secondary antibody at the appropriate dilution, as shown by table 
2.1.2, and incubating again at room temperature for 45 minutes, before washing 3 times in 1% 
(v/v) goat serum in 1x CB buffer then twice in distilled water and mounting onto a glass 
microscope slide using vector shield mounting medium containing dapi staining.  The slides 
were then viewed using the leica scanning confocal microscope using the 63x objective lens.  
When actin staining was included, 6.6µM phalloidin was added at a dilution of 1 in 100, at the 
same time as adding the secondary antibody, and the protocol continued as above.  For cells 
transfected with a GFP plasmid, the cells were seeded and fixed as above before being 
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Table 2.2.12 Composition of Buffers Used for Immunofluorescence Staining 
Name of Solution/Buffer Composition of Buffer 
10x Cytoskeletal Buffer 150mM Sodium Chloride 
5mM Magnesium Chloride 
5mM Ethylene Glycol Tetraacetic Acid (EGTA) 
5mM Glucose 
10mM 2-(n-morpholino)-ethansulphon Acid 
pH to 6.1 
1x Cytoskeletal Buffer 100mls 10x Cytoskeletal Buffer 
Made up to 1 Litre with Distilled Water 
 
Table 2.2.12 – Composition of cytoskeletal buffer used for immunofluorescence staining. 
 
2.2.13 Plasmid Construction 
 
2.2.13.1 Making and Running Agarose Gels 
 
A 1% (w/v) agarose gel was made by adding 0.5g agarose to 50mls of 1x TAE buffer (Table 
2.2.13.1) and heating in the microwave to dissolve the agarose, before adding 2.5µl ethidium 
bromide.  The gel was then poured into the cast and left to set.  Samples were loaded onto the 
gel by adding the appropriate amount of 5x loading dye, and run alongside 5µl of the 1kb DNA 
ladder from Fermentas to determine the correct size of plasmids or fragments.  The gel was 
run at 90V, in 1x TAE, until the dye front was close to the end of the gel, and imaged using the 
gene snap imager. 
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Table 2.2.13.1 Composition of Buffers for Agarose Gels 
Name of Solution/Buffer Composition of Buffer 
50x TAE Buffer 242g Tris 
51.7ml Glacial Acetic Acid 
100ml 0.5M EDTA pH 8.0 
Made up to 1L with Distilled Water 
1x TAE Buffer 20mls 50x TAE Buffer 
Made up to 1 Litre with Distilled Water 
5x Loading Dye 2mls 0.5M EDTA pH 7.5 
2mls 1% (w/v) Bromophenol Blue 
6mls Glycerol 
 
Table 2.2.13.1 – Composition of the different components to make and run an agarose gel. 
 
2.2.13.2 Isolation of plasmids 
 
Plasmids were grown from a frozen -80oC stock by inoculating 10mls 1x LB (Table 2.2.13.2) 
with 100µg/ml Ampicillin (LB Amp) or 40µg/ml Kanamycin (LB Kan) with the appropriate 
bacterial stock.  Bacteria was pelleted by centrifugation at 3,000 rpm at room temperature for 
5 minutes, resuspended in 250µl resuspension buffer (Promega kit) or Qiagen solution P1 
(Table 2.2.13.2), before the cells were lysed by adding 250µl lysis buffer (Promega kit) or 
Qiagen solution P2 (Table 2.2.13.2), followed by neutralisation by adding 350µl neutralisation 
solution (Promega kit) or Qiagen solution P3 (Table 2.2.13.2), after which cells were 
transferred to an eppendorf tube.  The tube was then centrifuged at 14,000 xg at room 
Page | 90  
 
temperature for 5 minutes, and transferred to a column from the Wizard® Plus SV Minipreps 
DNA Purification System kit from Promega, or into a fresh eppendorf tube for isopropanol 
precipitation. 
If transferred to a column, the solution was incubated for 1 minute at room temperature, 
before centrifugation at 14,000 xg.  Flow through was discarded and the column washed with 
0.8 ml wash solution from the kit, by centrifuging for around 10 seconds, removing the flow 
through, then centrifuging again at 14,000 xg at room temperature for 5 minutes.  The column 
was then transferred to an eppendorf tube, and 50µl distilled water pipetted onto the disc 
inside the column.  This was incubated at 37oC for a couple of minutes before centrifugation at 
14,000 xg at room temperature for 2 minutes. 
If transferred to an eppendorf tube, an equal volume of isopropanol was added, the contents 
thoroughly mixed, before leaving in the -80oC freezer for 10 minutes followed by the -20oC 
freezer for 20 minutes.  The tube was then centrifuged at 13,000 rpm at 4oC for 10 minutes, 
the supernatant removed, and the pellet washed with ice cold 70% (v/v) ethanol.  The pellet 
was then air dried, and resuspended in 50µl distilled water.  In both cases 5µl of the extracted 
DNA was run on a 1% (w/v) agarose gel to ensure purification was successful. 
 
Table 2.2.13.2 – Composition of Buffer Used for Plasmid Extraction 
Name of Solution/Buffer Composition of Buffer 
1x Luria Broth (LB) 20g LB 
Made up to 1 Litre with Distilled Water 
Autoclave 
Qiagen Solution P1 1ml 10mg/ml RNase A 
5ml 1M Tris pH 8.0 
2ml 0.5M EDTA 
Made to 100ml with Distilled Water 
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Qiagen Solution P2 0.2M Sodium Hydroxide 
1% SDS 
Qiagen Solution P3 29.5g Potassium Acetate 
Made to 100ml with Distilled Water 
pH to 5.5 with Glacial Acetic Acid 
 
Table 2.2.13.2 – Composition of the different buffers used to grow and isolate plasmids from 
bacteria. 
 
2.2.13.3 PCR of inserts 
 
PCR was carried out by adding the following into a PCR tube; 
2.5µl of 10x PCR buffer 
2µl of 10mM dNTPs 
5µl of 5uM forward primer 
5µl of 5µM reverse primer 
0.5µl DNA diluted 1 in 10 
0.5µl Taq polymerase 
9.5µl distilled water per reaction 
If MgCl2 wasn’t included in the PCR buffer, 1µl of 50mM MgCl2 was added and the amount of 
distilled water adjusted accordingly  
The tube was then placed into the PCR machine and run using the eEF1A programme, which 
was set up as follows; 
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Heat to 94oC and hold for 2 minutes 
94oC for 30 seconds 
50oC to 70oC for 30 seconds     
72oC for 1 minute and 30 seconds 
72oC for 5 minutes 
4oC until removed from machine 
The PCR product was then run on a 1% (w/v) agarose gel to ensure bands were observed. 
 
2.2.13.4 Purification of DNA bands from 1% (w/v) agarose gels 
 
The sample was run on a 1% (w/v) agarose gel, and the band of DNA to be purified identified, 
and the section of the gel containing the band cut out using a scalpel.  The gel slice was then 
put into an eppendorf tube and purified using the Promega Wizard® SV Gel and PCR Clean-Up 
Kit in the following way.  The gel slice was weighed and an equal volume of membrane binding 
solution added to the tube.  The gel slice was then dissolved by heating at 60oC, with frequent 
mixing, after which the solution was transferred to a column from the kit, and incubated in the 
column at room temperature for 1 minute.  The column was centrifuged at 16,000 xg for 1 
minutes, the flow through discarded, and 0.8mls wash solution added to the column.  
Centrifugation for around 10 seconds at the same speed was followed by removal of the flow 
through, and further centrifugation at the same speed for 2 minutes.  The columns were 
transferred to eppendorf tubes, and 50µl distilled water added to the disc inside the column, 
and incubated at 37oC for a couple of minutes, before centrifugation at the same speed for 2 
minutes.  5µl sample was loaded onto a 1% (w/v) agarose gel to check whether the 
purification was successful. 
 
2.2.13.5 Digestion of plasmids or PCR products 
 
Repeated 30 times 
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For each digestion the following was added into an eppendorf tube and incubated at 37oC for 
2-3 hours or overnight; 
20µl Plasmid/PCR product 
2.5µl Digestion enzyme buffer 
1µl Restriction enzyme (EcoR1 or EcoRV) 
1.5µl distilled water 
After digestion with a single restriction enzyme, to prevent religation of the plasmid without 
the insert, the digested plasmid was dephosphorylated by adding 2µl shrimp alkaline 
phosphatase to the eppendorf tube after digestion, and incubated at 37oC for 1-2 hours. 
 
2.2.13.6 Insertion of PCR products into cloning vector pST-Blue 
 
Once the purified PCR product was obtained, the overhangs had to be restored back onto the 
insert.  This was done by adding the following into a PCR tube and leaving at 72oC for 10 
minutes; 
20µl Purified PCR product 
2.5µl 10x PCR buffer 
2µl 10 mM dNTPs 
0.5µl Taq polymerase 
The insert was then inserted into a cloning vector, pst blue, by adding the following to an 
eppendorf tube and incubating at 16oC for 2 hours; 
0.5µl Acceptor vector 
4µl Purified PCR product with overhangs restored 
0.5µl Nuclease free water 
5µl Cloneables 2x ligation premix from the pSTBlue-1 AccepTor™ Vector Kit from Novagen 
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2.2.13.7 Ligation of purified insert into backbone 
 
The insert was ligated into the vector backbone by adding the following to an eppendorf tube 
and leaving for 3 hours at room temperature or overnight at 4oC; 
3µl plasmid 
15µl insert 
2µl ligation buffer 
1µl of ligase 
 
2.2.13.8 Preparation of competent bacteria 
 
Chemically competent cells were prepared by inoculating a colony of DH5α Escherichia coli 
(E.coli) cells in around 5mls 1x LB and growing overnight at 37oC shaking at 250rpm.  The 
overnight culture was then diluted 1:1000 into 50mls of fresh 1x LB, and the cells grown in the 
same conditions until the optical density (OD600) reached 0.3.  The cells were placed on ice for 
15 minutes, 50mls ice cold 2x TSS (Table 2.2.13.8) added, and the solution gently mixed, 
before leaving on ice for 20 minutes.  The cells were then pelleted by centrifugation at 1000 xg 
at 4oC for 10 minutes, and the pellet resuspended in 5mls ice cold 1x TSS (Table 2.2.13.8), and 
the cells aliquoted into 100µl aliquots, and snap frozen by placing into liquid nitrogen, then 
storing in the -80oC freezer. 
Electrocompetent bacteria were prepared by inoculating 500mls LB with a preculture of DH5α 
E.coli cells, and growing on a shaking incubator at 37oC at 300rpm to an optical density (OD600) 
of around 0.5-0.7.  Cells were then placed on ice for 20 minutes, centrifuged at 4000 xg for 15 
minutes at 4oC.  The supernatant was discarded, the pellet resuspended in 500mls ice cold 
10% (v/v) glycerol, before centrifugation under the same conditions.  The pellet was 
resuspended in 250mls 10% (v/v) ice cold glycerol, followed by centrifugation under the same 
conditions, then resuspended in 20mls 10% (v/v) ice cold glycerol, followed by centrifugation 
under the same conditions.  The cells were then resuspended in 1-2ml 10% (v/v) ice cold 
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glycerol, and 100µl of the cell suspension placed into eppendorf tubes.  The tubes were snap 
frozen by dropping the tubes into liquid nitrogen, then stored in the -80oC freezer until used. 
 
Table 2.2.13.8 Composition of Buffers Used to Make Competent Bacteria 
Name of Solution/Buffer Composition of Buffer 
2x TSS 20% (w/v) Polyethylene Glycol (PEG) 
100mM MgCl2 
10% Dimethyl Sulphoxide (DMSO) 
Dissolved in 1x LB  
pH to 6.5 
1x TSS Dilute 2x TSS 1:1 with 1x LB 
 
Table 2.2.13.8 – Composition of the different buffers used to make competent bacteria. 
 
2.2.13.9 Bacterial Transformation 
 
Bacterial transformation was carried out in two different ways, by heat shocking the bacteria 
or by electroporation.  When heat shocking, a tube of competent DH5α E.coli cells were 
removed from the -80oC freezer and placed on ice to thaw.  1µl of the ligated plasmid was 
added and the tube was gently agitated and replaced onto the ice for 30 minutes.  The cells 
were then heat shocked at 42oC for 40 seconds, then placed back onto ice for 2 minutes.  
800µl of 1x LB was added and the tube was placed into a shaking incubator set at 37oC and 
250 rpm and left for 1 hour.  The sample was then removed from the incubator, 100µl placed 
onto a 1x LB agar plate containing 100µg/ml ampicillin and a glass spreader sterilised with 75% 
(v/v) IMS in distilled water was used to gently spread the cells over the plate.  The remaining 
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cells were then pelleted by centrifugation at 5,000rpm for 10 minutes at room temperature, 
the supernatant removed, and the cells resuspended in approximately 100µl LB and added to 
another plate and spread in the same way as before.  The plates were then placed into a 37oC 
incubator overnight.   
Electrotransformation was carried out by thawing the competent cells on ice, and adding 1µl 
of ligated plasmid to the cells before mixing and leaving on ice for 1 minute after which they 
were transferred to a 0.2cm electroporation cuvette.  The cuvette was placed into the 
micropulser which was set to Ec2, and the pulse button pressed.  1ml 1x LB was added to the 
cells immediately, and the cells transferred to an eppendorf tube where they were placed in 
the shaking incubator at 37oC at 250rpm for 1 hour.  The cells were then plated in the same 
way as the bacteria transformed by heat shock. 
 
2.2.13.10 Screening of transformed colonies 
 
30µl of screening lysis buffer (Table 2.2.13.10) per colony was added to an eppendorf tube.  
The same number of tubes was also set up containing 1ml 1x LB broth containing 100µg/ml 
ampicillin or 40µg/ml kanamycin.  The colony was picked up using a yellow pipette tip, and 
then placed into the LB before being transferred into the screening lysis buffer, allowing some 
cells to be transferred into the LB and some cells to be transferred into the lysis buffer.  The 
tubes with the lysis buffer were incubated at 37oC for 5 minutes, and then placed on ice for 5 
minutes.  They were then centrifuged at maximum speed for 1 minute, and the sample loaded 
onto a 1% (w/v) agarose gel.  The size of the band was estimated by looking at migration of the 
band in the gel and comparing to a DNA ladder from Fermentas, and from this it was decided 
whether the plasmid was likely to contain the insert.  The tubes containing the 1x LB with the 
cells were placed on the shaking incubator with the same settings as above and left for one 
hour after which the samples were removed from the incubator and the positive samples 
were kept.  100μl of this 1x LB stock with the potential positive plasmid was then used to 
inoculate 10mls 1x LB with 100μg/ml ampicillin, and left to grow overnight in the shaking 
incubator in the same conditions as used before.  The plasmid was then extracted from the 
bacteria as described in section 2.2.13.2. 
Table 2.2.13.10 Composition of Buffer Used for Screening 
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Name of Solution/Buffer Composition of Buffer 




0.05% SDS        
 
Table 2.2.13.10 – Composition of screening lysis buffer used for the screening of potentially 
positive plasmids. 
 
2.2.13.11 Sequencing of newly created plasmids 
 
Sequencing of the inserts ligated into the new plasmids was carried out at Birmingham 
University.  The following was placed into a tube and the sequence determined using Sanger 
sequencing according to standard protocols; 
200-500ng plasmid 
3.2pMol Primer 
Made to 10µl with distilled water 
Sequence comparisons were carried out using ApE software. 
 
2.2.14 Transfection 
2.2.14.1 Transfection – Pool of transfected cells 
 
Page | 98  
 
Several conditions had to be trialled in order to optimise the best method for transfection of 
the cells.  This was done using a lifeact plasmid which contains the green fluorescent protein 
(GFP) gene and allows visualisation of the actin cytoskeleton allowing the cells containing the 
plasmid to be identified.  The manufacturer’s protocol for JetPEI™ suggested the use of a ratio 
of 1.2μl of Jetpei™ to 1μg DNA for CHO cells, therefore this was used to determine any 
potential difference in transfection efficiency between CHO and 2E2 cells.  50,000 cells or 
400,000 cells were seeded into a 24 well plate or a 6cm tissue culture dish and left to grow 
overnight.  The media was removed, and 0.5, or 5mls fresh DMEM was added, and left for 
around 30 minutes.  The concentration of plasmid DNA was quantified using the nanodrop, 
which allows the optical density at 260nm and 280nm to be determined to both quantify and 
determine the purity of the DNA sample, then 1μg DNA or 5μg DNA was added to 50μl or 
250μl NaCl solution, and 1.2μl or 6μl jetPEI™ was added to 50μl or 250μl of NaCl solution 
provided, depending on the number of cells.  The DNA and jetPEI™ solutions were vortexed, 
and the jetPEI™ added dropwise the DNA, after which the combined solution was vortexed 
and then incubated at room temperature for 30 minutes.  The solution was then added 
dropwise to the cells, and incubated overnight.  When quantifying, the number of transfected 
cells was counted along with the total number of cells, and a percentage calculated.  When 
transfecting to create new cells lines, the media was changed to selective media, or the cells 
passaged into selective media, and left until cell death from selection was complete and a 
healthy flask of cells remained. 
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2.2.14.2 Transfection – Clonal cells 
 
Transfection with jetPEI™ was carried out as described previously, though scaled up to a 10cm 
dish.  The cells were then incubated for 24 hours, after which they were passaged into a 10cm 
dish with selective DMEM containing 500μg/ml G418 and 200μg/ml zeocin.  The cells were 
then incubated until individual colonies started to form, and once these colonies were large 
enough, cloning cylinders were used to remove them.  One side of a sterile cloning cylinder of 
appropriate size was dipped into sterile grease, and placed around the colony of interest.  The 
cylinder was then gently pushed down to create a seal around the colony.  50μl trypsin was 
added and incubated at 37oC until cells were detached, after which 100μl of complete media 
was added, and the cells transferred to a well of a 24 well plate.  Once the cells were confluent 
they were passaged into a 6 well plate, and then into a T25cm2 flask, after which they were 
screened for expression of the plasmids by immunofluorescence and Western blotting. 
 
2.2.15 Polysome Profiling 
2.2.15.1 Mammalian Polysome Extraction With or Without CHX 
 
500,000 cells were seeded into a 10cm tissue culture dish, and left to grow until around 90% 
confluence.  If extracting in the presence of CHX, media was replaced with complete DMEM 
media containing 100μg/ml CHX, and incubated at 37oC for 15 minutes.  Media was then 
removed, cells washed with cold PBS, and 0.25mls of polysome lysis buffer with or without 
10mg CHX (Table 2.2.15.1) added.  Cells were then scraped off the plate, transferred to an 
eppendorf tube and centrifuged at 4oC at 10,000 rpm for 15 minutes.  The supernatant was 
then transferred to a fresh eppendorf tube and stored at -80oC until the sample was loaded 
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Table 2.2.15.1 Composition of Buffers Used for Polysome Extraction 
Name of Solution/Buffer Composition of Buffer 
Polysome Lysis Buffer Without CHX 20mM Tris pH 7.5 
10mM Potassium Chloride (KCl) 
10mM MgCl2 
1mM DTT 
1% (v/v) NP-40 
Protease Inhibitor Cocktail diluted to 1x 
RNase Inhibitor diluted to 1x 
 
Table 2.2.15.1 – Composition of polysome lysis buffer without CHX used for polysome 
extractions. 
 
2.2.15.2 Sucrose Gradients 
 
In order to create polysome profiles, the extraction weas run on a sucrose gradient made up of 
layers containing 10, 20, 30, 40 and 50% (w/v) sucrose, with the highest concentration at the 
bottom.  For each layer, the sucrose was weighed out, the 10x sucrose gradient buffer (Table 
2.2.15.2) added so that a 1x solution is achieved, and made up to volume using distilled water. 
The sucrose was dissolved and 2mls of each sucrose layer was pipetted into a centrifuge tube 
with care to avoid the transfer of solution from the sides of the pipette to the tube.  After each 
layer had been added, the gradients were frozen at -80oC before the next layer added, to 
ensure no mixing of the layers occurred.  The gradients were then stored in the -80oC freezer 
until needed, when they were removed from the freezer and allowed to thaw, either 
overnight or on the day of use.  
Table 2.2.15.2 Composition of Buffer Used to Make Sucrose Gradients 
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Name of Solution/Buffer Composition of Buffer 
10x Sucrose Gradient Buffer 50mM Ammonium Chloride 
50mM Tris Acetate pH7 
12mM Magnesium Chloride 
1mM Dithiothreitol 
 
Table 2.2.15.2 – Composition of the buffer used to make the sucrose gradients for separation 
of polysomes. 
 
2.2.15.3 Quantification and Centrifugation of Polysome Extractions 
 
The concentration of the polysome extract was determined by using the nanodrop.  The 
concentration of each extraction was read three times, after which an average concentration 
was determined.  200μg of extract was then gently added onto the top of a thawed sucrose 
gradient, and centrifuged at 38,000rpm for 2 hours at 4oC under a vacuum with slow 
deceleration.  The polysome profiles were then obtained by running them on the Gradient 
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3.0 The effect of reduced eEF1A protein expression on 
biological processes in CHO cells 
3.1 Introduction 
 
One protein that has been demonstrated to have essential functions in actin remodelling is 
eukaryotic elongation factor 1 alpha (eEF1A), which has the ability to both bind and bundle 
actin (Demma et al., 1990, Yang et al., 1990).  In particular it has been suggested to bind actin 
filaments into anti parallel square packed bundles, which exclude other actin binding proteins 
(Owen et al., 1992), however the direct roles of eEF1A on actin remodelling are not clear in 
vivo.  Overexpression of eEF1A has been linked to the metastatic properties of rat breast 
tumour cells (Edmonds et al., 1996).  In such cells, a high correlation between the intracellular 
distribution of filamentous actin and eEF1A is thought to play a key role in regulating cellular 
motility. Further work in cells using the more amenable yeast organism, Saccharomyces 
cerevisiae, has also highlighted the importance of eEF1A as a regulator of actin organisation. 
Indeed, overexpression of eEF1A in yeast results in a significant disruption of the actin 
cytoskeleton (Munshi et al., 2000).  Gross and Kinzy, 2005, demonstrated the importance of 
eEF1A in the overall physiological organisation of the actin cytoskeleton since mutant eEF1A 
proteins harbouring deficient actin bundling activities resulted in clear defects in overall actin 
remodelling (Gross and Kinzy, 2005, Gross and Kinzy, 2007).  Interestingly, affecting actin 
organisation did not result in significant changes in protein translation elongation.  eEF1A is 
present in large excess to the rest of the translational machinery, 17-35 fold molar excess 
compared to the ribosomes (Slobin, 1980), suggesting that  eEF1A has other functions outside 
of translation.  It has been hypothesised that eEF1A may be present in different pools within 
the cell allowing it to regulate different processes, for instance, it has been shown that eEF1B, 
the guanine nucleotide exchange factor (GEF) for eEF1A, is capable of distributing eEF1A to its 
different functions (Pittman et al., 2009).  
eEF1A has also been shown to have other functions as well as its role in protein translation 
and actin binding/bundling including microtubule binding bundling and severing (Durso and 
Cyr, 1994, Shiina et al., 1994, Moore et al., 1998), influencing apoptosis (Billaut-Mulot et al., 
1996, Kato, 1999, Duttaroy et al., 1998, Chen et al., 2000, Ruest, 2002, Talapatra et al., 2002, 
Borradaile et al., 2005), cell proliferation and cell cycle (Pecorari et al., 2009) where a 
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reduction of eEF1A protein expression resulted in an increase in the fraction of G1 cells and 
apoptotic cells and decrease in the fraction of cells in S phase (Pecorari et al., 2009).   
Specifically determining which roles of eEF1A are due to a direct regulatory function of this 
protein on certain cell processes, or merely the consequent results of protein synthesis 
fluctuations has remained elusive. Furthermore, aberrantly regulating the levels of eEF1A 
expression has continuously been impeded by  the abundance of the protein, as eEF1A is the 
second most abundant protein in the cell after actin, making up between 1-10% of total 
cellular protein in normally growing cells (Liu et al., 1996b, Merrick, 1992), therefore using the 
common method of siRNA to knock down the expression of eEF1A may not be sufficient to 
allow phenotypes to be observed and creating knockouts of eEF1A is not possible due to the 
essential nature of the gene.  For this reason a different strategy was required.  Whilst trying 
to identify genes involved in resistance to lipotoxic cell death, Borradaile et al, 2005, created a 
mutant CHO-K1 cell line which was the product of a single retroviral promoter trap integration.  
Interestingly, for one of the clones isolated, the integration was shown to have taken place in 
the promoter region of the eEF1A1 gene, deleting both the promoter and the first intron in the 
process resulting in the inactivation of that allele. Biochemical analysis further demonstrated a 
significant reduction in eEF1A protein expression without any direct effect on rates of protein 
synthesis (Borradaile et al., 2005).   
Using this invaluable mammalian cell system, we sought to analyse how low levels of eEF1A 
would alter overall cell behaviours, including cellular motility/adhesion and changes in 
cytoskeletal architectures.   
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3.2 Materials and Methods 
 
3.2.1 Attachment Assay 
 
1,000 cells were seeded in media either with or without serum into a 96 well tissue culture 
plate, of which some wells had previously been coated with fibronectin in PBS as described in 
section 2.2.12, but scaled down to a well of smaller size.  The cells were left to attach for 
either 30 or 60 minutes before gentle washing with 1x PBS pH 7.4.  The attached cells were 
then fixed and stained with 70% (v/v) ethanol with 0.5% (w/v) crystal violet, and incubated at 
room temperature for 15 minutes, after which the solution was removed, and the cells again 
washed with 1x PBS pH 7.4.  The crystal violet was then solubilised with 100μl 30% (v/v) acetic 
acid and the absorbance read on a plate reader at 540nm. 
 
3.2.2 Flow Cytometry for Cell Cycle 
 
750,000 cells were seeded into a 10cm dish, and left to grow for 2 days.  Cells were then 
trypsinised as before, and washed with 0.1% (w/v) BSA in PBS, before resuspending in 1ml 1x 
PBS.  Fixation of cells was done by adding the 1ml of cells to 9mls ice cold 70% (v/v) ethanol, 
before vortexing to mix and storing in the -20oC freezer overnight.  The following day cells 
were pelleted at 250xg for 5 minutes, and washed in 0.1% (w/v) BSA in PBS, before 
resuspending in 0.5mls staining solution (Table 3.2.2) and incubating at room temperature in 
the dark for 30-60 minutes.  The cells were then run on the flow cytometer using the cell cycle 
programme which measures the forward and side scatter, as well as the fluorescence 
intensity.  10,000 events were recorded for each cell line.  Potential doublet cells were 
excluded from analysis.  
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Table 3.2.2 Composition of Buffer for Flow Cytometry 
Name of Solution/Buffer Composition of Buffer 
Staining Solution (Flow Cytometry) 3.8mM Sodium Citrate pH 7.4 
50µg/ml Propidium Iodide (PI) 
0.5µg/ml RNase A 
 
Table 3.2.2 – Composition of the staining solution used during flow cytometry. 
 
3.2.3 Ratio of G Actin to F actin Assay 
 
The Cytoskeleton G-actin/F-actin In Vivo Assay Kit was used as per the manufacturer’s 
protocol.  500,000 cells were seeded into a 6cm plate and left to grow for 2-3 days until 
confluent.  The centrifuge was pre-warmed to 37oC before starting the assay, and LAS2 buffer 
made up in the following way; 
1ml LAS01 buffer (Lysis and F-actin stabilisation buffer) 
10µl BSA04 (100mM ATP stock solution) 
10μl PIC02 (100x protease inhibitor stock) 
The LAS2 buffer was pre-warmed to 37oC for 30 minutes before beginning the assay.  Media 
was removed from cells, 250µl LAS2 buffer added, cells scraped off and transferred to an 
eppendorf tube.  Cells were sonicated using a handheld sonicator set to around 8-10 amps and 
lysates incubated at 37oC for 10 minutes.  100µl was then transferred to an eppendorf tube, 
centrifuged at 350xg for 5 minutes at room temperature, supernatant transferred into a 
centrifuge tube, and centrifuged at 100,000xg for 1 hour at 37oC.  Supernatants were 
transferred to a clearly labelled tube, and 100µl of F-actin depolymerisation buffer added to 
the pellet which was incubated on ice for 1 hour with pipetting up and down to help pellet 
resuspension every 15 minutes.  25µl of 5x SDS sample buffer was added to both the pellet 
and supernatant samples, and the samples stored at -20oC until processed.  Samples were 
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processed by running 10µl on a 10% (v/v) SDS gel as described in section 2.2.8 and the 
Western blot performed as described in section 2.2.9.  The Western blot was probed with the 
actin antibody provided with the kit, at a dilution of 1 in 50 in 0.1% (w/v) TBS-T with milk, and 
incubated for 1 hour at room temperature.    
 
3.2.4 Modified ELISA for detection of eEF1A  
 
2,500, 5,000 and 10,000 cells were seeded into a 96 well plate and left to grow for 2-3days.  
Cells were then washed with 1x PBS and fixed with 3.7% (w/v) PFA in 1x PBS for 20 minutes at 
37oC.  Cells were then washed with 1x PBS, and permeabilised with 0.1% (v/v) or 5% (v/v) 
triton in 1x PBS for 2-5 minutes before washing and blocking in 5% (w/v) milk in 1x PBS for 30 
minutes at room temperature.  Primary antibody was then added at the relevant dilution 
shown in table 2.1.2 and left at 37oC for 1 hour.  The primary antibody was then washed off 
with 5% (w/v) milk in 1x PBS, and the appropriate HRP conjugated secondary antibody added 
at the dilution stated in table 2.1.2 and left at room temperature for 2 hours.  Cells were then 
washed with 5% (w/v) milk in 1x PBS, then again in 1x PBS, before 200μl of sigmafast OPD was 
added, made as per manufacturer’s instructions.  The plate was left in the dark at room 
temperature for 30 minutes for the colour to develop, before the plate was read at 490nm. 
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3.3 Results 
3.3.1 2E2 cells show a significant reduction in eEF1A expression when 
compared to control CHO cells 
 
   
Following on from the promoter trapping experiment, and the isolation of a specific clone, 
Borradaile et al, 2005, reported the disruption of the eEF1A1 locus, resulting in the low 
expression of the eEF1A proteins  in 2E2 cells as determined by Western and Northern 
blotting.  They assumed that the resulting expression of eEF1A proteins present was caused by 
eEF1A2 expression (Borradaile et al., 2005).  Such conclusions were based on the assumption 
that the remaining bands viewed on the Western blots showed eEF1A2 expression as a result 
of lack of specificity of the antibodies used, with the two isoforms indistinguishable.  It was 
therefore important to determine the level of eEF1A reduction in the 2E2 cells as well as which 
of the isoforms were affected.  It was also imperative to ensure that the decrease in eEF1A 
protein expression was uniform across the whole cell population, therefore Western blotting 
was used to check protein expression and immunofluorescence staining to ensure consistency 
throughout the cell population. 
Western blotting was performed by homogenising cells, running protein on a 10% (v/v) 
acrylamide gel, transferring to nitrocellulose and probing for eEF1A, eEF1A1 eEF1A2 or a 
loading control protein, α – adaptin or tubulin.  The blots were then developed and the 
intensity of the bands quantified using densitometry analysis on ImageJ.   
Expression of eEF1A using the antibody that does not differentiate between the two isoforms 
was found to be reduced by around 40% in the 2E2 cells compared to the control CHO cells 
(Figure 3.3.1 A & B).  When the blots were probed using the antibodies specific to human 
eEF1A1 or eEF1A2, no bands were observed for eEF1A1 (including in the positive control), 
suggesting that this antibody was not functioning properly, however the eEF1A2 antibody 
showed a reduced expression of around 67% (Figure 3.3.1 C & D).  Hela cells were used as a 
positive control to ensure the antibodies, in particular the eEF1A2 antibody, were functioning 
as Hela cells have been shown to express both isoforms (Datu and Bag, 2013).   
Cells for immunofluorescence staining were grown on coverslips and fixed and permeabilised 
before staining for eEF1A and viewing using fluorescence microscopy.   
Page | 111  
 
It was found that the level of eEF1A protein was uniform throughout the population in both 
CHO and 2E2 cells, and as already shown by Western blot, the 2E2 cells had a reduced level of 
eEF1A when compared to the control CHO cells (Figure 3.3.1 E).  
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Figure 3.3.1 – 2E2 cells show a 40% 
decrease in expression of eEF1A.  2E2 and 
control CHO cells were lysed and sonicated 
prior to an equal amount of total protein 
(10µg) loaded onto a 10% (v/v) acrylamide 
gel.  Proteins were then transferred to 
nitrocellulose, probed for eEF1A and α-
adaptin as a loading control, and the blots 
developed using ECL (A). Quantification was 
performed using ImageJ by analysing the bands of three independent protein extractions, and 
plotting the average along with the standard error of the mean.  Statistical significance was 
determined using an unpaired T test to a P value of <0.05 (B and D).  Blots probed for eEF1A1 
and eEF1A2 with tubulin as a loading control were prepared in the same way as above, though 
with 100µg total protein loaded onto the gel (C).  Immunofluorescence was carried out by 
seeding cells onto a fibronectin coated coverslip, fixing, permeabilising and staining for eEF1A 
with a FITC conjugated secondary antibody before mounting onto a microscope slide and 
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3.3.2 2E2 cells show no elongation block when compared to control 
CHO cells 
 
Borradaile et al, 2005, detected no change in rate of total protein translation reporting a rate 
of 1500-1700 cpm/µg protein for both cell lines using methionine incorporation (Borradaile et 
al., 2005), it is however possible that although no changes in total protein translation could be 
observed, some more subtle effects on the phase of elongation could be present.  In order to 
assess such possibility, polysome profiling was undertaken where differences in initiation or 
elongation can be highlighted due to a change in the ratio of the polysome to monosome (80S) 
peaks with or without the antibiotic cycloheximide (CHX), though if elongation blocks are 
expected extraction is usually performed without CHX as CHX can cause artificial elongation 
blocks on polysome profiles (Rivest et al., 1982).   
Polysomes were consequently extracted in the absence of CHX, separated on a sucrose 
gradient, and the gradient run on the gradient profiler.  Interestingly, the polysome profiles 
from the two cell lines collected in the absence of CHX showed that there was no observable 
elongation block in the 2E2 cells, with the polysome/monosome (P/M) ratios of 1.25 for CHO 
and 1.34 for 2E2 cells showing no differences (Figure 3.3.2). 
 
 







Figure 3.3.2 – The reduced expression of eEF1A observed in 2E2 cells causes no change in the 
polysome profile.  2E2 and control CHO cells were scraped into polysome lysis buffer with or 
without CHX, the supernatant collected and quantified and 200µg of the polysome extract 
loaded onto a sucrose gradient.  The gradient was centrifuged at 38,000rpm for 2 hours and 
run on the gradient profiler.  The polysome/monosome (P/M) ratio was worked out using 
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3.3.3 Reduced expression of eEF1A coincides with a slower growth 
phenotype 
 
Reduced expression of eEF1A in breast cancer cells has been shown to be linked to a reduction 
in cell proliferation (Pecorari et al., 2009). To establish whether this observation could also be 
seen in our cell system, we sought to establish whether the decrease in eEF1A protein levels 
seen in the 2E2 cells would affect the growth rate of the cells.  Growth curves were created 
using MTT and cell counting assays over a 96 hour period.  
It was found that the 2E2 cells had a significantly lower growth rate when compared to the 
control CHO cells, with the difference observable as early as 24 hours and gradually increased 
until 72 hours when the CHO cells had an OD550nm of 3 compared to 2.3 for the 2E2 cells (Figure 
3.3.3A).  To determine whether the differences seen were due to changes in cell number, or 
possibly a reduction of metabolic activities, cell growth assays were also carried out.  A similar 
reduction in cell number was seen in the 2E2 cells as observed in the MTT assay across the 
different time points. Whilst no changes could be seen at 24 hours, cell number decreased 
from 51000 in CHO cells to 43000 in 2E2 cells at 48 hours and much more significantly at the 
later time points, with more than 300000 cells per well for the control whilst 2E2 cells were 
around 150000 (Figure 3.3.3B). 

















Figure 3.3.3 – Reduced expression of eEF1A in 2E2 cells coincides with a significant decrease in 
growth rate.  For both assays, 10,000 cells were seeded, and left to grow for 4, 24, 48, 72 or 96 
hours. Following on from this incubation,  either MTT was added, solubilised with DMSO and 
the absorbance at 550nm read (A), or cells were trypsinised, and counted using a 
haemocytometer (B).  Results are presented as average values with standard error and 
analysed for statistical significance by an unpaired T test * p = <0.01, ** p = <0.005. 
* * * * 
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3.3.4 Reduced expression of eEF1A coincides with a decrease of cells in 
S phase and an increase in apoptotic cells 
 
 Low levels of eEF1A have led to a decreased S phase fraction as well as an increase in the 
fraction of cells with subG1 DNA content which indicates apoptosis in breast cancer cells 
(Pecorari et al., 2009).  A decrease in expression of eEF1A has also been linked to cellular 
senescence induced by many different factors (Byun et al., 2009), therefore given the changes 
we have seen in regards to their proliferation (Figure 3.3.3), we sought to determine if any 
differences in the stages of the cell cycle could be seen in our cell system. 
Flow cytometry was used to analyse cell cycle after trypsination, fixation and staining with 
propidium iodide before 10,000 events were recorded.  A decrease in the fraction of cells in S 
phase and G2/M phase, as well as an increase in the fraction of apoptotic cells could be 
observed in the 2E2 cells compared to the control cells (Figure 3.3.4). 
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Figure 3.3.4 – Reduced expression of eEF1A coincides with a decrease in S phase cells and an 
increase in apoptotic cells in 2E2 cells compared to control CHO cells.  Cells were trypsinised, 
washed and fixed in 70% (v/v) ethanol overnight at 4oC.  The cells were then washed and 
resuspended in 50µg/ml propidium iodide for 60 minutes before running on the flow 
cytometer with 10,000 events recorded.  
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3.3.5 Reduced expression of eEF1A results in an increase in actin stress 
fibres 
 
eEF1A was shown to be an actin binding and bundling protein as early as the 1990s (Demma et 
al., 1990, Yang et al., 1990), and since, this property has been shown to be conserved 
throughout many different species (Dharmawardhane et al., 1991, Collings et al., 1994, Gross 
and Kinzy, 2005, Liu, 2002).  We decided to focus our attention on the actin architecture in our 
cell system to establish whether the low levels of eEF1A would affect their cytoskeletal 
organisation. In the first instance, we wanted to establish if the overall level of actin 
expression was affected by Western blotting as well as determine if the two cell lines 
presented any significance changes in their overall organisation using immunofluorescence 
staining.   
Western blotting was performed by extracting the total protein, loading onto a gel, 
transferring and probing for actin (Arp3 as loading control).  No difference in actin protein 
expression was detected between the CHO and 2E2 cells (Figure 3.3.5 A & B), indicating that 
the overall levels of actin protein are constant and that lowering eEF1A levels does not affect 
its overall expression. 
Immunofluorescence staining for actin was carried out using rhodamine phalloidin (eEF1A co-
stain) and viewed using confocal microscopy.  The overall intensity for actin was comparable 
between the two cell lines in line with the data obtained after Western blotting, whilst a 
reduction in eEF1A protein in the 2E2 cells demonstrates a large presence of actin stress fibres 
throughout the cell body.  Quantification of these fibres was carried out by assuming the 
striations across the cell as fibres, and counting the number of fibres that cross the cell.  Stress 
fibre agglomeration at the cell periphery was not quantified as it is impossible to differentiate 
the different bundles. 
Quantification of these stress fibres indicated a significant increase in actin stress fibres, with 
the 2E2 cells presenting an average of 14 +/- 7.1 arc stress fibres per cell whilst the control 
counterparts were found to have 1 +/- 1.3 (Figure 3.3.6 C & D).  Large pools of actin punctate 
were however observed though not quantified in the control CHO cells, potentially likely to be 
short F-actin fibres which were absent in the 2E2 cells.  The 2E2 cells also appear to show a 
thinner cortical actin ring around the cell when compared to CHO cells based on observation 
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of the images.  In order to further characterise the observed stress fibres, other proteins 
known to be associated with actin stress fibres were analysed. 
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Figure 3.3.5 – Reduced expression of eEF1A 
coincides with an increase in the number of 
actin stress fibres in 2E2 cells compared to 
control CHO cells.  Western blotting was 
performed by extracting the total protein, 
running 50µg total protein on a 10% 
acrylamide gel and transferring onto 
nitrocellulose, before probing for actin and Arp3, and detecting with ECL (A).  ImageJ was used 
to quantify the bands from three independent protein extractions and plotting the average 
and standard error of the mean.  Statistical analysis was carried out by unpaired T test to a P 
value of *<0.05 (B).  Immunofluorescence staining was performed by seeding cells onto coated 
coverslips, before fixing, permeabilising, blocking and staining for actin (rhodamine phalloidin) 
and eEF1A (FITC conjugated secondary antibody).  Coverslips were then mounted and viewed 
using confocal microscopy (C).  Actin stress fibres were quantified by counting the number of 
fibres passing through the cells for each cell type with actin fibres surrounding the cell 
excluded from quantification as it was impossible to differentiate bundles of actin filaments 
(n=20).  Statistical significance was determined by an unpaired T test to a P value of *<0.05 
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3.3.6 Reduced expression of eEF1A correlates with a change in 
localisation of myosin filaments 
 
Actin stress fibres can be categorised into four different types, namely the perinuclear actin 
cap, transverse arcs, and dorsal and ventral stress fibres each with varying functions 
(Tojkander et al., 2012).  The types of actin stress fibres can be differentiated using 
immunofluorescence staining by observing where the fibres are localised, as well as the 
proteins associated with the stress fibre, for example, it has been shown that dorsal stress 
fibres do not contain myosin II at the trunk of the fibre (Kovac et al., 2012), and only attach to 
focal adhesions at one end, with transverse arcs having no association with focal adhesions at 
all, therefore observation of myosin II and focal adhesion proteins would allow further 
characterisation of the stress fibres, allowing them to be classified, as well as giving some 
insight into their function.  Myosin IIA is known to localise to actin filaments and stress fibres, 
giving the fibres the ability to contract (Weber and Groeschel-Stewart, 1974, Tojkander et al., 
2011).  Due to the increased number of actin stress fibres seen in the 2E2 cells compared to 
the control CHO cells (Figure 3.3.8), we sought to determine if myosin protein levels were 
affected and whether there were any differences in myosin IIA colocalisation with the 
observed fibres to further characterise the fibre structure.   
Extraction of the total lysate from the 2E2 and control CHO cells was performed before 
samples were run on an 8% (v/v) acrylamide gel and transferred and probed for myosin IIA 
(tubulin as loading control) before developing.  No difference in myosin IIA protein expression 
was observed between the two different cell lines (Figure 3.3.6 A & B), demonstrating that 
actual expression of the proteins is not affected in the cell system used.   
Localisation of myosin IIA was observed by immunofluorescence staining after cell 
permeabilisation using confocal microscopy.  Quantification of myosin IIA fibres was carried 
out in the same manner to those of actin (see in figure 3.3.5).  Immunofluorescence staining 
showed that myosin IIA localised to the actin stress fibres in 2E2 cells with the average number 
of myosin IIA striations per cell being 1 +/- 0.7 in CHO cells and 14 in 2E2 +/- 4.6 cells, 
therefore a reduction in eEF1A protein expression correlates with a statistically significant 
increase in the number of myosin IIA fibres across the cell (Figure 3.3.6 C & D), with the 
number of striations correlating closely to the number observed for the actin stress fibres. 





















Figure 3.3.6 – A reduction in the expression of 
eEF1A protein correlates with an increase in the 
number of myosin IIA fibres, but no change in 
myosin IIA protein expression in 2E2 cells when 
compared to control CHO cells.  Western 
blotting was performed by scraping cells into 
homogenising buffer, sonicating and quantifying the total protein.  25µg total protein was 
loaded onto an 8% (v/v) gel which was run, transferred, probed for myosin IIA (tubulin as a 
control) and developed using ECL (A).  ImageJ was used to quantify the bands from three 
independent protein extractions, plotting the average and standard error of the mean (B).  
Immunofluorescence staining was carried out by fixing, permeabilising, blocking and staining 
cells for myosin IIA (FITC conjugated secondary antibody) and actin (rhodamine phalloidin).  
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quantified by assuming the striations across the cells to be fibres similar to actin stress fibres 
and counting the number of fibres that passed through the cell in 20 cells for each cell line.  
The average fibre number was plotted with the standard error of the mean and statistical 
analysis was carried out by unpaired T test to a P value of *<0.05 (D).  White scale bars are 
equal to 25µM, blue scale bars are equal to approximately 7.5µM. 
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3.3.7 Reduced expression of eEF1A coincides with an increase in the 
number of paxillin and vinculin clusters 
 
Based on the position of the actin stress fibres in relation to the cell (Figure 3.3.5), and the 
localisation of myosin IIA to the fibres (Figure 3.3.6), it is likely that the stress fibres present in 
the 2E2 cells are ventral stress fibres.  Ventral stress fibres are the only type of stress fibre to 
attach the extracellular matrix by focal adhesions at both ends of the fibre (Pellegrin and 
Mellor, 2007), therefore to confirm the fibres as ventral stress fibres, and to provide further 
insight into the effect this increase in fibre number would have on the physical characteristics 
of the cell, focal adhesions were analysed.  Paxillin is one of the earliest proteins present in the 
formation of focal complexes (Zaidel-Bar et al., 2004), and has been shown to localise to early 
stress fibre focal adhesions (Zimerman et al., 2004).  Vinculin is another focal adhesion protein 
involved in the same complexes as paxillin, however it is recruited to focal complexes and the 
more mature focal adhesions later on in the formation process (Zaidel-Bar et al., 2004).  
Paxillin has also been shown to bind to vinculin potentially providing a mechanism for the 
recruitment of vinculin to the focal complex (Turner et al., 1990), therefore a change in paxillin 
localisation would potentially be mirrored by vinculin localisation. 
Western blotting was carried out by quantifying the total protein, loading onto a gel, running 
and transferring onto nitrocellulose.  The blots were then probed for paxillin (actin as loading 
control) or vinculin (tubulin as a loading control) and developed.  No difference in protein 
expression was observed for paxillin or vinculin (Figure 3.3.7 A & B and E & F). 
Visualisation of focal adhesion number was analysed using confocal microscopy by observing 
paxillin and vinculin clusters following immunofluorescence staining.  Clusters were quantified 
by manually counting the number of clusters per cell in 20 cells of each type.  2E2 cells were 
found to have a statistically significant increase in the number of paxillin clusters when 
compared to control CHO cells, with 2E2 cells having an average of 43 +/- 12.9 clusters per cell 
and the CHO cells 8 +/- 3.8 clusters per cell (Figure 3.3.7 C & D).  A similar phenotype was 
observed for vinculin.  The number of vinculin clusters was significantly increased in the 2E2 
cells compared to the control CHO cells, with the average number of vinculin clusters per cell 
in 2E2 cells being 50 +/- 11.5 and in CHO cells 13 +/- 5.2 (Figure 3.3.7 G & H).  Both paxillin and 
vinculin clusters localised to both ends of the actin stress fibres, therefore strengthening the 
view that the stress fibres seen are ventral stress fibres, which allowed further characteristics 
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to be deduced regarding the nature and potential functions and consequences of this increase 
in ventral stress fibre number. 





































































































































Figure 3.3.7 - Reduced expression of eEF1A 
coincides with an increased number of paxillin and 
vinculin clusters that localise to the ends of the 
actin stress fibres in 2E2 cells when compared with 
control CHO cells.  Total protein was extracted from 
cells and 10μg loaded and run on gels, before 
transferring to nitrocellulose.  The blots were then probed for paxillin (actin as control) or 
vinculin (tubulin as control) followed by HRP conjugated secondary antibodies.  The blots were 
then developed using ECL (A & E).  The intensity of bands from three independent protein 
extractions were analysed by densitometry analysis using ImageJ, and the average with 
standard error of the mean plotted (B & F).  Immunofluorescence staining was carried out by 
growing cells on coated coverslips prior to fixing and staining for paxillin or vinculin (FITC 
conjugated secondary) and actin (rhodamine phalloidin). Cells were mounted and viewed 
using confocal microscopy. The white rectangles define the selected cell for the magnified 
image (C & G).  Paxillin and vinculin clusters were quantified by counting the clusters in 20 
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significance determined by unpaired T test  to a P value of * < 0.05 (D & H).  White scale bar 
equals 25µM, blue scale bar equals approximately 7.5µM.  
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3.3.8 Reduced expression of eEF1A results in no change in VASP 
localisation 
 
Vasodilator-stimulated protein (VASP) has been shown to promote the assembly of actin 
filaments by recruiting profilin, a G-actin binding protein (Reinhard et al., 1995) and is known 
to be associated with focal adhesions and stress fibres (Reinhard et al., 1992, Price and 
Brindle, 2000), likely due to its ability to bind to vinculin (Brindle et al., 1996, Reinhard et al., 
1996).  This apparent recruitment to vinculin, along with the potential of VASP to elongate 
actin fibres through profilin recruitment make it an interesting to protein to analyse to 
determine whether the reduced level of eEF1A which coincides with the actin, myosin IIA, 
paxillin and vinculin phenotypes already observed, would affect the localisation of VASP.   
Immunofluorescence staining was used to analyse any differences in localisation of VASP and 
was performed by seeding cells onto coverslips, fixing, permeabilising, blocking and staining 
for VASP, before mounting coverslips onto microscope slides and viewing by confocal 
microscopy.  After analysis of the staining images, no difference in localisation of VASP was 
observed when eEF1A protein expression level was reduced (Figure 3.3.8). 











Figure 3.3.8 - Reduced expression of eEF1A does not lead to changes in VASP localisation.  
Cells were grown on fibronectin coated coverslips prior to fixing, permeabilising, blocking and 
staining for VASP (FITC conjugated secondary). Coverslips were mounted and viewed using 
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3.3.9 Reduced expression of eEF1A does not coincide with a change in 
Arp3 protein expression or localisation 
 
The increase in stress fibres observed in the 2E2 cells are thought to be ventral stress fibres, 
and although the protein expression of actin was unchanged in 2E2 cells compared to control 
CHO cells (Figure 3.3.5) what is unknown is where the F actin for the stress fibres is originating 
from, relocalisation of F actin fibres, polymerisation of new fibres or annealing of smaller 
fibres to create the longer fibres.  The Arp2/3 complex been shown to be essential for the 
formation of transverse arcs, which have been suggested to combine with dorsal stress fibres 
to make ventral stress fibres (Hotulainen and Lappalainen, 2006), therefore observing the 
localisation of the Arp2/3 complex could help to answer the question.  The Arp2/3 complex 
has also been shown to be associated with vinculin (DeMali et al., 2002), the localisation of 
which has already been shown to be affected by the decreased eEF1A expression observed in 
the 2E2 cells compared to the control CHO cells (Figure 3.3.7). 
No difference in Arp3 protein expression, as demonstrated by densitometry analysis was 
detected between the two cell lines following separation of total proteins and Western 
blotting using an Arp3 antibody (Figure 3.3.9 A & B). 
Immunofluorescence images were created by fixing, permeabilising, blocking and staining for 
Arp3 and actin, after which coverslips were mounted onto microscope slides, and viewed 
using confocal microscopy.  No difference in Arp3 localisation was observed in the CHO and 
2E2 cells, indicating that reduced levels of eEF1A have no effect on the overall distribution of 
Arp3 (Figure 3.3.9 C).  It is however worth noting that the association of the Arp2/3 complex 
with vinculin observed by DeMali et al, 2002, was only observed in early focal complexes 
rather than mature focal adhesions, therefore association of Arp3 with vinculin may have been 
present, and as focal adhesion formation and disassembly is a dynamic, constantly changing 
process, it may be that Arp3 is associated with early focal complexes, but that these 
complexes mature too quickly to allow observation by this method.  








































































Figure 3.3.9 – Reduced expression of eEF1A results in no change in Arp3 protein expression or 
localisation in 2E2 cells compared to control CHO cells.  Cells were lysed, protein quantified, 
and 50µg total protein loaded onto a 10% acrylamide gel which was run and transferred to 
nitrocellulose.  The blot was probed for Arp3 and actin as a loading control, and developed 
using ECL (A).  Bands from three independent protein extractions were quantified by 
densitometry using ImageJ, and the average and standard error of the mean plotted (B).  Cells 
for staining  were seeded onto fibronectin coated coverslips, and grown for 48 hours, after 
which they were fixed, permeabilised, blocked and stained for Arp3 with a FITC conjugated 
secondary antibody and co-stained for actin with rhodamine phalloidin.  Coverslips were 
mounted onto microscope slides and viewed by confocal microscopy.  The white rectangles 
define the selected cell for the magnified image (C).  White scale bars equal 25µM, blue scale 
bar to 5µM and the green scale bar to 2.5µM. 
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3.3.10 Reduced expression of eEF1A does not affect beta-1 integrin 
localisation 
 
All of the above observed phenotypes focus on the actin stress fibres and their association 
with focal adhesion proteins, where an increase in actin stress fibre numbers was equally 
mirrored by an increased number of focal adhesions (Figure 3.3.7).  All focal adhesions 
connect to the extracellular matrix via integrins, therefore it was of interest to determine 
whether there was a similar change in the localisation of integrins.  The problem faced when 
analysing this subset of proteins, is the range of different isoforms. However, many studies 
have established that CHO-K1 cells endogenously express β-1 integrin subunit (Jaspers et al., 
1994, Balzac et al., 1994).  Because of the importance of the β-1 integrin subunit and its role in 
fibronectin binding (Johansson et al., 1997), an antibody specific to β-1 integrin was chosen to 
determine any differences in localisation between the CHO and 2E2 cells. 
Immunofluorescence staining was performed by fixing and staining cells for β-1 integrin and 
actin before viewing by confocal microscopy.  No change in β-1 integrin localisation was 
observed in 2E2 cells when compared to control CHO cells, suggesting that a change in eEF1A 
protein expression does not have an effect (Figure 3.3.10).  It is possible that other isoforms of 
the integrin family are affected by the change in eEF1A protein expression, however, the tools 
to observe all different isoforms were not readily available.  
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Figure 3.3.10 – Reduced expression of eEF1A does not affect the localisation of β-1 integrin in 
2E2 cells compared to control CHO cells.  Cells seeded onto fibronectin coated coverslips then 
fixed and stained for β-1 integrin with a FITC conjugated secondary antibody, and co-stained 
for actin with rhodamine phalloidin.  Coverslips were then mounted onto microscope slides 
and viewed by confocal microscopy.  The white rectangles define the selected cell for the 
magnified image.  White scale bars are equal to 25µM, the blue scale bar 5µM and the green 
scale bar approximately 7.5µM. 
Page | 136  
 
3.3.11 Reduced expression of eEF1A has no observable effect on the 
expression level nor localisation of other cytoskeletal structures  
 
Microfilaments have been shown to be affected by the reduced level of eEF1A in the 2E2 cells 
compared to the control CHO cells (Figures 3.3.5 & 3.3.6).  Given that eEF1A is capable of 
binding/bundling, severing and stabilising other cytoskeletal structures, including microtubules 
(Durso and Cyr, 1994, Moore et al., 1998, Shiina et al., 1994), it was of interest to determine 
whether our observations so far were specific to the actomyosin architecture or were part of 
more global changes in cytoskeletal protein localisation.   
Tubulin and vimentin protein expression were analysed by Western blotting by extracting the 
total protein, loading onto a gel and transferring to nitrocellulose prior to probing for tubulin 
or vimentin and developing.  In parallel immunofluorescence staining for the same proteins 
was carried out prior to viewing using confocal microscopy.  No significant difference in 
tubulin or vimentin protein expression was observed by Western blotting (Figure 3.11 A – B & 
D - E) and immunofluoresence staining showed no observable difference in tubulin or vimentin 
localisation in 2E2 cells compared to control CHO cells (Figure 3.11 C & F), confirming that the 
observed actin phenotype is not due to a global change in cytoskeletal protein, but is specific 
to actin and its associated proteins. 
Page | 137  
 
A B 



























































































































































Figure 3.3.11 – Reduced expression of eEF1A does not affect protein expression or localisation 
of tubulin or vimentin.  Western blotting was carried out by scraping cells into homogenising 
buffer, sonicating, quantifying and loading 10μg or 50μg of total protein onto a gel, which was 
run, then transferred onto nitrocellulose.  The blots were then probed for tubulin (α – adaptin 
as control) or vimentin (actin as control), and developed using ECL (A & D).  Bands from three 
independent protein extractions were quantified using densitometry analysis on ImageJ and 
the average and standard error of the mean plotted (B & E).  Immunofluorescence staining 
was performed by seeding cells onto coated coverslips after which they were fixed, 
permeabilised, blocked and stained for tubulin (FITC conjugated secondary antibody) and actin 
(rhodamine phalloidin) or vimentin (cy3 conjugated primary antibody).  Coverslips were then 
mounted and viewed using confocal microscopy by z-stack, with the presented image the 
merged view of the images from the z-stack.  The white rectangles show the areas selected for 
the magnified photographs (C & F).  White scale bars are equal to 25µM and the green scale 
bars approximately 7.5µM. 
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3.3.12 Reduced expression of eEF1A coincides with a significantly 
increased rate of cell attachment  
 
Our results have so far shown that the number of actomyosin fibres is increased in 2E2 cells 
when compared to the control CHO cells (Figures 3.3.5 and 3.3.6), and that these fibres are 
more likely to be ventral stress fibres that are complexed to the focal adhesion proteins 
paxillin and vinculin (Figure 3.3.7).  Focal adhesions allow the actin cytoskeleton to connect to 
the extracellular matrix through a link with integrins, therefore it was of interest to determine 
whether the differences reported so far would impact on the cells ability to attach and adhere 
to the substratum.   
To detect any differences in cell attachment cells were seeded into a 96 well plate and left to 
attach for 30 or 60 minutes.  Cells were then washed, and stained with crystal violet, before 
washing and solubilising prior to the optical density being measured.  A robust and significant 
increase in the number of 2E2 cells attached compared to control CHO cells was seen at both 
time points with an approximate average absorbance of 0.6 +/- 0.06 in CHO cells after 30 
minutes and 0.73 +/- 0.1 in 2E2 cells (Figure 3.3.12). 
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Figure 3.3.12 – 2E2 cells show a significant change in cell attachment when compared to 
control CHO cells.  Cells were seeded into a well of a 96 well plate for 30 or 60 minutes after 
which the media was removed, the cells gently washed with PBS, 0.5% (w/v) crystal violet in 
70% (v/v) ethanol added for 15 minutes at room temperature, before cells were washed again 
with PBS and the crystal violet solubilised with 30% (v/v) acetic acid and the absorbance at 
570nm read and recorded.  The differences observed were found to be statistically significant 
after analysis using a T test to compare CHO and 2E2 cells for each condition to a P value of 
*<0.05.   
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3.3.13 Reduced expression of eEF1A coincides with a reduction in cell 
migration 
 
Cell migration relies on attachment of the cell to the ECM followed by contraction, and 
detachment of the adhesions at the rear of the cell (Lauffenburger and Horwitz, 1996).  
Attachment of the cell relies on the formation of focal complexes which mature to focal 
adhesions, which anchor the cell to the ECM.  Contraction of the cell relies on the actomyosin 
fibres in the cell, whether cortical actin or stress fibres, with the contraction of the actomyosin 
fibres causing the detachment of the focal adhesions at the rear of the cell.  A slight increase in 
cell attachment was observed in the 2E2 cells compared to the control CHO cells (Figure 
3.3.12), therefore this slight increase in the attachment of the cell to the matrix could assist 
cell migration or hinder it.  An increased number of actomyosin fibres was also observed in 
2E2 cells compared to control CHO cells (Figures 3.3.5 and 3.3.6), which could affect the 
contractile force of the cells and therefore affect cell migration, therefore it was of interest to 
determine whether these changes would lead to a change in the motile properties of the 
different cell lines using the well defined would healing closure assay. 
Cells were seeded with or without fibronectin and grown until confluent. The monolayer was 
scratched and cell motility analysed on the Cell IQ, with images being taken at specified 
intervals (Figure 3.3.13 A & B).  Analysis of results allowed the percentage wound closure over 
time to be determined (Figure 3.3.13 C & D).   
The reduced expression of eEF1A in the 2E2 cells results in a severe decrease in migration both 
on untreated plates or in the presence of fibronectin compared to the control CHO cells.  
Fibronectin was seen to improve the overall motility of the CHO cells showing 95% closure 
after 10 +/- 2.8 hours in the presence of fibronectin whilst cells grown without coating were 
found to close the gap within 17 +/- 4.4 hours.  Under the same conditions, cells expressing 
low levels of eEF1A were found to complete their migration in 18 +/- 3.0 hours with 
fibronectin and after 34 +/- 2.7 hours in uncoated conditions (Figure 3.3.13 E).  Interestingly, 
video analysis suggested some further differences in the directionality or persistence of the 
cells, with the 2E2 cells appearing to migrate in a more random fashion than the consistent 
motility observed with the CHO cells. 













































































































Figure 3.3.13 – Reduced expression of eEF1A in 2E2 cells results in a significant reduction in 
cell migration when compared to control CHO cells.  Cells were grown until confluent on 6 well 
plates either untreated or coated with fibronectin and a scratch made through the confluent 
monolayer with a yellow pipette tip.  Cells were washed, fresh media added, and cellular 
motility and wound closure measured over time using the Cell IQ setup.  Images were taken 
approximately every 30 minutes.  Images of three different time points for each condition are 
shown (A & B), with white scale bars equal to 50µM.  Nine different points on each scratch 
were chosen on triplicate or duplicate scratches.  The average wound closure of the 9 points 
was taken for each scratch resulting in two or three curves (C & D).  The thresholds of the 
scratches were determined using the Cell IQ software, and the percentage wound closure of 
each individual scratch analysed.  All of the closures from each individual scratch were 
combined and the percentage closure over time plotted (C & D).  The average time taken for 
each scratch to reach 95% closure was then recorded and plotted, along with the standard 
error of the mean (E & F).  The results were found to be statistically significant to a P value of 
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3.3.14 Migrating CHO cells show an increased number of actomyosin 
stress fibres  
 
The reduced expression of eEF1A in the 2E2 cells compared to the control CHO cells resulted in 
a robust decrease in the closure of the wound and consequently a suggestion that these cells 
had a reduced speed of motility with a more random directionality of migration (Figure 
3.3.13).  Ventral actin stress fibres in migrating cells have been shown to orient perpendicular 
to the direction of motion, and have been suggested to have an effect on directionality of 
migration by detaching from the adhesions at the rear of the cell, and reattaching to 
adhesions at the front of the cell, with the new direction of movement perpendicular to that 
of the stress fibre that formed (Rid et al., 2005). Based on the increased number of actomyosin 
stress fibres in the 2E2 cells with the reduced level of eEF1A protein expression (Figures 3.3.5 
and 3.3.6) we sought to determine if we could monitor changes in the number and/or 
orientation of actomyosin stress fibres in migrating cells.  Observing localisation of myosin IIA 
to any stress fibres present would also enable the characteristics of the stress fibres to be 
determined, as myosin IIA creates the contractile force for the stress fibre to pull the cell 
along. 
To assess this, cells were seeded onto fibronectin coated coverslips and grown to confluency 
prior to scratching through the monolayer.  The cells were left to migrate for around 6 hours, 
prior to fixing, permeabilising and staining for actin and eEF1A or myosin IIA before viewing 
using confocal microscopy.   
Stationary CHO cells showed a very limited number of actin stress fibres, presenting an 
average of only 1 +/- 1.1 per cell (as described previously (Figure 3.3.5), whereas migrating 
CHO cells, at the edge of the wound demonstrated a statistically significant increase in actin 
stress fibres in comparison, with an average of 5 +/- 2.6 fibres per cell. Interestingly, migrating 
CHO cells still demonstrated fewer actin stress fibres than both stationary 2E2 cells and 
migrating 2E2 cells which were both found to have an average of 12 +/- 3.0 fibres per cell.  The 
difference in actin stress fibre number between the migrating and stationary CHO cells was 
statistically significant, as well as the difference between the stationary and migrating CHO 
cells and their 2E2 counterparts.  No difference in actin stress fibre number was observed 
between migrating and stationary 2E2 cells.  It was also observed that whereas stress fibres in 
the migrating CHO cells seemed to be perpendicular to the direction of the scratch, the stress 
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fibres in the 2E2 cells showed a less organised orientation in comparison, with a lot of fibres 
oriented parallel to the direction of the scratch (Figure 3.3.14 A & B). 
Myosin IIA was shown to localise to the actin stress fibres observed in the 2E2 cells (Figure 
3.3.6) therefore the localisation of myosin IIA to the newly formed stress fibres in the 
migrating CHO cells was unsurprising (Figure 3.3.14 C).  Migrating CHO cells were found to 
have an average of 6 +/- 2.6 myosin IIA fibres per cell, and stationary CHO cells 1 +/- 1.1 with 
both stationary and migrating 2E2 cells having an average of 12 +/- 2.8 and 12 +/- 3.2 fibres 
per cell repectively (Figure 3.3.14 D).  The orientation of the myosin IIA fibres appeared to be 
different between the CHO and 2E2 cells that were at the migratory front, with more of the 
myosin IIA fibres arranged so that they were perpendicular to the direction of motion 
compared to 2E2 cells, with the myosin IIA fibres in 2E2 cells appearing more randomly 
orientated.  
























































































































































Figure 3.3.14 – Induced motility leads to a greater 
number of actomyosin stress fibres in CHO cells, 
but not in 2E2 cells.  Cells were grown to 
confluence on a fibronectin coated coverslip, and 
a scratch made through the confluent monolayer.  
Once cells were migrating, they were fixed, 
permeabilised, blocked and stained for actin 
(rhodamine phalloidin) and eEF1A (FITC 
conjugated secondary antibody; A) or myosin IIA (FITC conjugated secondary antibody; C) and 
actin (rhodamine phalloidin).  Coverslips were then mounted onto microscope slides and 
viewed using confocal microscopy (A & C).  Actin and myosin IIA fibres were quantified by 
counting the number of fibres that crossed over the cell in 20 cells for each cell type, both at 
the migrational front and behind.  The average number of fibres with the standard error of the 
mean was plotted and statistical analysis performed using GraphPad Prism, using the 1 way 
D 
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ANOVA with Tukeys post test and results were significant to a P value of *<0.05 (B & D).  White 
error bars are equal to 25µM.  Blue error bars are equal to approximately 7.5µM. 
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3.3.15 Paxillin and vinculin localise to the ends of actin stress fibres in 
stationary and migrating cells 
 
The increase in actomyosin stress fibres in migrating CHO cells compared to stationary CHO 
cells (Figure 3.3.14) indicated that this increase would provide the optimal condition for 
migration, however, in order for actin stress fibres to affect the motility of the cell, the fibres 
have to connect to the ECM. We sought to determine whether changes in the organisation 
and localisation of focal adhesion proteins would be observed following induced motility using 
the same type of experiments.  
Observation of paxillin clusters during migration was carried out by growing the cells to 
confluence on a fibronectin coated coverslip, scratching and allowing them to migrate for 
approximately 6 hours into the newly created space prior to fixing, permeabilisation and 
staining  for paxillin or vinculin and actin before viewing using confocal microscopy.  Paxillin 
and vinculin clusters were observed again localised to the ends of the stress fibres in both CHO 
and 2E2 cells (Figure 3.3.15) as previously demonstrated (Figure 3.3.7).  When cells were 
confluent, it could not be determined which cell the clusters at the periphery belonged too, 
therefore quantification of the clusters was not possible.   
 
 














































Figure 3.3.15 - Migrating CHO and 2E2 cells show paxillin and vinculin clusters localised to the 
ends of the observed actin stress fibres.  Cells were grown to confluence on a fibronectin 
coated coverslip, and a scratch made through the confluent monolayer using a yellow pipette 
tip.  Once cells were migrating, they were fixed, permeabilised, blocked and stained for paxillin 
or vinculin (FITC conjugated secondary antibody) and actin (rhodamine phalloidin).  Coverslips 
were then mounted onto microscope slides and viewed using confocal microscopy (A & B).  
White error bars are equal to 25µM.  Blue error bars are equal to approximately 7.5µM. 
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3.3.16 Arp3 localisation is not affected in cells with normal or reduced 
level of eEF1A protein during migration 
 
No difference was detected in either protein expression or localisation of Arp3 when eEF1A 
protein level is reduced in 2E2 cells compared to CHO cells (Figure 3.3.9).  An increase in the 
number of ventral actin stress fibres has been shown in 2E2 cells compared to CHO cells 
(Figure 3.3.5) as well as in migrating CHO cells compared to stationary CHO cells (Figure 
3.3.14).  Arp3 has been shown to be essential for formation of transverse arcs, which have 
been shown to connect with dorsal stress fibres to form ventral stress fibres (Hotulainen and 
Lappalainen, 2006), as well as being associated with focal adhesions, especially new focal 
adhesions (DeMali et al., 2002), therefore it was of interest to determine whether there was 
any localisation of Arp3 to the new stress fibres observed in the migrating CHO cells compared 
to the stationary CHO cells.  The Arp2/3 complex has also been shown to be critical for the 
formation of lamellipodia, the sheet like protrusions that support cell migration and have been 
shown to be important for directional migration as well as being the site of formation of focal 
adhesions (Wu et al., 2012), therefore based on the change in cell motility of the 2E2 cells 
when compared to the control CHO cells, observing the localisation of Arp3 during cell 
migration was of interest. 
Following confluent growth on a fibronectin coated coverslip, a scratch was made through the 
monolayer and the cells were left to migrate for approximately 6 hours before fixation, 
permeabilisation and staining for Arp3 and actin.  The coverslips were then mounted onto 
microscope slides and viewed by confocal microscopy.  No difference in Arp3 localisation was 
observed between migrating and stationary CHO cells, or between the CHO and 2E2 cells 
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Figure 3.3.16 – Reduced expression of eEF1A results in no change in Arp3 localisation in 
migrating or stationary cells.  Cells were seeded on to fibronectin coated coverslips, and grown 
to confluence.  A yellow pipette tip was used to make a scratch through the confluent 
monolayer, and the cells left to start migrating.  The cells were then fixed, permeabilised, 
blocked and stained for Arp3 with a FITC conjugated secondary antibody, and actin with 
rhodamine phalloidin.  The coverslips were then mounted onto microscope slides, and viewed 
using confocal microscopy.  The white rectangles show the areas selected for the magnified 
images.  White error bars are equal to 25µM.  Blue error bars are equal to approximately 
7.5µM. 
Page | 154  
 
3.3.17 Beta-1 integrin localisation is not affected in cells with normal 
or reduced level of eEF1A protein during migration 
 
The localisation of β-1 integrin was unaffected by the change in protein expression of eEF1A in 
the 2E2 cells compared to the control CHO cells (Figure 3.3.10).  Integrins play an integral role 
in cell migration, and as it has been shown that there was an increase in actin stress fibres, and 
their associated focal adhesion proteins in migrating CHO cells compared to stationary CHO 
cells, it was of interest to determine whether there was any difference in localisation of β-1 
integrin in migrating CHO cells compared to migrating 2E2 cells. 
The cells were grown to confluence on a fibronectin coated coverslip, a scratch made through 
the monolayer, and the cells left for approximately 6 hours to start migrating, after which they 
were fixed and stained for β-1 integrin and actin.  The coverslips were then mounted onto 
microscope slides and viewed by confocal microscopy.  No difference in β-1 integrin was 
observed between CHO and 2E2 cells, or between migrating or stationary cells (Figure 3.3.17). 
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Figure 3.3.17 – Reduced expression of eEF1A does not affect β-integrin localisation in 
migrating or stationary cells.  Cells were seeded onto fibronectin coated coverslips and grown 
to confluence.  A yellow pipette tip was used to make a scratch through the confluent 
monolayer, and the cells left to migrate.  Once migrating the cells were fixed and stained for β-
1 integrin, with a FITC conjugated secondary antibody, and co-stained for actin with 
rhodamine phalloidin.  The coverslips were then mounted onto microscope slides and viewed 
using confocal microscopy.  The white rectangles show the areas selected for the magnified 
images.  White error bars are equal to 25µM.  Blue error bars are equal to approximately 
7.5µM. 
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3.3.18 The ratio of G-actin to F-actin is increased in 2E2 cells compared 
to control CHO cells 
 
The reduced expression of eEF1A results in an increase in the number of ventral stress fibres, 
without revealing significant changes in the overall levels of actin protein expression (Figure 
3.3.5).  Our data however suggests potential differences in the level of polymerised actin 
filaments between the CHO and 2E2 cells lines, an important criterion that cannot be assessed 
when performing Western blotting on whole cell lysates.  It was of interest to determine 
whether the reduction in eEF1A level would correlate with differences in the levels of G- and 
F- actin and their overall ratio.  
Cells were scraped and the lysate homogenised before centrifugation to separate the different 
pools of G and F-actin.  Both the pellet and supernatant were collected, corresponding to the 
F- and G- actin respectively in cells at the time of isolation and the ratio of actin determined by 
Western blotting of the samples, followed by quantification using ImageJ.  
In order to determine that the centrifugation was sufficient to separate the F actin and G actin, 
an inhibitor was used to increase the amount of F actin, therefore when the inhibitor was 
used, the amount of F actin should increase and G actin should decrease.  It can be seen that 
when the inhibitor is used, the level of F actin becomes greater than the level of F actin, 
however when no inhibitor is used, the level of G actin is higher as would be expected in 
normal samples.  Interestingly the ratio of F-actin to G-actin was found to be statistically 
increased in the 2E2 cells when compared to the control CHO cells from 1 : 0.47 +/- 0.09 to 1 : 
0.67 +/- 0.04  indicating that there is an increase in the amount of F-actin in the 2E2 cells when 
compared to the CHO cells (Figure 3.3.18). 















Figure 3.3.18 – 2E2 cells have a higher ratio of F-actin to G-actin when compared to control 
CHO cells.  Cells were scraped into buffer, homogenised and centrifuged at 100,000 xg for 1 
hour.  The supernatants and pellets were collected and Western blotting performed by loading 
10µl of each sample onto a 10% (v/v) acrylamide gel before running and transferring to 
nitrocellulose.  The blots were probed for actin followed by detection with ECL (A).  Duplicate 
bands were quantified using ImageJ, the average and standard error of the mean plotted, and 
ratios determined by normalising F-actin protein expression to G-actin.  Ratios are included as 
numerical values on the graph for ease of viewing (B).  Statistical analysis was done by T test 
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3.3.19 2E2 cells show reduced localisation of eEF1A with the 
cytoskeleton when compared to control CHO cells 
 
It has so far been demonstrated that the 2E2 cells show an increased number of ventral stress 
fibres compared to the control CHO cells (Figure 3.3.5 & 6), and that this change is due to an 
increase in the amount of F-actin compared to G-actin rather than relocalisation of the F-actin 
already present (Figure 3.3.18) suggesting that the decrease in eEF1A affects the 
polymerisation of G-actin to F-actin, whether directly or indirectly, and the newly formed F-
actin is then organised into the observed stress fibres by an actin binding protein.  eEF1A is a 
known actin binding protein (Demma et al., 1990, Yang et al., 1990), therefore suggesting that 
reducing its level would equally lead to a decrease in actin bundling, an observation that is not 
seen given the high numbers of stress fibres seen in the 2E2 cells (Figure 3.3.5).  Importantly, 
eEF1A has been shown to bundle actin fibres into square packed bundles in a way that has 
been suggested to exclude other actin binding proteins (Owen et al., 1992).  We hypothesise 
that, at physiological levels, when present at abundant levels, eEF1A prevents other actin 
binding proteins from forming actin stress fibres. By contrast, reducing the level of eEF1A 
protein expression creates the opportunity for other actin binding proteins to bind and bundle 
actin.  For this reason we sought to analyse the localisation of eEF1A with the actin stress 
fibres, or the cortical actin surrounding the cell, using immunofluorescence staining, ELISA and 
Western blotting on triton washed cells, therefore removing the majority of cytosolic proteins, 
leaving only the triton insoluble cytoskeleton and proteins associated with the cytoskeleton 
behind (Kobayashia et al., 1982). 
Immunofluorescence staining was carried out by seeding cells onto fibronectin coated 
coverslips before fixing, permeabilising with a high concentration of triton for two minutes 
before blocking and staining for eEF1A and viewing using confocal microscopy. 
The ELISA was carried out by growing, fixing, and permeabilising cells with different 
concentrations of triton, and then blocking before probing for eEF1A, and developing using 
OPD as per manufacturer’s instructions.   
Western blotting with triton treatment was carried out by growing cells before washing, 
adding triton, washing, homogenising and loading total protein onto a gel.  The gel was run, 
transferred to nitrocellulose, probed for eEF1A and actin and developed.  Quantification of 
bands was performed by densitometry analysis using ImageJ.   
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Following immunofluorescence staining, actin fibres in both cell lines were magnified, to 
observe any localisation of eEF1A to the fibre, however no localisation was observed in either 
cell line to actin fibres around the outside of the cell or to the actin stress fibres across the cell 
(Figure 3.3.19 A). 
ELISA quantification, following gentle cell permeabilisation, demonstrated a significant 
reduction in the level of eEF1A in 2E2 cells at 52% of the expression of CHO cells when 
normalised to tubulin expression (Figure 3.3.19 B), supporting the data collected during 
Western blotting, and further highlighting the suitability of this method for quantification of 
eEF1A levels.  When a high concentration of triton was added to remove the majority of 
cytosolic eEF1A the 2E2 cells showed only 73% of the eEF1A protein levels when compared to 
CHO cells (Figure 3.3.19 B).  If the level of eEF1A association with the cytoskeleton was the 
same in both cell lines, the percentage expression value for 2E2 cells should be 100%, 
therefore a value of 73% suggests that less eEF1A is associated with the cytoskeleton in 2E2 
cells when compared to control CHO cells. 
Protein was extracted from CHO and 2E2 cells without triton treatment, which showed a 40% 
decrease in eEF1A expression in 2E2 cells compared to CHO cells which correlates to the same 
observed difference in expression shown in figure 3.3.1, however, after treatment with triton, 
and after normalising eEF1A expression to actin, the treated 2E2 cells were shown to have a 
decreased proportion of eEF1A protein compared to the treated CHO cells, around 85% in 
comparison to 100% in control CHO cells, indicating that less eEF1A protein is associated with 
the cytoskeleton in 2E2 cells when compared to the control CHO cells (Figure 3.3.19 C & D).   
 











10µM 10µM 10µM 2.5µM 2.5µM 2.5µM 
7.5µM 7.5µM 7.5µM   5µM   5µM   5µM 













Figure 3.3.19 – No localisation of eEF1A to actin fibres can be observed through 
immunofluorescence staining, however, less eEF1A is associated with the cytoskeleton in 2E2 
cells when compared to control CHO cells as analysed by ELISA and Western blotting.  Cells 
were fixed then permeabilised with 10% triton (v/v) for 2 minutes before blocking and staining 
for eEF1A (FITC conjugated secondary antibody) and actin (rhodamine phalloidin).  Coverslips 
were mounted onto microscope slides and viewed using confocal microscopy.  Actin fibres in 
individual cells were zoomed into to attempt to visualise localisation (A).  For the ELISA, 2,500 
or 5,000 cells were seeded into a 96 well plate and grown for two days before fixing, 
permeabilising with 0.1% (v/v) or 5% (v/v) triton, and blocking.  Cells were then probed for 
eEF1A and tubulin with a HRP conjugated secondary antibody, and the ELISA developed using 
OPD as per the manufacturer’s instructions.  Results for 2,500 and 5,000 cells were combined 
to create an average reading, and percentage expression of eEF1A to control CHO cells 
presented after normalisation to the tubulin control (B).  For Western blotting, cells were 
grown to confluence, before media was washed off, 10% (v/v) triton incubated for 1 minute at 
room temperature, after which cells were again washed, homogenised and total protein 
quantified.  Protein was loaded onto a gel, the gel run and transferred onto nitrocellulose 
before being probed for eEF1A and actin (C).  Blots were then developed and the bands 
quantified by densitometry analysis performed using ImageJ (D). 
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3.4 Discussion  
 
Previous studies on eEF1A have focused on determining how the cell is affected by 
overexpression of eEF1A (Munshi et al., 2000, Gross and Kinzy, 2005), as overexpression of 
eEF1A can lead to several different types of cancer.  However, in order to establish the normal 
functions of eEF1A it is also important to determine the effect of reduced expression of eEF1A 
in cell systems.  The canonical function of eEF1A is in the elongation stage of protein 
translation, however, another important function of eEF1A is actin binding and bundling 
(Dharmawardhane et al., 1991).  Studies, at least in yeast,  have so far suggested that these 
two functions are independent of each other, as work by Gross and Kinzy, 2005 & 2007, 
showed expression of mutated forms of eEF1A that affected actin binding/bundling without 
affecting protein translation, at least at the elongation step (Gross and Kinzy, 2005, Gross and 
Kinzy, 2007).  Determining whether these functions are independent in mammalian cells is 
important to further understand the mechanism by which eEF1A can carry out its multiple 
functions. 
CHO-K1 cells with a reduced expression of eEF1A were created by Borradaile et al, 2005, in 
their pursuit to determine factors affecting resistance to lipotoxic cell death through the 
random integration of a retroviral promoter trap in the eEF1A gene (Borradaile et al., 2005).  
The target of the random retroviral insertion was determined using 5’ RACE (rapid 
amplification of cDNA ends), with BLAST comparison to which it was found to align with part of 
the 5’ untranslated region of hamster eEF1A1.  This was confirmed using PCR with primers 
specific to both eEF1A1 and eEF1A2, establishing that eEF1A1 was the only isoform affected, 
and that eEF1A1 expression was completely abolished.  When protein levels were analysed, an 
eEF1A antibody was used that recognised both isoforms, therefore it was assumed that based 
on the previous data eEF1A1 expression was completely removed, and the remaining band 
was due to expression of eEF1A2.  CHO-K1 cells are known to be functionally hemizygous at 
many different loci (Borradaile et al., 2005), therefore it is possible that by targeting one gene, 
the expression of that gene could be abolished and the likelihood of more than one retrovirus 
infecting the same cell and therefore affecting two different genes would be highly unlikely, as 
they used a low multiplicity of infection such that there was only one integration per every 10 
genomes.  Unfortunately no data could be found about whether CHO-K1 cells are hemizygous 
at the eEF1A1 or eEF1A2 locations. 
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Importantly, analysis of total protein translation by methionine incorporation in this system 
showed that there was no change in total protein synthesis between the two different cells 
(Borradaile et al., 2005).  This therefore provided a tool in which the level of eEF1A had been 
greatly reduced with no global change in the level of protein translation, suggesting that the 
remaining eEF1A protein in these cells was sufficient to satisfactorily complete its translational 
role.  We set about to determine if these cells presented differences in cellular behaviours and 
characteristics where eEF1A has been highlighted as a major regulator.  
Initially it was important to clearly establish the level of reduction of eEF1A protein and also to 
decipher which isoforms of the factor were actually expressed.  Western blotting was 
performed on the two cell lines with the same antibody used by Borradaile et al, 2005, 
confirming the low expression of the eEF1A protein.  The reduction in eEF1A protein 
expression was however found to be less severe in our analysis, with a decrease of around 
40% (Figure 3.3.1 A & B). 
Antibodies specific to human eEF1A1 and eEF1A2 were purchased to determine the true 
changes in the protein expression of the two isoforms.  A reduction in eEF1A2 expression 
could be seen whilst no detection was observed in either cell lines, including other controls 
when probing for eEF1A1 proteins (Figure 3.3.1 C & D). 
These results alone would suggest that the expression of eEF1A2 has been affected by the 
retroviral insertion, however, the specificity of the antibody used was only determined in 
human cells, and the specific epitope recognised is unknown, therefore it is possible that the 
antibody is recognising both isoforms of eEF1A in the hamster cells used.  Based on the 
different gene disruption it is also unlikely that induced mutation can affect more than one 
gene, and furthermore it is highly unlikely that both eEF1A1 and eEF1A2 would randomly be 
affected especially as the two isoforms are found on different chromosomes with eEF1A1 
found on chromosome 6q14 and eEF1A2 found on chromosome 20q13.3 (Lund et al., 1996). It 
is at this stage difficult to explain how the different levels of eEF1A have been affected, since 
CHO-K1 cells are hemizygous at many loci (Borradaile et al., 2005), however it seems sensible 
to suggest that these cells may have two copies of the eEF1A1 gene.  This would explain the 
40% reduction in eEF1A protein expression as the retroviral insert would only affect one of the 
copies and therefore result in half of the normal expression.  Throughout this work it was 
assumed based on the argument put forth before that eEF1A1 protein expression was 
reduced. 
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Although global protein synthesis had been shown not to be significantly affected by the 
reduction in eEF1A protein, it was unclear whether such a decrease was mirrored by more 
subtle changes in elongation, where eEF1A plays essential roles. To directly assess this, 
polysome profiling for the two cell lines was performed, allowing for a detailed and specific 
analysis of each stage of translation through changes in the polysome to monosome ratio. If 
an elongation block was to be observed, the polysome peaks would increase and the 
monosome peaks would decrease leading to an increased polysome ratio in the absence of 
cycloheximide.  When the CHO and 2E2 cells were analysed in this context, the polysome 
profiles were found to be very similar with the polysome to monosome ratios of 1.25 and 1.34 
respectively, suggesting that the reduced expression of eEF1A in the 2E2 cells does not affect 
the overall rate of protein synthesis elongation (Figure 3.3.2), confirming the results from 
Borradaile et al, 2005. Furthermore data collected throughout this chapter also clearly suggest 
that overall levels of protein expression is rarely affected, as a large panel of proteins, known 
as regular housekeeping genes (actin, tubulin and others) were always found at similar levels 
in the two cell lines (Figures 3.3.5-3.3.7, 3.3.9 & 3.3.11).   
The concept that loss of such a high proportion of eEF1A does not lead to direct overall 
protein synthesis should not be surprising since the amount of eEF1A is in 17-35 fold molar 
excess to other components of the translational machinery (Slobin, 1980). This finding 
supports the theory that there is a large excess ofeEF1A protein in cells and suggests their use 
for other different but conserved cellular functions.  
One of the best characterised secondary functions for eEF1A is its ability to bind and bundle 
actin in vitro (Demma et al., 1990, Yang et al., 1990), as well as its vital role in actin 
remodelling in yeast (Munshi et al., 2000).  We were therefore interested to determine if any 
cytoskeletal changes in the mammalian CHO cell system could be observed given the large 
reduction in eEF1A protein expression. 
Whilst low levels of eEF1A did not lead to significant changes in overall actin protein levels, 
they resulted in a significantly increased number of actin stress fibres as observed using 
confocal microscopy (Figure 3.3.5), therefore indicating that the difference observed relates to 
a regulatory process rather than more global changes in translation of actin.  Myosin IIA was 
found to be localised to the actin stress fibres and its striations were significantly increased in 
the 2E2 cells compared to the control CHO cells, though no difference in myosin IIA protein 
expression was observed (Figure 3.3.6).  Staining for both paxillin and vinculin (Figure 3.3.7), in 
CHO and 2E2 cells showed an increase in the number of clusters when eEF1A level was 
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decreased, correlating with the increase in the number of actin stress fibres.  It was observed 
that the clusters were found at both ends of the actin stress fibres, which along with the 
localisation of myosin IIA within, further suggested that they were ventral stress fibres, as only 
this category of fibres attach to the extracellular matrix via focal adhesion proteins (Tojkander 
et al., 2012).   
This increase in ventral actin stress fibres in the 2E2 cells poses the questions of 1) how are the 
fibres organised into stress fibres? and 2) where do the actin filaments come from?   In fact, 
very little is known about the specific proteins that are involved in inducing stress fibre 
formation, however, Rho A is known to be involved in the signalling pathway, usually through 
the activation of ROCK which can increase the activity of myosin to potentially recruit actin 
fibres (Naumanen et al., 2007, Verkhovsky et al., 1995).  Rho A has also been shown to 
activate formins, which can induce actin assembly, therefore increasing the number of fibres 
to be bundled.   
Though eEF1A has been linked to actin binding and bundling, no studies have linked eEF1A 
with stress fibre formation, although a large proportion of eEF1A in cells have been shown to 
be associated with the actin cytoskeleton (Edmonds et al., 1995).  Given that  previous studies 
have shown, not only that can eEF1A bind and bundle actin fibres, but that this bundling 
results in the exclusion of other actin binding proteins, in particular orthogonal ABPs, (Owen et 
al., 1992), a reduced level of eEF1A could result in more eEF1A free actin filaments  therefore 
giving the opportunity for other actin binding proteins to replace eEF1A, resulting in stress 
fibre formation. 
α-actinin is an orthogonal cross-linking ABP that binds to the side of the actin filaments and 
has been shown to associate with transverse arcs, dorsal and ventral stress fibres.  When 
eEF1A is abundantly present, it is possible to suggest that  the binding of eEF1A to the side of 
the actin filament could be sufficient to compete with the binding of α-actinin (Owen et al., 
1992) to the same filament, therefore preventing the bundling of filaments into stress fibres.  
α-actinin is known to be associated with stress fibre formation, in particular with its known 
alternating pattern with myosin IIA (Pellegrin and Mellor, 2007), it therefore presents a 
potential candidate which, when allowed to bind to the filaments in the absence of eEF1A in 
the 2E2 cells, could be involved in the formation of the ventral stress fibres observed.  
Similarly, tropomyosin is another side filament ABP which stabilises actin filaments which 
could be provided with the opportunity to bind when eEF1A is no longer present in 
abundance.  eEF1A and α-actinin offer similar binding affinity, between 0.1-10µM (Pollard et 
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al., 2007) and  1-5µM (Pollard et al., 2007) respectively, and given the large difference in 
protein levels between the two, it is possible to hypothesise that the binding of eEF1A to actin 
would exclude the binding of α-actinin.  This competitive binding of ABPs is not a new concept, 
it has been known for decades that actin binding proteins can compete for the same site of on 
the actin fibre, for example, α-actinin and tropomyosin are known to compete for the same 
binding site, and since this discovery many other actin binding protein have also been shown 
to compete, such as tropomyosin and cofilin (Drabikowski and Nowak, 1968, Remedios et al., 
2002),  
Since myosin IIA has also been shown to induce formation of actin bundles as well as 
influencing the alignment of actin and myosin filaments (Verkhovsky et al., 1995), it is possible 
that its presence in these stress fibres may not only help to characterise the fibres but may 
also influence their formation, as with reduced expression of eEF1A, more actin fibres would 
be free to be assembled into the observed stress fibres, potentially allowing the myosin IIA to 
induce formation of the actin bundles (Verkhovsky et al., 1995), possibly alongside the other 
actin binding proteins mentioned before.   
To support our hypothesis that the reduced level of eEF1A leads to more availability for other 
actin binding proteins to bundle actin into the observed stress fibres, it was of interest to first 
determine if indeed eEF1A would be found to be less associated with the cytoskeleton in the 
2E2 cells compared to the control CHO cells.  Localisation of eEF1A with the actin cytoskeleton 
was first performed using immunofluorescence as performed by others (Edmonds et al., 
1995).  No localisation of eEF1A could be detected either with the cortical actin present mostly 
in the control CHO cells or with the actin stress fibres present in the 2E2 cells (Figure 3.3.19 A).  
This could be due to the diffuse nature of the eEF1A protein as well as its interactions with 
other cytoskeletal proteins such as microtubules.  It is possible that any localisation of eEF1A 
to actin could be masked by this level of diffusion of the eEF1A protein, and therefore more 
specific, quantifiable methods were carried out. 
The total amount of eEF1A associated with the cytoskeleton was also quantified by both a 
modified ELISA, as well as Western blotting.  Cytosolic eEF1A was removed by treatment with 
triton, which has been shown to remove cytosolic proteins leaving behind the triton-insoluble 
material which is primarily made of cytoskeletal structures (Kobayashia et al., 1982).  The 
amount of eEF1A was therefore quantified and validated to the amount present in both cell 
lines before removal of cytosolic eEF1A.  It was found that less eEF1A was associated with the 
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actin cytoskeleton in the 2E2 cells when compared to the control CHO cells by both ELISA 
(Figure 3.3.19 B) and Western blotting after normalisation to the amount of actin present 
(Figure 3.3.19 C).  This suggests that less eEF1A is indeed found in the triton insoluble material, 
possibly indicating that less may be bound to the actin fibres or actin bundles in the 2E2 cells 
when compared to the control CHO cells which provides further evidence to suggest the 
molecular mechanisms that may be put in place to promote the formation of the ventral actin 
stress fibres observed in the 2E2 cells.    
As well as the question of which actin binding proteins are responsible for this increase in actin 
stress fibres, there is also a question as to where the stress fibres originate from.  Current 
thinking suggests that they are formed due to 1) increased polymerisation of free G actin into 
F actin, 2) relocalisation of F actin stress fibres already formed from the cortical actin ring, 3) 
annealing of smaller F actin fibres into longer fibres or 4) a combination of relocalisation, 
polymerisation and/or annealing.  Consequently, it is possible that in CHO cells, the fibres 
could be the result of increased polymerisation of F actin fibres from G actin.  Though the level 
of actin protein expression was found to be unchanged between the two cell lines, the actin 
antibody used for Western blotting does not differentiate between the two forms of actin, 
therefore changes in the levels of G and F actin cannot be determined using this antibody.  
An assay was therefore used in order to establish any differences in the actin pools in the 
different CHO cells.  It was found that there was an increased ratio of G actin to F actin in 2E2 
cells suggesting that there is an increase in polymerised actin molecules in the absence of 
eEF1A.  This would rule out the appearance of the stress fibres as a relocalisation of current F 
actin fibres from the cortical actin ring, as well as the merging of smaller F actin fibres, 
suggesting that the stress fibres are formed by an increase in actin polymerisation of G actin to 
F actin.  This is unsurprising as bundling of eEF1A has been shown to inhibit polymerisation of 
actin (Murray et al., 1996), therefore it is possible that the removal of eEF1A from actin would 
result in fewer eEF1A associated actin bundles and would therefore also remove this inhibitory 
effect of eEF1A allowing polymerisation of actin to occur. This was further supported by our 
work using Triton permeabilisation which equally demonstrated a reduction in eEF1A 
associated with the insoluble material (Figure 3.3.19).  Such data further supports the 
hypothesis that the removal of the ‘pool’ of eEF1A for actin binding and bundling can provide 
the opportunity for the other actin binding protein mentioned previously to bind and bundle 
actin fibres that are now more abundant due to the lack of inhibition of actin polymerisation 
by eEF1A (Murray et al., 1996).   
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The Arp2/3 complex and VASP, are both ABPs that bind to the actin filament in different ways 
but can both affect actin polymerisation.  The Arp2/3 complex is involved in both nucleation, 
as well as capping of actin filaments (Cooper and Schafer, 2000, Winder and Ayscough, 2005), 
therefore has an important role in regulating the polymerisation of actin filaments.  It has also 
been shown to be involved in the formation of transverse arcs which can merge with two 
dorsal stress fibres to form a ventral stress fibre (Hotulainen and Lappalainen, 2006).  It is 
therefore possible that Arp2/3 could be involved in the formation of the ventral stress fibres 
that are formed when eEF1A protein level is reduced.  VASP has been shown to have a role as 
an anti capping protein by antagonising capping proteins at the barbed end of the actin 
filament (Krause, 2002), and has been shown to be involved in the formation of actin stress 
fibres in endothelial cells (Price and Brindle, 2000), therefore observing VASP localisation to 
the newly formed stress fibres was also of interest to determine whether VASP could play a 
role in the formation of the newly formed actin stress fibres.  Both Arp2/3 and VASP have also 
been shown to bind to vinculin (Brindle et al., 1996, DeMali et al., 2002), which as vinculin has 
been shown to localise to both ends of the new actin stress fibres (Figure 3.3.7), provides 
further reason for these two proteins to potentially be affected in the new cell system. 
Western blotting and immunofluorescence staining was carried out to determine if there was 
any difference in expression or localisation of VASP or Arp3 between the two cells lines, 
however no difference was detected for the former (Figures 3.3.8 and 3.3.9).  The expression 
VASP was not determined, as the antibody used was apparently unsuitable for Western 
blotting, however the expression of Arp3 was unaffected by the reduced expression of eEF1A 
in the 2E2 cells compared to the control CHO cells.  Based on the previous findings that actin, 
myosin IIA, paxillin and vinculin were found to have the same protein expression in both cell 
lines this result was unsurprising.  The localisation of VASP was found to be rather diffuse 
throughout the cytosol, therefore it was impossible to determine any localisation to the fibres, 
for this reason it is difficult to say with any certainty whether VASP is involved in the formation 
of these stress fibres (Figure 3.3.8).  The localisation of Arp3 showed no difference between 
the two cell lines, however, as with VASP no specific localisation could be observed within the 
cell (Figure 3.3.9).  As the localisation of VASP or Arp3 to stress fibres could not be observed 
using this method, further studies on interactions between both VASP and Arp3 would be of 
interest to analyse any differences between the two cell lines in order to determine whether 
they play a part in the increased polymerisation of actin in the 2E2 cells, and whether eEF1A 
could play an inhibitory role in their activation. 
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Focal adhesions are connected to the ECM by integrin clusters, therefore for the increase in 
focal adhesions observed in the 2E2 cells compared to the control CHO cells to have an effect 
on cell adhesion or migration, a change in integrin localisation would be expected to enable 
the focal adhesions to contact the ECM in order to function.  CHO cells are known to express 
β-1 integrin (Balzac et al., 1994, Jaspers et al., 1994), therefore β-1 integrin protein expression 
and localisation was observed.  Localisation of β-1 integrin was found to be unaffected in 
either the 2E2 or counterpart control (Figure 3.3.10), however this does not mean that there is 
no change in other integrin types.   
Whilst our data unequivocally demonstrated changes in the number of actomyosin fibres, 
perhaps coincidently, when eEF1A levels are regulated, it was unclear if remodelling of other 
cytoskeletal structures could be taking place. Indeed eEF1A has been shown to affect the 
binding and bundling of microtubules, as well as affecting their stabilization and severing 
(Moore and Cyr, 2000, Moore et al., 1998, Shiina et al., 1994).  In our cell system, the reduced 
expression of eEF1A observed in the 2E2 cells resulted in no observable difference in either 
localisation or protein expression of tubulin or vimentin (Figure 3.3.11).  These negative results 
further suggest that the difference in actin and myosin IIA localisation observed in the 2E2 
cells are indeed specific to the loss of function of eEF1A and not due to a general collapse of 
cell integrity. 
 All of the cytoskeletal changes observed so far in the 2E2 cells show specific alteration of 
organisational morphology but do not provide any biological consequences of these changes.  
Ventral stress fibres are considered to be contractile structures under normal physiological 
conditions (Pellegrin and Mellor, 2007).  The localisation of myosin IIA gives the fibres the 
ability to contract, therefore giving the cell the ability to move (Weber and Groeschel-Stewart, 
1974, Tojkander et al., 2011).  Ventral stress fibres have also been shown to be important in 
the retraction of the tail end of the cell, as well as potentially affecting the persistence of the 
cell by relocating to the front of the cell after detachment at the back (Rid et al., 2005).  This 
increase in ventral stress fibres could therefore have a significant impact upon both cell 
adhesion and migration. 
When cell attachment was monitored, the 2E2 cells were found to attach to the ECM 
significantly faster than the control CHO cells regardless of the presence of fibronectin coating 
(Figure 3.3.12).  This suggests that the focal adhesions observed at the ends of the stress fibres 
are likely to be functional. 
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The presence of actin stress fibres in cells has been shown to impact cell migration both 
positively and negatively (Tojkander et al., 2012).  There is a fine balance between cell 
attachment and motility, if the cells adhere too strongly then the adhesions at the rear of the 
cell will not be able to detach therefore impeding cell migration, however if the cells don’t 
attach strongly enough there is not enough contact with the ECM for the cell to pull itself 
forward via myosin IIA contraction.  For this reason it was of interest to determine whether 
there was any change in cell migration between the two cell lines.   
It was found that the reduced expression of eEF1A coincided with a significantly reduced rate 
of migration in the 2E2 cells compared to the control CHO cells with and without fibronectin 
(Figure 3.3.13).   
The increased speed of migration observed with fibronectin coating in both cell lines when 
compared to migration without fibronectin is unsurprising as, using fibronectin as the ECM 
would increase the ligand concentration, which has been shown to affect the migration rate of 
cells (Palecek et al., 1997).  The rate of cell migration is dependent upon a fine balance 
between the contractility of the cell as well as the strength of cell adhesion to the extracellular 
matrix.  It would be expected that as the concentration of fibronectin was increased past the 
optimal level the migration rate would start to reduce, and if the migration assay was carried 
out at varying concentrations of fibronectin a curve would be observed where the migration 
speed would be optimal at intermediate levels of fibronectin because, at lower levels the rate 
of migration would be slower due to the cells not adhering as well to the ECM, and at higher 
concentrations the cells would adhere that tightly that they would also take much longer to 
migrate (Palecek et al., 1997).  In our cell system it would seem that the addition of fibronectin 
provides a more favourable environment for the cell, and potentially allows greater adherence 
to the ECM, therefore reducing the rate of cell migration.  This can also explain the reduced 
speed of the 2E2 cells when compared to the control CHO cells, as the 2E2 cells have been 
shown to have more focal adhesions and therefore presumably more contacts with the ECM.   
The 2E2 cells were shown to adhere to the ECM more strongly than the control CHO cells 
(both in the presence and absence of fibronectin), it is therefore logical to suggest that the 
increased adhesion of the 2E2 cells to the matrix in this system, may be in part responsible for 
the impediment in cell migration.  The stress fibres observed in the 2E2 cells in much higher 
numbers than in the CHO cells were classified as ventral stress fibres by their location, the 
localisation of myosin IIA to the fibre and the localisation of both paxillin and vinculin to both 
ends of the fibre, therefore the increased strength of cell attachment is unsurprising as the 
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focal adhesions at the ends of the stress fibres would be highly likely to contribute towards an 
increased cell adhesion in the 2E2 cells compared to the control CHO cells. 
Interestingly, the reduced expression of eEF1A in the 2E2 cells also appears to affect the 
directionality of migration of the cells compared to the control CHO cells.  When observing 
individual cells migrate in the CHO cell population by observing single cells from the videos, 
the single cell starts to migrate in one direction, usually straight towards to wound gap with 
very little deviation, however when observing the individual cells in the 2E2 cell population, 
they appear to migrate in a less ordered fashion, with much greater deviation in the direction 
of motion.  Though this is currently only an observation, it would be of interest to characterise 
or quantify this change in persistence or directional migration with migration studies using 
chemotaxis chambers and differing chemoattractants to enable better understanding of this 
phenomenon and by observing the orientation of the stress fibres while the cells were 
migrating. 
Ventral stress fibres have been shown to affect rear cell retraction in migrating cells, as well as 
affecting the persistence by detaching from the rear of the cell and relocalising to attach at the 
front of the cell, the direction of the cell has then been shown to change according to the 
direction of the newly localised fibre (Rid et al., 2005).  Both fibroblasts and epithelial cells 
have been shown to assemble stress fibres in response to mechanical tension during wound 
healing (Pellegrin and Mellor, 2007), and the rate of cell migration has been shown to be 
linked to the balance between cell attachment and cell contractility.  Based on the change in 
cell migration observed between the CHO and 2E2 cells as well as the apparent change in cell 
persistence, stress fibres in migrating cells of both cell lines were observed by fixing the cells 
once they had started to migrate to determine any change in stress fibre number in either cell 
line and to visualise the orientation of the stress fibres in the 2E2 cells in particular.  
It was found that whilst there was no change in the stress fibre number observed in the 2E2 
cells during migration, the control CHO cells had a significantly increased number of stress 
fibres in migrating cells at the front of the scratch, when compared to the stationary cells 
imaged within the confluent monolayer behind the scratch (Figure 3.3.14 A).  Myosin IIA was 
found to localise to these newly formed actin stress fibres, which is unsurprising as 
presumably it is the formation of the actin stress fibres that promotes the migration of the 
CHO cells at the scratch boundary (Figure 3.3.14 B).  Both paxillin and vinculin were found to 
localise to these new actin stress fibres (Figures 3.3.15), allowing them to be characterised as 
ventral stress fibres, which are known to be contractile and can encourage cell movement as 
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they are anchored to the ECM at both ends of the fibre allowing the contractility of the fibre to 
be transferred to the ECM and therefore allow the cell to pull itself forward.  This increase in 
the number of ventral stress fibres in migrating CHO cells would also be likely to help the rear 
tail retraction of the cell, as well as to help with persistence (Rid et al., 2005).   
Though it was impossible to quantify or statistically analyse the orientation of the actin stress 
fibres, after visual comparison of the orientation of the stress fibres visible in the 2E2 cells with 
those visible in the control CHO cells, it appears that the fibres in both cell lines orient 
perpendicular to the direction of the cell movement, but there appear to be more cells along 
the migrational front with actin stress fibres perpendicular to the direction of the scratch in 
the control CHO cells when compared to the 2E2 cells, such that more 2E2 cells have fibres 
oriented with the direction of the scratch as opposed to perpendicular to it.  This could 
provide some insight into why the cells move more randomly, as although the fibres align to 
the direction of cell migration, this direction does not appear to align perpendicular to the 
scratch to allow uniform scratch closure.  Ventral stress fibres have been shown to affect 
persistence of cells through the mechanism of rear cell detachment, however, the proteins 
involved in ensuring that the ventral stress fibres are lined up perpendicular to the direction of 
motion have not yet been established.  Palladin has been shown to affect the persistence of 
cells (Naumanen et al., 2007), and a wound healing assay on neural cells showed a reduced 
migration rate in null palladin cells (Luo et al., 2005), which would match nicely to the 
observed phenotype, including the presence of stress fibres, however this again is only one 
such protein that could impact this system and without further studies, it is impossible to say 
which proteins are involved in our cell system. 
The Arp2/3 complex is involved in nucleation of new actin filaments, capping fibres and has 
been shown to be essential for the formation of transverse arcs, which can connect to dorsal 
stress fibres to form ventral stress fibres, therefore, though there was no difference in Arp3 
localisation or protein expression in stationary cells (Figure 3.3.9), it was of interest to 
determine whether the newly formed ventral stress fibres observed in the migrating CHO cells 
would lead to a change in localisation of Arp3. This could give further indication as to the 
formation of the stress fibres in the 2E2 cells, as if localisation was observed with stress fibres 
in the migrating CHO cells, but no localisation is observed to the stress fibres in the 2E2 cells, it 
would point to a different regulatory mechanism of formation, however, no difference in Arp3 
localisation was observed between either the migrating and stationary CHO or 2E2 cells 
(Figure 3.3.16).   
Page | 173  
 
Beta-1 integrin localisation was also observed through immunofluorescence staining in CHO 
and 2E2 cells, however no difference was detected (Figure 3.3.10), potentially as the stress 
fibres and their associated focal adhesion complexes attached to the ECM through a different 
isoform of integrin.  As newly formed stress fibres were observed in migrating CHO cells when 
compared to stationary CHO cells, it was of interest to determine whether there was a 
difference in β-1 integrin localisation in migrating CHO and 2E2 cells when compared to 
stationary cells, which would give an indication as to which integrin isoform the migrating CHO 
stress fibres were interacting with and so whether they were behaving in the same way as the 
previously characterised stress fibres observed in the stationary and migrating 2E2 cells.  No 
difference was detected in the migrating CHO or 2E2 cells when compared to either each 
other or their stationary counterparts, therefore it is likely that the stress fibres observed in 
the 2E2 cells compared to the control cells attach to the ECM through the same integrin 
isoform as the newly formed stress fibres in the migrating CHO cells (Figure 3.3.17), though 
without determining which isoform this is, it is not possible to say for sure that they complex 
with the same isoform, just that neither complex with β1 integrin. 
To establish whether lower levels of eEF1A expression resulted in changes in proliferation rate, 
different viability assays were performed.  Using both the MTT assay (Figure 3.3.3A) and a cell 
counting assay (Figure 3.3.3B), we found significant changes in growth rate between the two 
cell lines, with the control CHO cells presenting more rapid growth over 72 hours.  Supporting 
differences in growth were also obtained from flow cytometry analysis where an increase in 
both apoptotic cells and G phase cells, and a decrease in S phase cells were obtained for the 
2E2 cells (Figure 3.3.4).  Aberrant eEF1A protein expression levels have been shown to affect 
the rate of proliferation in both yeast and mammalian cells (Gross and Kinzy, 2005, Pecorari et 
al., 2009, Anand et al., 2002). In human breast cancer cells, a reduction in eEF1A expression 
coincides with a decrease in cell proliferation, which was shown to correlate with an increase 
in the fraction of G1 phase and apoptotic cells and a decrease in the fraction of S phase cells as 
determined by flow cytometry.   
Disruption of the actin cytoskeleton has been shown to induce apoptosis in both yeast and 
eukaryotic cells (Gourlay and Ayscough, 2005), therefore it is likely that the increase in the rate 
of apoptosis, as well as the reduced cell growth rate result from changes in the organisation of 
the actin cytoskeleton caused by the reduced level of eEF1A protein expression.   
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The actin cytoskeleton has been suggested to be an early modulator of commitment to 
apoptosis, as well as being a target of the apoptotic process (White et al., 2001).  Many 
different actin binding proteins have also been shown to be biomarkers of the apoptotic 
process , therefore it seems sensible to suggest the reduced level of eEF1A expression, which 
coincides with the disruption of the organisation of the actin cytoskeleton and the suggested 
change in actin binding proteins that associate to the cytoskeleton in the absence of eEF1A, 
could lead to a change in apoptotic potential. 
In order to provide an explanation for these observed phenotypes it must be proved that the 
change in expression of eEF1A is the sole difference between the two cell lines, and that the 
phenotypes are therefore eEF1A dependent.  By up-regulating the level of eEF1A1 or eEF1A2 
in the 2E2 cells, not only can we determine the dependence of the phenotypes on eEF1A but 
also potentially to determine whether there are any differences in non canonical functions 
between the two isoforms (Chapter 4).   






Chapter 4:  
Rescue of Phenotypes with 
Full Length eEF1A1 or 
eEF1A2 
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The 2E2 cells used in the previous chapter were shown to have around a 40% reduction in 
eEF1A protein expression when compared to the control CHO cells (Figure 3.3.1).  The cells 
were created by the random insertion of a retroviral promoter trap into the CHO-K1 cells 
which was found, by 5’RACE and confirmed by PCR, to have inserted into the eEF1A1 gene 
(Borradaile et al., 2005).  Based on the low multiplicity of infection used when the cells were 
created it is highly unlikely that more than one gene was targeted, therefore eEF1A1 was 
assumed to be the only isoform affected, and the only gene affected in the 2E2 cells, however 
it remained to be determined whether all of the phenotypes observed in these cells, were 
solely due to the low expression of eEF1A.  It was therefore essential to prove that increasing 
the level of eEF1A in the 2E2 cells back to that of physiological levels could restore the 
observed phenotypes. 
It was also of interest to determine whether expression of either isoforms of the human eEF1A 
protein, namely eEF1A1 and eEF1A2 would equally be capable of restoring the different 
phenotypes.  Human isoforms were chosen as they are almost identical to the hamster 
isoforms and were more readily available.  eEF1A2 has been demonstrated to have the same 
canonical function in protein translation as eEF1A1 (Kahns et al., 1998), however, numerous 
studies have suggested that there may be differences in the non canonical functions of the 
two isoforms.  In fact the eEF1A isoforms have in some instances been shown to have 
opposing effects, for example in apoptosis where eEF1A1 has been shown to have a pro-
apoptotic effect whilst eEF1A2 supports a more anti-apoptotic role (Chen et al., 2000, Ruest, 
2002).  eEF1A2 has also been suggested to act as a possible oncogene, especially where 
aberrant eEF1A2 expression is observed in tissues that would normally only express eEF1A1 
(Anand et al., 2002, Tomlinson et al., 2005, Lee and Surh, 2009), therefore understanding the 
functions of eEF1A may provide evidence about how eEF1A2 causes such problems.   
Using the established CHO system, we aimed to generate both cellular pools and clones of 
cells expressing either eEF1A1 or eEF1A2.  Generating such transgenes would allow to 
demonstrate the sole role of eEF1A in rescuing the phenotypes reported in the last chapter.  
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Furthermore the different lines would also provide a invaluable system to examine some of 
the non-canonical functions of eEF1A1 and eEF1A2 and determine how they could affect the 
restoration of different biological changes reported.  
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4.2 Results 
4.2.1 Creation of plasmids expressing human eEF1A1 or eEF1A2  
 
In order to restore the level of eEF1A in the 2E2 cells to establish whether the phenotypes are 
eEF1A dependent, we first needed to engineer plasmids expressing the different isoforms.  
The vector backbone chosen for such purpose was the pcDNA3.1 zeo plasmid, given that 
selection others than G418 needed to be used, since the latter antibiotic had already been 
used for selection. 
Appropriate cloning procedures were followed to first isolate and amplify the open reading 
frames of both eEF1A1 and eEF1A2. Purification of previously cloned eEF1A1 and eEF1A2 
plasmids was first carried out by miniprep (Figure 4.2.1 A1), generating a profile and size that 
is expected for the vector of interest.  Primers were designed for PCR amplification, allowing 
for addition of a kozak sequence and the restrictions sites XbaI and EcoRI.  This produced a 
large amount of genetic material, consistent with the size expected, migrating at around 1.5kB 
(Figure 4.2.1 A2) and which was successfully purified further (Figure 4.2.1 A3).  The purified 
PCR produce was then ligated into the cloning vector pST Blue-1, for ease of digestion, and the 
plasmids transformed into E.coli.  The plasmids were then screened to determine which 
plasmids contained inserts (Figure 4.2.1 A4).  The higher bands indicate potential positive 
plasmids.  The pcDNA3.1 zeo backbone was prepared by extracting the plasmid by miniprep 
(Figure 4.2.1 B1), followed by digestion with EcoRI (Figure 4.2.1 B2), dephosphorylation to 
prevent ‘self’ ligation, and purified (Figure 4.2.1 B4).  The eEF1A1 and eEF1A2 (not shown) 
inserts were digested out of the pST Blue-1 vector with EcoRI (Figure 4.2.1 B3), and purified 
(Figure 4.2.1 B4).  The inserts were then ligated into the pcDNA3.1 zeo vector backbone and 
the plasmids screened for positives (Figure 4.2.1 B5).  The potential positives were then 
extracted by miniprep (Figure 4.2.1 B6) and digested with EcoRI to ensure a fragment was 
released (Figure 4.2.1 B7).  In order to ensure the orientation of the insert was correct, eEF1A1 
plasmids were digested with EcoRV, where if a large insert was released, the plasmid should 
contain the insert with the correct orientation (Figure 4.2.1 B8), and eEF1A2 plasmids were 
digested with BamH1, where if a small insert was observed the plasmid should contain the 
insert in the correct orientation (not shown).  The plasmids were then sent for sequencing at 
Birmingham University, and a sequence comparison carried out against the known sequences 
of eEF1A1 and eEF1A2 (Appendix 6.1 & 6.2). 
















Figure 4.2.1 – Creation of eEF1A1 and eEF1A2 expressing plasmids in the pcDNA3.1 zeo 
backbone vector.  Inserts - Plasmids containing either the eEF1A1 (SGB51 as described in Table 
2.1.4) or eEF1A2 (SGB42 as described in Table 2.1.4) gene were isolated using a miniprep kit 
(A1), PCR was used to amplify the inserts from plasmids (A2), followed by gel purification from 
the agarose gel (A3).  The inserts were then ligated into the sub-cloning vector pST Blue-1, the 
plasmids transformed into E.coli and the vectors screened for those containing the insert (A4).  
Plasmids - The pcDNA3.1 zeo plasmid backbone was isolated using a miniprep kit (B1), before 
digestion (B2) alongside the eEF1A1 or eEF1A2 pST Blue-1 cloning vector plasmid (B3) with 
EcoRI.  The digested pcDNA3.1 zeo backbone was dephosphorylated, and the digested 
fragments purified using a gel purification kit (B4).  The purified digested fragments were then 
ligated and transformed into E.coli, after which the colonies were screened for potential 
positives (B5).  The positive colonies were grown, the plasmids isolated using a miniprep kit 
(B6), and digested with EcoRI to ensure that an insert was released (B7).  The eEF1A1 plasmid 
was then digested with EcoRV to ensure correct orientation (B8).  
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4.2.2 Determination of the minimal zeocin concentration sufficient to 
cause death in both CHO G418 and 2E2 cells 
 
The plasmid created for the expression of eEF1A1 and eEF1A2 in the 2E2 cells, along with the 
control plasmid to be transfected into the CHO G418 and 2E2 cells, contain the zeocin 
resistance gene, sh ble, the product of which can bind to zeocin to prevent it from cleaving the 
DNA, and therefore prevent cell death.  To select for transfected cells, the concentration of 
zeocin that can kill wild type CHO and 2E2 cells needed to be established using an MTT assay 
after growing the cells in different concentrations of zeocin.   
Cells were seeded in varying concentrations of zeocin between 0-500 µg/ml, and their effects 
determined over 96 hours by viability measurement using MTT solubilisation with DMSO, and 
the absorbance read on a plate reader.   
Both CHO and 2E2 cells were found to die in a dose dependent manner, with concentrations 
above 200µg/ml reducing the absorbance to levels similar to the starting absorbance after 96 
hours (Figure 4.2.2).  One way ANOVA with Tukeys post test was used to analyse the 
significance of the values recorded after 96 hours, and significant differences were observed 
between the 0µg/ml concentration when compared with all others, and the 100µg/ml and 
150µg/ml concentrations showed significantly different results compared to some of the 
higher concentrations, however no significant difference was observed between the 200µg/ml 
concentration when compared to the higher concentrations.  For this reason, though it was 
found that both 100µg/ml and 150µg/ml did cause cytotoxicity in both CHO G418 and 2E2 
cells, the 200µg/ml concentration was deemed to be the most efficient concentration for 
selection.  All significance was measured to a P value of <0.05. 

















Figure 4.2.2 – Zeocin causes cytotoxicity in both CHO G418 and 2E2 cells in a dose dependent 
manner.  10,000 cells, either CHO (A) or 2E2 (B) were seeded into wells of a 24 well plate in 
DMEM with 500µg/ml G418 and 0, 100, 150, 200, 250 or 500µg/ml zeocin.  The cells were 
then incubated for 24, 48, 72 or 96 hours, after which MTT was added, solubilised in DMSO, 
and the absorbance read at 550nm and recorded.  One way ANOVA with Tukeys post test was 
used to determine which concentrations were significantly different, and 200µg/ml was found 
to be the lowest concentration that was significantly different to the lower concentrations to a 
P value of <0.05, whilst having no significant difference when compared to the higher 
concentrations. 
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4.2.3 Reduced expression of eEF1A causes no significant change in 
transfection efficiency 
 
The reagent chosen for transfection was jetPEI™, which is provided with a manufacturers 
protocol with optimised conditions for CHO cells, however with the differences already 
observed in the 2E2 cells compared to the control CHO cells, as well as the control cells being 
CHO-K1 cells, it was important to first establish the optimal conditions for the two cell lines.  A 
plasmid containing lifeact was used to allow visualisation of the transfected cells. 
Cells were seeded onto a fibronectin coated coverslip, before transfection, using jetPEI™ and 
the lifeact plasmid.  The mixture was added to the media, incubated for 24 hours then 
removed after which cells were fixed, coverslips mounted onto microscope slides, and viewed 
using fluorescence microscopy.   
No significant difference in transfection efficiency was seen between the 2E2 cells and the 
control CHO cells, with CHO cells showing 23 +/- 9% efficiency, and 2E2 cells showing 32 +/- 
12% efficiency (Figure 4.2.3), a yield which should be sufficient to generate stable transfected 
clones and a pool of cells.  Statistical analysis was carried out using an unpaired T test to a P 
value of <0.05. 











Figure 4.2.3 – No difference in transfection efficiency is observed between CHO and 2E2 cells.  
50,000 cells were seeded onto coated coverslips and grown overnight.  1.2µg of jetPEI™ was 
added to 50µl NaCl, and 1µg lifeact plasmid DNA was added to 50µl NaCl.  The jetPEI™ solution 
was added to the DNA solution, mixed and incubated at room temperature for 30 minutes.  
The solution was then added to the media on the cells and incubated for 24 hours.  The cells 
were then fixed and the coverslips mounted with mounting media containing DAPI onto a 
microscope slide and viewed by fluorescence microscopy.  The number of transfected cells 
was counted by observation of GFP fluorescent cells, and the percentage of cells transfected 
determined by comparing this number to the total number of cells counted by using DAPI 
staining.  The average number of transfected cells was plotted with the standard error of the 
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4.2.4 Transfected 2E2 cells show a range of different levels of 
expression throughout the cell population 
 
After optimisation of the transfection efficiency in 2E2 cells, and determining the optimal 
concentration for selection of transfected cells, the 2E2 cells were transfected with the eEF1A1 
zeo and eEF1A2 zeo plasmids, and selected with 200µg/ml zeocin in order to generate a pool 
of stably transfected cells expressing different levels of the eEF1A proteins. 
Immunofluorescence staining for eEF1A was performed to observe the expression of eEF1A 
throughout the cell population.   
Immunofluorescence staining was carried out by seeding cells onto coated coverslips, before 
fixing, permeabilising, and staining for the eEF1A proteins.  The coverslips were then mounted 
onto microscope slides, and viewed using confocal microscopy.   
It was found that, as would be expected from a pooled population of transfected cells, there 
was a range of different protein expression levels of eEF1A throughout the cell population, 
and the cells that were highly transfected could be easily identified using this method (Figure 
4.2.4).  
 



















Figure 4.2.4 – Transfection of 2E2 cells with eEF1A1 and eEF1A2 plasmids leads to a varied 
expression of eEF1A across the cell population, with both high and low expression of eEF1A 
being observed in cells.  10,000 cells were seeded, left to grow for 48 hours then fixed, 
permeabilised and stained for eEF1A with a FITC conjugated secondary antibody.  Coverslips 
were then mounted with DAPI containing mounting media onto microscope slides and viewed 
using confocal microscopy.  White scale bars are equal to 25µM. 
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4.2.5 High expression of either eEF1A1 and eEF1A2 in single 2E2 cells 
leads to fewer stress fibres  
 
It was observed that the 2E2 cells had an increased number of actin stress fibres compared to 
control CHO cells, though no difference in actin protein expression was observed (Figure 
3.3.5), therefore immunofluorescence staining was used to determine whether transfected 
cells with a high level of eEF1A1 or eEF1A2 expression showed a restoration in the number of 
actin stress fibres.     
Cells were seeded onto coated coverslips, before fixing, permeabilising, blocking and staining 
for eEF1A and actin, the coverslips were then mounted onto a microscope slide and viewed 
using confocal microscopy.  Cells with a high level of eEF1A, determined by the level of green 
fluorescence were observed, as well as cells with a low level of eEF1A, and actin stress fibres 
quantified by counting the number of actin fibres that passed across the cell in 20 different 
cells for both high and low expression of both plasmids, and control cells.   
It was found that in cells that had a higher expression of eEF1A, as determined by visual 
comparison, the actin stress fibre number was low, 1 +/- 1.8 per cell for eEF1A1 transfected 
cells and 2 +/- 2.0 per cell for eEF1A2 transfected cells, similar to control CHO cells with 1 +/- 
1.5 fibre per cell, however, in cells that were transfected but had only a low eEF1A protein 
expression, the number of actin stress fibres was similar to that of the control 2E2 and 2E2 zeo 
cell lines, with the low eEF1A1 transfected cells showing 10 +/- 4.4 fibres per cell, the low 
eEF1A2 transfected cells showing 11 +/- 2.5 fibres per cell and the 2E2 and 2E2 zeo cells 
showing 12 +/- 4.9 and 12 +/- 5 fibres per cell respectively (Figure 4.2.5).  This difference 
between number of actin stress fibres in the highly transfected and low transfected 2E2 cells 
was found to be statistically significant to a P value of <0.05. 























Figure 4.2.5 – Restoration of eEF1A in 2E2 cells 
reduces the number of actin stress fibres back to 
control levels.  Cells were grown, then fixed, 
permeabilised, blocked and stained for eEF1A 
(FITC conjugated secondary) and actin 
(rhodamine phalloidin), after which coverslips 
were mounted onto coverslips, and viewed using 
confocal microscopy.  Red rectangles show the areas selected for the magnified images (A).  
Actin stress fibres were quantified by counting the number of actin filaments that passed 
across the cell in 20 different cells for each cell type and plotting the average with the 
standard error of the mean (B).  Differences were found to be statistically significant with a P 
value *<0.05 as determined by one way ANOVA with a Tukey post test.  White scale bars are 
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4.2.6 Clonal transfected cell lines show a change in eEF1A protein 
expression level, with expression varying between different clones 
 
The transfected cells used so far were created as a pool of transfected cells, and could 
therefore only be used to observe changes in phenotypes in single cells, but as a proof of 
principle, appeared to provide correlative evidences between high levels of eEF1A expression 
and number of actin stress fibres.  In order to analyse how 2E2 cells with an increased eEF1A 
protein expression behave as a population, clonal cell lines expressing varying levels of the 
proteins needed to be established.  Generating such cell systems would prove to be an 
invaluable tool for studying the possible reversions of all phenotypes analysed so far. 
2E2 cells were therefore transfected using the JetPEI™ reagent and incubated in selective 
conditions until cell colonies started to form.  A cloning cylinder was placed around the outside 
of a colony, and the cells within the cylinder detached with trypsin and expanded to create 
new clonal cell lines.  The different cell lineages were grown until large amounts of cellular 
material could be isolated and characterise further. 
Western blotting was used to determine eEF1A protein expression in each clone by lysing the 
cells and extracting protein.  Protein was then loaded onto a gel, run, transferred to 
nitrocellulose and the blots probed for eEF1A and tubulin, before developing and quantifying 
using densitometry analysis on ImageJ.   
All clones showed an increased expression of eEF1A when compared to the 2E2 cells, with the 
eEF1A2 clone 1 showing an intermediate level of eEF1A of approximately 80% eEF1A 
expression, and the other clones, such as eEF1A1 clone 3 showing an eEF1A expression level as 
high as the control CHO cells at 101%, and some clones showing a higher level of eEF1A 
expression than the control CHO cells, such as eEF1A1 clone 4, and eEF1A2 clones 3, 4 and 5, 
which show 116%, 121%, 130% and 157% expression respectively (Figure 4.2.6).  
 



















Figure 4.2.6 – Clones of transfected 2E2 cells show an increase in eEF1A protein expression at 
varying levels between clones.  Cells were homogenised, protein extracted, quantified, 25µg 
total protein loaded, and run on a gel before transferring to nitrocellulose.  The blot was then 
probed with eEF1A and α – adaptin or tubulin primary antibodies, and HRP conjugated 
secondary antibody.  Blots were then developed (A) and the intensity of the bands quantified 
using densitometry analysis on ImageJ (B).  The clones chosen for further experimentation are 
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4.2.7 Increased expression of eEF1A in clonal cell lines can be seen as 
consistent throughout the cell population 
   
After analysis of the level of eEF1A protein expression in the transfected clones which showed 
an increase in eEF1A protein expression in the clonal cell lines (Figure 4.2.6), it was essential to 
determine that the level of expression was consistent throughout the cell population, and that 
the clones truly were clones from one single cell.  Immunofluorescence staining was used to 
analyse individual cells within the population.   
Cells were seeded onto a coated coverslip, and the cells fixed, permeabilised, blocked and 
stained for eEF1A, after which the coverslips were mounted onto a microscope slide and 
viewed using confocal microscopy.   
The staining for eEF1A was found to be similar in intensity throughout the whole cell 
population for all clones (Figure 4.2.7), and the expression level of eEF1A in most clones 
appeared higher than that of the 2E2 cells, which correlates to the eEF1A protein expression 
determined by the Western blotting (Figure 4.2.6).  From the information gathered from 
Western blotting and staining it was determined that for further experiments, eEF1A1 clones 3 
and 4, and eEF1A2 clones 3 and 5 would be used to analyse rescuing of the observed 
phenotypes.  
 





















Figure 4.2.7 – All transfected cell lines show consistent eEF1A protein expression throughout 
the cell population.  eEF1A1 clonal cells (A) and eEF1A2 clonal cells (B,) were fixed, 
permeabilised, blocked and stained for eEF1A (FITC conjugated secondary antibody), before 
mounting coverslips onto microscope slides and viewing using confocal microscopy.  Scale bars 
are equal to 25µM. 
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4.2.8 Increased expression of neither eEF1A1 or eEF1A2 was sufficient 
to rescue the slow growth phenotype  
 
It was previously shown that the decrease in eEF1A protein level in 2E2 cells compared to CHO 
cells resulted in a decrease in growth rate by both MTT and cell counting assays (Figure 3.3.3), 
which was consistent with previous findings by Pecorari et al, 2009.  For this reason an MTT 
assay was used to determine whether restoring the level of eEF1A expression would be 
sufficient to rescue the previously observed phenotype. 
Two clones for each eEF1A1 and eEF1A2 were chosen to determine restoration of the 
phenotypes.  These clones, 3 and 4 for eEF1A1 and 3 and 5 for eEF1A2, were chosen as they 
gave either the same level of expression of eEF1A, or higher than was observed in the CHO 
cells.  Cells were seeded and left to grow for the appropriate length of time, before MTT was 
added and solubilised with DMSO and the plate read at 550nm.  The MTT assay was carried 
out in both the presence and absence of selection to ensure that any changes were not caused 
by changes in selective pressure between the cell lines (data not shown). 
No difference in cell growth was determined with clones with increased eEF1A1 or eEF1A2 
expression (Figure 4.2.8).  The curves of the clones remained similar to that of the 2E2 cells 
whilst the rate of growth of the CHO cells can be seen to be faster.  Statistical analysis by one 
way ANOVA with Tukeys post test showed a significant difference between the CHO cells and 
all 2E2 cells after 96 hours, however no statistical difference was detected between the other 
three cell lines for either eEF1A1 or eEF1A2 after 96 hours to a P value of <0.05.  
 





















Figure 4.2.8 – Increased expression of eEF1A1 or eEF1A2 is not sufficient to restore the growth 
phenotype.  10,000 cells were seeded and left to grown for 24, 48, 72 or 96 hours, after which 
MTT added and solubilised, before the absorbance at 550nm was read and recorded.  Results 
were normalised to the CHO cells at 24 hours so that curves could be directly compared (A & 
B).  Statistical analysis was performed using one way ANOVA with Tukeys post test with the 96 
hour time point to a P value of <0.05.   
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4.2.9 Restored level of eEF1A results in decreased numbers of actin 
stress fibres 
 
When actin organisation was observed in 2E2 cells it was found that the decrease in eEF1A 
resulted in an increase in the number of actin stress fibres compared to the control CHO cells 
as determined by immunofluorescence staining, however, the protein expression of actin was 
unaffected (Figure 3.3.5).  This change in the number of actin stress fibres was restored when 
actin localisation was observed in the pool of transfected cells expressing high levels of eEF1A 
(Figure 4.2.5).  By analysing the number of actin stress fibres in the clonal cell lines, the rescue 
of the phenotype could be further confirmed.   
Immunofluorescence staining was carried out by fixing, permeabilising, blocking and staining 
cells for eEF1A and actin before mounting coverslips and viewing using confocal microscopy.  
Fibres were quantified by counting the number of actin stress fibres that passed across the cell 
in 20 random cells from each cell line.   
 
It was found that the transfected clones with increased expression of eEF1A protein had a 
decreased number of actin stress fibres compared to the control 2E2 zeo cells, with clones 
showing a similar number of actin stress fibres to that observed in control CHO cells (Figure 
4.2.9).  Control CHO cells were found to have an average of 3 +/- 2.5 actin fibres per cell, with 
the eEF1A1 clones having 4 +/- 2.6 and 4 +/- 2.5 and the eEF1A2 clones having 5 +/- 2.9 and 4 
+/- 1.5, compared to the 2E2 cells which had an average number of 15 +/- 2.9.  These results 
were found to be statistically significant to a P value of < 0.05. 
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Figure 4.2.9 – Increased expression of eEF1A1 or eEF1A2 results in a reversion of the actin 
stress fibre phenotype.  Cells were fixed, permeabilised, blocked and stained for eEF1A (FITC 
conjugated secondary antibody) and actin (rhodamine phalloidin), before coverslips were 
mounted onto microscope slides, and viewed by confocal microscopy (A).  White scale bars are 
equal to 25µM, blue scale bars are equal to approximately 7.5µM.  Fibres were quantified by 
counting the number of actin stress fibres that passed across the cell in 20 cells per cell line, 
with the average number of fibres and the standard error of the mean plotted (B).  Statistical 
analysis was carried out by way of 1 way ANOVA followed by Tukey post test to a P value of 
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 4.2.10 Increased level of eEF1A results in a decrease in myosin IIA 
fibres  
 
Myosin IIA was shown to localise to the actin stress fibres observed in the 2E2 cells, with the 
number of myosin IIA fibres increased in 2E2 cells when compared to control CHO cells (Figure 
3.3.6).  Immunofluorescence staining of the clonal cells would determine whether the increase 
in eEF1A in the 2E2 cells would result in a rescue of the myosin IIA phenotype. 
Cells were stained by fixing, permeabilising and blocking cells before staining for myosin IIA 
and actin.  Coverslips were then mounted onto microscope slides and viewed using confocal 
microscopy, before myosin IIA was quantified by assuming the observed striations to be fibres, 
and counting the number of fibres that passed across the cell.   
It was found that the increase in expression of both eEF1A1 and eEF1A2 in the clones was 
sufficient to restore the myosin IIA phenotype (Figure 4.2.10).  The CHO cells were found to 
have an average number of 1 +/- 1 myosin fibres, with the eEF1A1 clones showing an average 
number of 2 +/- 2 and 3 +/- 3, and the eEF1A2 clones showing an average of 6 +/- 2 and 4 +/- 
3, compared to the 2E2 cells which showed an average number of 14 +/- 4 myosin fibres.  
These results were found to be statistically significant to a P value of <0.05. 
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Figure 4.2.10 – Increased expression of eEF1A1 or eEF1A2 in clonal cell lines is sufficient to 
rescue the observed myosin IIA phenotype.  Cells were fixed, permeabilised, blocked and 
stained for myosin IIA (FITC conjugated secondary) and actin (rhodamine phalloidin) before 
mounting coverslips onto microscope slides and viewing using confocal microscopy (A).  White 
scale bars are equal to 25µM, blue scale bars are equal to approximately 7.5µM.  
Quantification was carried out by assuming the striations of myosin IIA observed to be fibres, 
and counting the number that pass across the cell in 20 cells of each cell type, with the 
average and standard error of the mean plotted (B).  Statistical analysis was performed on 
GraphPad Prism by way of 1 way ANOVA followed by Tukey post test, and results deemed to 
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4.2.11 Increased level of protein expression of eEF1A is sufficient to 
rescue the number of paxillin and vinculin clusters 
 
Immunofluorescence staining for paxillin and vinculin in CHO and 2E2 cells showed that when 
eEF1A protein expression level was decreased, the number of paxillin clusters increased, and 
localised to the ends of the actin stress fibres that passed through the cell (Figure 3.3.7).  By 
using the clonal cell lines with a uniform expression of eEF1A throughout the cell population, it 
was possible to determine whether or not the increase in eEF1A1 or eEF1A2 was sufficient to 
restore the paxillin phenotype.   
Cells were seeded onto coated coverslips, before fixing, permeabilising, blocking and staining 
for paxillin or vinculin and actin.  The coverslips were then mounted onto a microscope slide 
and viewed using confocal microscopy.  Clusters were quantified by counting the number of 
clusters per cell for 20 cells or each cell type.   
Results showed that the expression of eEF1A1 or eEF1A2 in clonal cell lines was sufficient to 
rescue the paxillin phenotype, such that 2E2 and 2E2 cells showed an increased number of 
clusters compared to control CHO cells, but clonal transfected cells show a decreased number 
of clusters compared to the 2E2 cells, with a similar cluster number to the control CHO cells 
(Figure 4.2.11) with results shown to be statistically significant to a P value of < 0.05.  The 
average number of paxillin clusters in the CHO cells was found to be 10 +/- 5, with the average 
number of paxillin cluster in the eEF1A1 clones being 15 +/- 5 and 16 +/- 6, and the eEF1A2 
clones 20 +/- 6 and 15 +/- 6, compared to the 2E2 cells showing an average number of 48 +/- 
6.  The number of vinculin clusters was shown to be similar in clonal cells compared to control 
CHO cells, with the average number of vinculin clusters in CHO cells as 10 +/- 6, with the 
eEF1A1 clones having an average of 17 +/- 6 and 15 +/- 5, and the eEF1A2 clones having an 
average of 19 +/- 6 and 15 +/- 6.  The 2E2 cells in contrast showed an average vinculin cluster 
number of 48 +/- 6. 
 





























































































Figure 4.2.11 – Increased expression of eEF1A protein in clonal transfected cells results in a 
restoration of the paxillin and vinculin phenotypes.  Cells were fixed, permeabilised, blocked 
and stained for paxillin (FITC conjugated secondary antibody) and actin (rhodamine 
phalloidin), before mounting coverslips onto microscope slides and viewing using confocal 
microscopy (A & C).  White scale bars are equal to 25µM, blue scale bars are equal to 
approximately 7.5µM.  Clusters were quantified by counting the total number of clusters per 
cell for 20 cells of each type, the average number and standard error of the mean plotted, and 
statistical significance determined using 1 way ANOVA on GraphPad Prism to a P value of 
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4.2.12 Increased expression of eEF1A1, but not eEF1A2, resulted in 
restoration of the migration phenotype,  
 
The reduced eEF1A protein expression in the 2E2 cells compared to the control CHO cells 
coincided with a reduced rate of cell migration as determined by a scratch assay analysed 
using the Cell IQ software (Figure 3.3.13), therefore to prove that this was dependent on 
eEF1A, the scratch assay was repeated on the clonal cell lines.  
One clone for each eEF1A1 and eEF1A2 was chosen for the scratch assay.  The clones chosen 
were those which showed the closest level of eEF1A expression to the control CHO cells.  Cells 
were grown to confluence, before being scratched, washed and positions to be imaged 
selected.  Images were taken and then wound closure analysed using the Cell IQ software. 
Increased expression of eEF1A1 in clone 3 showed an increased rate of wound closure similar 
to that of the CHO cells, with the clonal cell line closing after approximately 15 hours 
compared to 18 hours for the CHO cells and 31 hours for the 2E2 cells, however no change in 
wound closure was seen in the eEF1A2 clone 3 when compared to 2E2 cells with a wound 
closure time of 28 hours (Figure 4.2.12).   
 












































Figure 4.2.12 – Increased expression of eEF1A1 is capable of restoring the rate of cell 
migration, however increased expression of eEF1A2 is not sufficient.  Cells were grown until 
confluent after which a scratch was made through the confluent monolayer with a yellow 
pipette tip.  The cells were then washed and media replaced.  The plate was loaded into the 
Cell IQ machine and three different points in each of the three replicate scratched were 
selected and images taken (A).  Scale bars represent 50µM.  The threshold of the scratch was 
then set, and the average percentage wound closure recorded over time (B).  The average 
times at which each point reached 95% closure were recorded and plotted, along with 
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To restore the level of eEF1A in the 2E2 cells, a plasmid that would allow sufficient eEF1A 
expression and selection of transfected cells was created (Figure 4.2.1).  The pcDNA3.1 zeocin 
plasmid was used as the 2E2 cells already had G418 resistance following a retroviral promoter 
trap insertion, therefore this plasmid should allow both sufficient expression and selection.  To 
determine the concentration of zeocin required to achieve cell death, both CHO and 2E2 cells 
were grown in varying concentrations of zeocin and an MTT assay used to determine cell 
viability (Figure 4.2.2).  All concentrations used, 100-500 µg/ml caused cell death, however the 
200µg/ml zeocin concentration was the lowest concentration that was found to cause 
significant death after 24 hours, with the cell viability reduced to that of the starting OD540nm 
after 96 hours, therefore this concentration was deemed to be the least stressful 
concentration that would cause sufficient death to select cells that had been transfected.  
Zeocin causes cell death by cleaving the DNA resulting in double strand breaks.  The 200µg/ml 
concentration is in line with other studies using zeocin for selection of CHO-K1 cells which 
have used a selection concentration between 150-200µg/ml (Satoh et al., 2005, Vanblokland 
et al., 2007).    
The transfection efficiency of the CHO and 2E2 cells was then determined using the standard 
protocol to ensure maximal transfection efficiency in each cell line (Figure 4.2.3).  Both cell 
lines were found to have a similar efficiency, consistent with the conditions recommended for 
this cell type therefore the standard protocol for transfection was followed.  This was 
important to establish as the function of eEF1A in integration of transfected genes is unknown 
therefore it is possible that reducing the level of eEF1A could affect transfection efficiency.  
Based on the similarity on transfection efficiency between the two cell lines it seems that 
eEF1A protein expression does not affect this integration. 
After transfection and selection of the 2E2 cells, a pool of transfected cells was created which 
showed a varied eEF1A protein expression throughout the cell population (Figure 4.2.4).  This 
varied pattern of expression of the transfected gene is common as the level of protein 
expression is dependent upon where the transfected gene integrates into the host cell 
genome.  This varied protein expression allows for clones of differing expression levels to be 
achieved.  The pool of transfected cells was a useful tool to observe cells expressing differing 
levels of eEF1A within the cell population by immunofluorescence which would allow a 
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correlation to be observed between eEF1A protein level and stress fibres (Figure 4.2.5), 
however, phenotypes such as migration and cell growth require cells expressing a 
homogenous protein level in order to observe any potential rescuing.  For this reason, clonal 
cell lines were also created and showed a homogenous eEF1A protein expression throughout 
the cell population (Figure 4.2.7).  Both the pool of transfected cells and the clones provided 
valuable tools to observe whether the phenotypes were restored with an increased level of 
eEF1A. 
2E2 cells with a reduced level of eEF1A protein expression were found to have a significantly 
increased number of actin stress fibres (Figure 3.3.5), to which myosin IIA was found to 
localise (Figure 3.3.6).  The focal adhesion proteins paxillin and vinculin were found to localise 
to both ends of the stress fibres (Figure 3.3.7), allowing them to be characterised as ventral 
stress fibres.  With the pool of transfected cells allowing cells with both high and low eEF1A 
protein expression levels to be observed, co-staining of eEF1A and actin was carried out.  It 
was found that the cells with increased eEF1A1 or eEF1A2 expression had a reduced number 
of actin stress fibres, with the number similar to the control CHO cells, and the cells with a low 
level of eEF1A1 or eEF1A2 were found to have a similar number of actin stress fibres to the 
2E2 cells (Figure 4.2.5), indicating that the increased expression of either eEF1A1 or eEF1A2 is 
sufficient to restore the actin stress fibre number.  This was further confirmed by 
immunofluorescence staining of the clonal cell lines which proved that the increased 
expression of both eEF1A1 and eEF1A2 was sufficient to restore the level of actin stress fibres 
(Figure 4.2.9). 
Immunofluorescence of both eEF1A1 and eEF1A2 in clonal cell lines were found to result in 
the restoration of the myosin IIA phenotype with the number of myosin IIA fibres in the clonal 
cell lines being similar to that of the control cells (Figure 4.2.10).  Using the clonal cells it was 
also determined that the both the paxillin and the vinculin phenotypes were also rescued, with 
the number of clusters in the 2E2 transfected clones being similar to that observed in the 
control CHO cells (Figure 4.2.11). 
This rescue of the actin, myosin IIA, paxillin and vinculin phenotypes proved that the increased 
number of ventral stress fibres in the 2E2 cells was due to the reduced expression of eEF1A 
protein, and also that both eEF1A1 and eEF1A2 are capable of restoring these phenotypes.  
Though eEF1A1 and eEF1A2 have been suggested to have different non canonical functions, 
this result is unsurprising as both isoforms have been shown to have the ability to affect the 
actin cytoskeleton (Amiri et al., 2007, Doyle et al., 2011, Edmonds et al., 1995).  It is therefore 
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possible that as suggested before, the reduced expression of eEF1A results in an insufficient 
amount of eEF1A protein that can bind to the actin fibre in order to prevent other actin 
binding proteins from causing rearrangement of the actin cytoskeleton.  When eEF1A level is 
then boosted back up by transfection of the eEF1A1 or eEF1A2 plasmids, the eEF1A protein 
level is once again sufficient to bind actin in such a way that other actin binding protein are 
excluded (Owen et al., 1992). 
In order to determine whether the migration phenotype observed could be rescued by eEF1A1 
or eEF1A2, clonal cells had to be used.  The pool of transfected cells was not suitable for this 
analysis as only a small percentage of cells were highly transfected, therefore any change in 
migration would have been undetectable from the overall population of cells.  Once clonal cell 
lines had been isolated and expanded, the eEF1A expression level was detected by Western 
blotting (Figure 4.2.6), and uniform expression was determined by immunofluorescence 
staining (Figure 4.2.7).  From these expanded clonal cell lines, two clones were chosen for both 
eEF1A1, clones 3 and 4, and eEF1A2, clones 3 and 5.  These clones were chosen as they gave 
either the same level of expression of eEF1A, or higher than was observed in the CHO cells.  
For the migration assay, only one clone was chosen, which was decided based upon which of 
the two clones had the closest expression level to that of the control CHO cells.   
It was found that eEF1A1 clone 3 was able to rescue the observed phenotype (Figure 4.2.12).  
This is unsurprising as the migration phenotype observed is likely to be due to the disruption 
of the actin cytoskeleton, therefore by restoring cytoskeletal organisation would result in 
restoration of the migration speed, however contradictory to this theory is that the eEF1A2 
clone was not able to rescue the migration phenotype in spite of showing the ability to rescue 
the disruption to the actin cytoskeleton.  This would therefore imply the possibility that 
eEF1A1 but not eEF1A2 could be capable of affecting cell migration independently of the 
observed change in the actin cytoskeleton.  This supports the theory that the two isoforms 
carry out the same function in protein translation but have different non canonical functions, 
and could also explain the increased association of eEF1A with metastatic cancers (Pencil et 
al., 1993, Edmonds et al., 1996).  The mechanism for how this may be regulated is unknown 
and would require further studies into the downstream effectors of the pathway. 
eEF1A has been shown to be able to significantly increase the rate of actin polymerisation, 
therefore it could be possible that under normal conditions, the polymerisation of actin seen 
at the leading edge of the cell to form the filopodia and lamellipodia is controlled by eEF1A to 
regulate the speed and direction of migration.  In our situation, where the level of eEF1A 
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protein expression has been reduced by such a significant amount, the level of eEF1A may not 
be sufficient to regulate this actin polymerisation in order to produce the structures required 
for cell migration at the same speed as when it is present in abundance.  This could explain 
why the rate of cell migration is reduced in cells that have a reduced expression of eEF1A, but 
also why the migration phenotype is only rescued by eEF1A1 even though the actin stress 
fibres phenotype is rescued by both eEF1A1 and eEF1A2.  It provides a mechanism by which 
eEF1A1 could regulate cell migration independently of its role in actin binding and bundling. 
It was found that neither the eEF1A1 or eEF1A2 clones were sufficient to restore the cell 
growth defect observed (Figure 4.2.8).  In chapter 3 this change in cell growth rate was 
suggested to be due to the disruption of the actin cytoskeleton which, as the actin 
cytoskeleton is essential for proper regulation of cell proliferation and cell cycle progression, 
would be a sensible suggestion, however the lack of restoration would seem to contradict this.  
A potential explanation for this would be that, although care was taken to ensure that only 
one gene was affected by the retroviral insertion when the cells were created, it is possible 
that more than one gene in the cells was disrupted, and this may have caused the change in 
cell proliferation observed, hence why it was not rescued by the increased level of eEF1A1 or 
eEF1A2 in the clones.  The link between eEF1A expression and cell growth rate has been 
demonstrated in the past by various other studies, therefore it is also possible that the 
phenotype is eEF1A dependent, however the level of eEF1A in the clones is not sufficient to 
restore the phenotype as the species of eEF1A used to restore the level of eEF1A was not 
mouse but human, therefore overexpression of this isoform may be needed to provide the 
same effect.  Although the level of eEF1A expression in the clones is similar to that of the 
control cells, it may be that, as the translational role of eEF1A along with the actin 
organisational role are likely to be the most highly conserved, it may take an increased level of 
expression in order to restore the proliferation phenotype.  It would make sense for eEF1A to 
be a regulator of cell growth independently of actin organisation as, from the results achieved 
in this chapter, it would appear that eEF1A1 and eEF1A2 have similar actin binding activity, 
however, eEF1A1 is usually expressed in rapidly dividing cells, in comparison to eEF1A2 which 
is usually expressed in terminally differentiated cells which divide very slowly.  This could 
implicate eEF1A directly in the regulation of cell growth by affecting the progression of the cell 
through the cell cycle, indeed, eEF1A has been shown to affect the cell cycle not only in this 
study (Figure 3.3.6), but also in other studies (Pecorari et al., 2009), as well as being implicated 
in cellular senescence (Byun et al., 2009, Cavallius et al., 1986b).  Clones which overexpress 
eEF1A1 and eEF1A2 to levels higher than that observed in the control CHO cells would further 
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confirm whether the level observed is simply not high enough to provide the rescue of this 
phenotype, or whether the phenotype is not eEF1A dependent but caused by some other 
change in the cells used.  
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5.0 Reduction of eEF1A Protein Levels in Yeast and its 
effects on cellular processes 
5.1 Introduction 
 
The primary function of eEF1A is in protein translation, however, eEF1A is present in a 17-35 
fold molar excess compared to the other components of the translational machinery (Slobin, 
1980).  eEF1A has also been demonstrated to affect actin cytoskeletal organisation (Chapter 3 
Figure 3.3.5) as well as many other cellular functions including microtubule binding, bundling 
and severing, apoptosis, and protein degradation (Shiina et al., 1994, Moore et al., 1998, 
Moore and Cyr, 2000, Duttaroy et al., 1998, Chen et al., 2000, Gonen et al., 1994, Chuang et 
al., 2005).  Work has been done to show that overexpression of eEF1A can disrupt the actin 
organisation of the cell without affecting the rate of protein synthesis (Munshi et al., 2000, 
Gross and Kinzy, 2005) suggesting that these functions are independent.   
The theory that there may be different ‘pools’ of eEF1A conserved for different functions is 
something that has been suggested, however not investigated.  Indeed it has been shown that 
the intracellular pH can affect the affinity of eEF1A to actin, with the affinity decreasing as pH 
increases, which could potentially allow for an increased localised concentration of eEF1A that 
is freely available to interact with tRNA for protein synthesis as pH increases providing a 
potential mechanism for how eEF1A can carry out these two roles in an independent manner 
(Edmonds et al., 1995, Liu et al., 1996b).  The role of the actin cytoskeleton in the regulation of 
protein translation has been hypothesised (Kim and Coulombe, 2010), and based on the 
regulatory function of eEF1A on the organisation of the actin cytoskeleton, as well as the 
apparent mutual exclusivity of binding of eEF1A to actin and tRNA which can be controlled by 
changes in the local pH, eEF1A is a very likely candidate for the link between the two cellular 
functions. 
Our work so far has shown, in mammalian CHO-K1 cells, that a reduction of eEF1A level to 
around 50% of its normal content, leads to significant changes in cytoskeletal reorganisation 
and overall growth among other characteristics.  We set about to further establish how 
growth, viability and other biological processes would be affected with varying reduced levels 
of eEF1A (from no expression to physiological levels) in the easy amenable yeast organism, 
Saccharomyces cerevisae. Using this model system we sought to determine whether 
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fluctuations in eEF1A protein level would lead to specific phenotypic changes in actin 
organisation and protein translation.  Due to its very amenable genetics, different strategies 
for reducing the level of eEF1A in yeast are available including knock down using siRNA, gene 
knock out and transformation of plasmids with different copy numbers and/or transfection of 
plasmids with differing promoters into deletion strains, each with their own advantages and 
disadvantages.  siRNA knock down should provide a range of different levels of eEF1A 
expression, however this method is not only expensive, but also time consuming, as a plasmid 
encoding the genes for Ago2, Dicer and TRBP has to be transformed into the cells before siRNA 
can be performed to allow it to be processed (Suk et al., 2011).  Given that eEF1A is so 
abundant, to knock down the level of eEF1A to a sufficient level to affect translation by this 
method would be unlikely, therefore siRNA was deemed impractical to create the varying 
levels of eEF1A required for our purpose.   
A very useful tool to enable manipulation of eEF1A expression levels in yeast was created by 
Sandbaken and Culbertson, 1988, by creating a strain in which both chromosomal copies, TEF1 
and TEF2 were disrupted such that they were no longer functional, with the only copy of 
eEF1A found on an episomal plasmid (Sandbaken and Culbertson, 1988), providing us with an 
invaluable tool to use different plasmids to regulate the level of this protein.   
The level of protein expression from a plasmid is dependent upon both the copy number and 
the promoter used.  The copy number of a plasmid refers to the number of copies that are 
present in the host cell, therefore usually, the higher the copy number of the plasmid, the 
higher the level of protein expression controlled by the plasmid, however it has been found 
that there is an inverse link between plasmid copy number and plasmid stability, such that 
high copy number plasmids are less stable and therefore provide less stable phenotypes than 
those with a lower copy number (Futcher and Cox, 1984).  For our purpose, a wide range of 
different protein expression levels were required, therefore as changing the copy number of 
the plasmid had limitations for both stability and the range of protein expression achievable, 
an alternative method was used.   
Varying the promoter can create a big change in the level of expression of the protein of 
interest.  Glycolytic promoters such as glyceraldhehyde-3-phosphate dehydrogenase (GAP) 
and alcohol dehydrogenase 1 (ADH1) are the strongest promoters in Saccharomyces cerevisiae 
and though initially thought to be constitutively active, were found to be induced by the 
addition of glucose (Romanos et al., 1992).  The CYC1 promoter has been found to be a weak 
promoter, and the TEF promoter a strong promoter (Mumberg et al., 1995), therefore 
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transforming plasmids with different promoters such as the GAP, ADH1, TEF1 or CYC1 
promoter, into a strain can result in differential expression of the protein of interest.  The level 
of protein expression under the weaker promoter may also still be too high in order to achieve 
the desired end result.  It has also been shown that constantly high ectopic expression of some 
proteins can be detrimental to the cell and therefore cause unwanted side effects (Weinhandl 
et al., 2014). 
To achieve a wide range of expression levels, plasmids containing inducible or repressible 
promoters rather than constitutive promoters can be used, of which there are many different 
types available including the tetracycline, glucose/galactose and copper systems.  The 
glucose/galactose system is the most commonly used, which causes an increase in expression 
of the protein of interest in the presence of galactose and a decrease in the expression in the 
presence of glucose which is regulated by the binding of the GAL4 and GAL80 proteins to the 
upstream activation sequences (UASs) (Romanos et al., 1992), however this system requires 
drastic changes to the growth media that could potentially affect the characteristics of the cell, 
and therefore lead to misleading phenotypes.  The tetracycline system relies on addition of 
differing concentrations of tetracycline to the media to alter the expression of the protein of 
interest by regulating the binding of activator or repressor molecules to the tetO promoter 
(Bellí et al., 1998), however the limitation of this system is the presence of the antibiotic which 
could negatively affect cellular characteristics.  Both of these regulatable promoter systems 
have been shown to allow tight regulation of the expression of the protein of interest.  Further 
to these systems of regulatable promoters, the glucose repressible alcohol dehydrogenase 2 
(ADH2) promoter has been shown to be able to affect the copy number of the plasmid when 
inserted in front of the CEN3 sequence, enabling the carbon source to affect expression of the 
protein of interest by affecting the copy number of the plasmid (Chlebowicz-Śledziewska and 
Śledziewski, 1985).  Another regulatable system also available is the copper repressible system 
which was the system chosen for this study. 
The copper repressible system is based on the CTR1 gene which encodes a membrane 
associated copper transport protein, the expression of which is repressed in the presence of 
copper, and increased during copper starvation (Labbe et al., 1997).  The regulation of 
expression is dependent on two copper responsive cis acting elements, and controlled by a 
copper sensing transcription factor called Mac1, therefore the CTR1 promoter region was 
cloned into a plasmid with variable cloning sites to allow insertion of the gene of interest in 
order to study the differential expression of that gene under the control of the copper 
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repressible promoter (Labbe and Thiele, 1999).  For our purposes the eEF1A coding sequence 
from the TEF1 gene was inserted downstream of the copper repressible promoter and the 
newly generated plasmid transformed into a yeast strain where both genomic copies of eEF1A, 
namely TEF1 and TEF2 had been removed providing us with a cellular organism where the 
amount of copper in the media should control the level of eEF1A transcription.  This strategy 
was deemed most logical to allow a range of different eEF1A protein expression levels to be 
achieved consistently, with changes in expression occurring very rapidly and controlled by 
adding either bathocuproine disulphonate (BCS), a copper chelator, or copper sulphate 
(CuSO4).   
This chapter therefore focuses on carefully downregulating the expression of eEF1A in 
Saccharomyces cerevisae, with the aim to determine if the biological consequences of the 
regulated withdraw/reduction of the expression on different cellular process. 
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5.2 Materials and Methods 
5.2.1 Materials Used for Yeast Work 
5.2.1.1 Yeast plasmids and Strains Used 
 




Cu414 expression vector CEN TRP1 Cu2+ 
repressible 
TKB579 
His tagged TEF1 into TKB561 digested with 
BamH1 
 
Table 5.2.1.1.1 – Yeast plasmids used to create the yeast strain used. 
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Strain with disrupted TEF1 and TEF2 genes 
with episomal TEF1 to maintain viability 
TKY622 An elongation defective yeast strain 
SGY5 
TKY102 transformed with TKB579 after 
removal of TEF1 URA with FOA 
TKY102 & TKB561 TKY102 transformed with TKB561 
 
Table 5.2.1.1.2 – Yeast strains used to create SGY5 strain and control strains. 
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5.2.1.2 Antibodies Used for Yeast Work 
 
Table 5.2.1.2 Antibodies Used for Western Blotting 
 
Name of Antibody Secondary Antibody 
Used 
Source Dilution 
Western Blotting – Primary Antibodies 
eEF1A Rabbit  1 in 10,000 
EF2 Mouse  1 in 20,000 
Western Blotting – Secondary Antibodies 
Anti- Mouse - Sigma Aldrich 1 in 5,000 
Anti- Rabbit - Sigma Aldrich 1 in 5,000 
 
Table 5.2.1.2 – Primary and secondary antibodies used for all Western blots for this chapter, 
including dilutions, and where they were purchased from. 
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5.2.2 Methods for Yeast Work 
 
5.2.2.1 Creation of SGY5 strain 
 
5.2.2.1.1 Isopropanol Precipitation of Plasmid 
 
Bacteria containing the plasmid to be purified were grown from a -80oC stock in LB amp (Table 
5.2.2.1.1) overnight in a shaking incubator at 37oC at 250 rpm.  The bacteria were pelleted by 
centrifugation at 3,000 rpm for 5 minutes at room temperature, before the supernatant was 
removed, and the pellet resuspended in 250µl Qiagen solution P1 (Table 5.2.2.1.1).  Cells were 
then lysed by adding 250µl Qiagen solution P2 (Table 5.2.2.1.1), and neutralised by adding 
350µl Qiagen solution P3 (Table 5.2.2.1.1), before transferring to an eppendorf tube and 
centrifuging at 14,000 rpm for 5 minutes at room temperature.  Supernatant was transferred 
to a new eppendorf tube, and an equal amount of isopropanol added.  The tube was 
vigorously mixed, before transferring to the -80oC freezer for 10 minutes, followed by the -
20oC freezer for 20 minutes, after which the tube was put in the centrifuge at 13,000 rpm for 
20 minutes at 4oC.  The supernatant was removed, and the pellet washed with ice cold 70% 
(v/v) ethanol, before drying the pellet and resuspending in 50µl of distilled water.  Some of the 
purified plasmid was then mixed with 5x loading dye (Table 5.2.2.1.1), run on a 1% (w/v) 
agarose gel as described in section 2.2.13.1, and viewed using a UV box, to ensure that the 
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Table 5.2.2.1.1 Composition of Buffers Used for Plasmid Extraction 
Name of Solution/Buffer Composition of Buffer 
LB Amp 20g LB powder 
Made to 1L with distilled water 
Autoclaved 
Once cooled, 1ml 100mg/ml Ampicillin added 
Qiagen Solution P1 1ml 10mg/ml RNase A 
5ml 1M Tris pH 8.0 
2ml 0.5M EDTA 
Made to 100ml with Distilled Water 
Qiagen Solution P2 10ml 2M Sodium Hydroxide 
10ml 10% SDS 
Made to 100ml with Distilled Water 
Qiagen Solution P3 29.5g Potassium Acetate 
Made to 100ml with Distilled Water 
pH to 5.5 with Glacial Acetic Acid 
5x DNA Loading Dye 250mM Tris pH 6.8 
40% (v/v) Glycerol 
4% (w/v) Sodium Dodecyl Sulphate (SDS) 
4% (v/v) 2-Mercaptoethanol 
Bromophenol Blue to Colour 
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Table 5.2.2.1.1 – Composition of solutions used for growth of bacteria and extraction of 
plasmids 
 
5.2.2.1.2 Transformation of Yeast Strain 
 
Yeast strain TKY102 was grown in 10mls YEPD (Table 5.2.2.1.2) overnight to an optical density 
at 600nm (OD600) of between 0.3-1.  Cells were centrifuged at 2,000 rpm for 5 minutes at room 
temperature, before the supernatant was discarded, the pellet resuspended in 5mls LiAc/TE 
(Table 5.2.2.1.2), and pelleted again by centrifugation under the same conditions, whilst the 
salmon sperm DNA (ssDNA) was boiled for 5 minutes, after which it was put onto ice.  The 
supernatant from the cells was discarded, and the pellet resuspended in 1ml LiAc/TE, before 
the following was added to an eppendorf tube; 
 
12µl ssDNA 
10µl Plasmid DNA (Dependent on the concentration of the preparation) 
100µl Yeast 
 
1ml of 40% (w/v) PEG (Table 5.2.2.1.2) was then added and the tube inverted and tapped to 
mix, before placing in a 30oC incubator for 30 minutes.  The cells were then placed at 42oC for 
10 minutes to heat shock, before centrifugation at 3,000 rpm for 5 minutes.  The supernatant 
was then removed, and the pellet resuspended in 100µl sterile distilled water, after which the 
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Table 5.2.2.1.2 Composition of Buffers Used for Yeast Transformation 
Name of Solution/Buffer Composition of Buffer 
YEPD 20g Peptone 
10g Yeast Extract 
Made to 900mls with Distilled Water 
Autoclaved 
20g Glucose made up to 100mls with 
Distilled Water 
Glucose Solution Sterile Filtered to make 1L 
LiAc/TE 5mls 1M Tris pH 7.5 
5.1g Lithium Acetate 
1ml 0.5M EDTA 
Made up to 500mls with Distilled Water 
Autoclave 
40% Polyethylene Glycol (PEG) 5mls 1M Tris pH 7.5 
5.1g Lithium Acetate 
1ml 0.5M EDTA  
200g PEG 
Made up to 500mls with Distilled Water 
Autoclave 
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c-trp Plates 1.7g Yeast Nitrogen Base – Amino Acids 
5g Ammonium Sulphate 
20g Glucose 
20g Agar 
1.26g c-trp Drop Out Mix 
Made to IL with Distilled Water 
Autoclave 
Pour into Petri Dishes 
 
Table 5.2.2.1.2 – Composition of solutions used to transform plasmids into yeast strains. 
 
5.2.2.1.3 Removal of TEF2-Ura3 Plasmid from Transformed Strain 
 
Several colonies from the plate of transformed yeast were taken and transferred to a fresh c-
trp plate, creating a square patch of cells for each colony, before plates were placed into the 
30oC incubator to grow.  Once grown the cells were replica plated using sterile velvet fabric 
onto a c-trp and a 5-FOA plate (Table 5.2.2.1.3), and placed into the incubator at 30oC to grow.  
The cells growing on the 5-FOA plate were then replica plated onto a fresh 5-FOA plate, and 
again placed into the 30oC incubator, before finally being replica plated onto a c-trp plate and 
left to grow in the 30oC incubator.  Cells were then streaked onto a c-trp or YEPD plate to use 
as a stock plate.  For long term storage the new SGY5 strain was frozen by growing the strain 
in 10mls c-trp, before taking 1ml of yeast and adding 0.5mls 60% (w/v) glycerol, and placing 
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Table 5.2.2.1.3 Composition of 5-FOA Plates 
 
Name of Solution/Buffer Composition of Buffer 
5-Fluoroorotic Acid (5-FOA) Plates 1.7g Yeast Nitrogen Base – Amino Acids 
5g Ammonium Sulphate 
20g Glucose 
20g Agar 
1.3g Complete Amino Acid Mix 
Make up to 700ml with Distilled Water 
Autoclave 
Dissolve 1g 5-FOA in 300mls Distilled Water 
Filter Sterilise 5-FOA into Mix 
Pour into Petri Dishes 
 
Table 5.2.2.1.3 – Composition of 5-FOA plates for removal of URA3 plasmid. 
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5.2.2.2 Liquid Growth Assay 
 
A preculture of yeast was grown from the stock plate by inoculating a colony in c-trp (Table 
5.2.2.2) or YEPD, and shaking at 250 rpm at 30oC overnight.  Cells were then diluted into c-trp 
or YEPD containing different concentrations of either bathocuproine disulfonate (BCS), or 
copper sulphate (CuSO4), so that all bottles had the same OD600 at the start time point.  Cells 
were then left to grow for around 12-16 hours, after which 1ml of cells were transferred to a 
cuvette and the OD600 read and recorded.  If the OD600 was higher than 1, the sample was 
diluted to maintain accuracy. 
 
Table 5.2.2.2 Composition of c-trp Media 
Name of Solution/Buffer Composition of Buffer 
c-trp 1.7g Yeast Nitrogen Base – Amino Acids 
5g Ammonium Sulphate 
20g Glucose 
1.26g c-trp Drop Out Mix 
Made to IL with Distilled Water 
Autoclave 
 
Table 5.2.2.2 – Composition of c-trp media for growing yeast cells 
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5.2.2.3 Protein Extraction for Western Blotting 
 
Cells were grown overnight in c-trp or YEPD to and OD600 of between 0.3-0.8.  Cells were 
centrifuged at 3,000 rpm for 5 minutes at room temperature, before discarding supernatant 
and resuspending the pellet in 5mls distilled water.  Cells were then pelleted by centrifugation 
with the above conditions, after which the pellet was resuspended in 100µl cold lysis buffer 
(Table 5.2.2.3).  The cells were transferred into an eppendorf tube containing around 50µl of 
glass beads and either vortexed for 30 seconds, followed by 30 seconds on ice repeated 7 
times, or placed into the fast prep at 50 for 45 seconds.  The eppendorf tubes were then 
centrifuged at 13,000 rpm for 5 minutes at 4oC, and the supernatant collected in a fresh tube.  
Protein quantification was carried out as described in section 2.2.7.  50µl 5x loading dye was 
added to 50µl sample, and gel electrophoresis and Western blotting performed as described in 
sections 2.2.8 and 2.2.9 respectively. 
 
Table 5.2.2.3 Composition of Lysis Buffer 
Name of Solution/Buffer Composition of Buffer 
Lysis Buffer 0.5ml 1M Tris pH 8.0 
1.65mls 60% (v/v) Glycerol 
5µl 1M DTT 
25µl 200mM PMSF 
Made up to 5mls with Distilled Water 
 
Table 5.2.2.3 – Composition of lysis buffer used for protein extraction. 
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5.2.2.4 Solid Growth Assay 
 
A 5ml preculture of cells was grown in c-trp overnight shaking at 250 rpm at 30oC.  The OD600 
of the cultures was read, and diluted to equal the OD600 of the lowest reading sample.  90µl of 
culture was the placed into the 1st well of a 96 well plate, and 90µl c-trp placed into the next 4 
wells.  10µl of culture was taken from well 1, placed into well 2 and mixed, before 10µl of 
culture was taken from well 2 and transferred to well 3.  This was continued until all 5 wells 
contained cells as a dilution across the wells.  A spotter was then used to spot a drop of the 
culture from each well onto c-trp plates containing different concentrations of BCS or CuSO4.  
One c-trp plate or each condition was inoculated by hand by pipetting 5µl of each culture onto 
the plate.  The plates were then grown at 30oC until spots appeared, after which photographs 
were taken.  
 
5.2.2.5 Actin Staining 
 
Cells were grown in c-trp with varying concentrations of BCS or CuSO4 overnight shaking at 250 
rpm at 30oC.  OD600 was read, and the cells diluted into 5mls of YEPD such that the OD600 would 
be around 0.2, and put back on the shaking incubator with the same conditions for 4 hours.  
The OD600 was read again, and the cell pelleted by centrifugation at 2,000 rpm for 5 minutes at 
room temperature, before resuspending in 5mls fixation solution (Table 5.2.2.5), and 
incubating at room temperature on a rotary shaker for 90 minutes.  Cells were then washed in 
1 ml of 1x PBS, before resuspending again in 1 ml 1x PBS.  Approximately 25 million cells were 
transferred to an eppendorf tube, and centrifuged under the same conditions as before, after 
which the pellet was resuspended in 100µl of 0.6µM rhodamine phalloidin in 1x PBS.  Cells 
were then washed with 1x PBS three times before finally resuspending in 50µl mounting 
media (Table 5.2.2.5), after which cells were stored at -20oC until viewing.  When viewed, 1µl 
of cells was added to a microscope slide, and a coverslips placed on top and firmly pressed 
down, and viewed by scanning confocal microscopy. 
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Table 5.2.2.5 Composition of Buffers for Actin Staining 
Name of Solution/Buffer Composition of Buffer 
Fixation Solution 4.45mls 1x PBS 
50µl MgCl2 
0.54ml Formaldehyde 
Mounting Media 2.4g Mowiol 
6g Glycerol 
6mls Distilled Water 
12mls 0.2M Tris-Cl, pH 8.5 
2.5% (w/v) 1,4-diazobicyclo-[2.2.2]-octane 
(DABCO) 
 
Table 5.2.2.5 – Composition of buffers used for actin staining of yeast cells. 
 
5.2.2.6 Yeast Polysome Extraction With or Without CHX 
 
10ml yeast cultures were grown overnight on the shaking incubator at 250 rpm at 30oC.  The 
OD600 of the precultures was read, and the appropriate amount added to 200mls c-trp or 
100mls YEPD with or without BCS or CuSO4, so that the cultures would have an OD600 of 
around 0.8 by the time of extraction.  If CHX was used, 0.1mg/ml CHX was added to the 
culture and incubated for a further 15 minutes.  The cultures were transferred to 250ml 
centrifuge bottles, and filled with ice, before centrifugation at 7,000 rpm for 5 minutes at 4oC.  
The media was discarded, and the pellet resuspended in 10mls of freshly prepared polysome 
lysis buffer with or without CHX (Table 5.2.2.6), and the solution transferred to a 15 ml tube.  
The cells were pelleted at 3,000 rpm for 5 minutes at 4oC, the supernatant discarded and cells 
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resuspended in 0.25mls polysome lysis buffer.  The solution was transferred to a breaking tube 
containing around half the volume of glass beads, and the cell lysed using the cell lyser at 50 
for 3 minutes.  The tubes were centrifuged at 13,000 rpm for 20 minutes at 4oC, before 
transferring the supernatant to a fresh tube.  The extraction was quantified, centrifuged on 
sucrose gradients prepared as described in 2.2.15.2, and run on the gradient profiler as 
described in section 2.2.15.3. 
 
 
Table 5.2.2.6 Composition of Buffers Used for Polysome Extraction 
Name of Solution/Buffer Composition of Buffer 





0.2% (v/v) Diethyl phthalate (DEP) 




0.2% (v/v) DEP 
 
Table 5.2.2.6 – Composition of buffers used to extract polysomes in the presence and absence 
of CHX. 
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5.3 Results 
5.3.1 Creation of strain with copper regulatable levels of eEF1A 
 
The yeast strain TKY102 was created by Sandbaken and Culbertson (1988), and the 
predominant characteristic of this strain is that both chromosomal copies of the genes 
encoding eEF1A, namely TEF1 and TEF2 have been disrupted, yielding no functional expression 
of the protein.  To maintain viability, the TEF1 gene was inserted back into the TKY102 strain 
by way of an episomal plasmid with a URA3 marker (Cottrelle et al., 1985, Sandbaken and 
Culbertson, 1988).  Plasmid shuffling can therefore be obtained through introduction of 
another form of TEF1/eEF1A followed by removal of the episomal URA3 plasmid using 5-
fluoroorotic acid (5-FOA).  For the purpose of this study an eEF1A regulatable expressing 
vector was chosen, TKB579.  Plasmid shuffling following transformation of TKB579 and 
elimination of the episomal URA3 eEF1A plasmid created a strain in which the only form of 
eEF1A present was controlled by the copper repressible promoter, theoretically allowing 
varying levels of eEF1A to be achievable by increasing and or sequestering the concentration 
of copper in the media.  This strategy is schematically represented in figure 5.3.1.  The newly 
created yeast strain was named SGY5. 
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Figure 5.3.1 – Schematic representation of plasmid shuffling used to create the SGY5 strain.  
The plasmid containing eEF1A with the copper repressible promoter was transformed into the 
yeast strain, after which the episomal TEF1 plasmid was removed using 5-FOA to create the 
new SGY5 strain in which the only copy of eEF1A was controlled by the copper repressible 
promoter. 
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5.3.2 A range of different eEF1A expression levels were obtained from 
cells grown in media containing between 1µM CuSO4 and 12.5µM BCS 
 
After creation of the SGY5 strain containing the plasmid encoding expression of eEF1A 
controlled by the copper repressible promoter, we sought to establish a dose response effect 
of different concentrations of bathocuproine disulphonate (BCS) and copper sulphate (CuSO4), 
in order to regulate the transcriptional activity of the promoter for eEF1A, to determine which 
concentrations would give the appropriate changes in eEF1A protein expression.  A range of 
concentrations between 1µM CuSO4 and 12.5µM BCS were selected after a simple growth 
experiment showed that this range would provide the greatest change in cell growth (data not 
shown).   
To verify the level of expression of eEF1A, the yeast cells were grown for 24 hours in medium 
containing varying concentration of CuSO4 and BCS, protein extracted, quantified and run on a 
gel, transferred to nitrocellulose, before being probed for eEF1A (EF2 as a loading control) and 
developed using standard Western blotting techniques.  The presence of 12.5µM BCS resulted 
in a similar level of eEF1A protein expression as the control strain, suggesting that this 
concentration is capable of eliminating all traces of copper and inducing the full expression of 
eEF1A, replicating the level of expression seen in physiological conditions (Figure 5.3.2). 
When the cells were grown without BCS, the level of eEF1A protein expression was reduced to 
approximately 40%, and the presence of 1µM CuSO4 led to further reduction of the expression 
to a minimal 20% of the levels seen in the control strain, indicating that as the amount of 
copper in the media increases, the level of eEF1A protein expression decreases in a dose 

























Figure 5.3.2 – Addition of varying levels of BCS or CuSO4 to the synthetic growth media results 
in change in eEF1A protein expression.  Cells were grown overnight in c-trp in exponential 
phase with varying concentrations of BCS or CuSO4 to and OD600 of approximately 0.8, before 
total protein was collected and quantified. 5ug of total protein was loaded onto a gel, run, 
transferred to nitrocellulose, before being probed for eEF1A, and EF2 as a loading control and 
developed using ECL (A). The intensity of the bands was quantified by densitometry analysis 
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5.3.3 The same concentrations of BCS and CuSO4 in YEPD show a less 
gradual change in eEF1A expression, resulting in a more all or nothing 
response 
 
The previous analysis (Figure 5.3.2) clearly demonstrated the presence of copper in synthetic 
medium, indicating that this level, endogenously found in the different media preparation 
needs to be taken into consideration. It was therefore important to determine whether or not 
the same gradual change in eEF1A expression could be achieved by addition of BCS and CuSO4 
in YEPD medium.  YEPD is a much more nutrient rich media, containing yeast extract and 
tryptone, where concentrations of copper are much less characterised. It is also a potentially 
more ‘forgiving’ medium.   
In order to determine the regulatory effects of the copper inducible promoter on eEF1A 
expression under such conditions, cells were grown in YEPD with varying concentrations of 
BCS or CuSO4 overnight, before total protein was extracted and quantified and a Western blot 
performed for eEF1A (EF2 as a loading control).  Whereas in c-trp media, 12.5µM BCS gave an 
eEF1A protein expression level similar to that of the control strain (Figure 5.3.2), in YEPD, only 
around 40% expression was observed. The gradual reduction of eEF1A protein expression 
controlled by BCS/CuSO4 seen in synthetic media was not observed in YEPD, as concentrations 
of BCS lower than 12.5µM BCS showed only minimal eEF1A protein expression, and addition of 
1µM CuSO4 resulted in almost undetectable levels of eEF1A protein expression (Figure 5.3.3), 
suggesting that in YEPD growth, the expression of eEF1A is much less regulatable and that 

























Figure 5.3.3 – Addition of BCS or CuSO4 to the growth media results in change in eEF1A protein 
expression in YEPD. Cells were grown in YEPD overnight in exponential phase with the 
corresponding concentrations of BCS and CuSO4 to an OD600 of approximately 0.8, before total 
protein was extracted and quantified.  5µg total protein was then loaded onto a gel, run, 
transferred to nitrocellulose and probed for eEF1A and EF2 as a loading control, before 
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5.3.4 Level of expression of eEF1A as determined by addition of BCS 
and CuSO4, correlates to growth rate in both C-trp and YEPD 
 
Addition of varying concentrations of CuSO4 and BCS lead to significant changes in the level of 
eEF1A expression in c-trp (Figure 5.3.2) but less so in YEPD (Figure 5.3.3).  We now sought to 
determine how the downregulation of eEF1A protein level would affect yeast growth and 
viability on both liquid and solid cultures.   
Growth assays were performed by monitoring either absorbance of overnight liquid growth or 
by colony size formation on plates in varying concentrations of BCS and CuSO4 concentrations 
as used to achieve the varying level of eEF1A protein expression (Figure 5.3.4).  Cells grown in 
the presence of 12.5µM BCS in c-trp, which has an eEF1A protein expression level similar to 
that of the control strain, also demonstrated similar growth rates at around 90%.  Cells grown 
in absence of BCS, which results in an eEF1A protein expression level of around 40% resulted 
in a growth rate of 40%, whilst cells incubated in 1µM CuSO4, with an eEF1A protein 
expression level of 20% presented a growth rate of approximately 20%.  This data indicates a 
high proportionally between eEF1A expression and growth.  This difference in growth rate was 
confirmed using the solid growth assay, which showed a gradual decrease in growth with 
decreasing concentration of BCS, with the lowest growth rate observed in cells grown in the 
presence of 1µM CuSO4 (Figure 5.3.4 B). 
The correlation of growth to eEF1A protein expression was not as robust in YEPD conditions, 
since the different concentrations of BCS all led to a similar 80% growth rate, with only cells 
grown in 1µM CuSO4 resulting in severely reduced eEF1A protein expression level showing 

























Figure 5.3.4 – The growth rate of yeast cells is reduced with a reduced level of eEF1A protein 
expression.  Liquid growth assays were performed by using precultures to inoculate media at 
the same starting OD600, grown overnight, and the OD600 read and recorded the following day.  
The percentage expression compared to the control TKY102 & TKB561 strain was plotted onto 
a graph (A).  Solid growth assays were performed by creating a serial dilution of cells by 
diluting a preculture of cells so that the starting concentrations were the same before adding 
100µl to a 96 well plate.  10µl of this solution was taken and transferred to the next well along 
with 90µl of media, and this continued until 5 wells contained cells and spotting onto c-trp 
plates containing 0, 0.1 or 5µM BCS or 1µM CuSO4.  The plates were then incubated at 30oC 
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5.3.5 Reduced expression of eEF1A results in changes in actin 
organisation 
 
Overexpression of eEF1A in yeast has been shown to cause a slow growth phenotype that has 
been suggested to be due to the change in actin organisation rather than a change in protein 
translation (Munshi et al., 2000, Gross and Kinzy, 2005), however, the effect of reduced 
expression of eEF1A on actin organisation in yeast has not been investigated.   
Using the SGY5 strain and the different concentrations of BCS and CuSO4 to create a gradient 
of different eEF1A expression levels, the yeast were grown in c-trp, fixed and stained for actin 
using rhodamine phalloidin before viewing using confocal microscopy.  As has been shown 
before, both the control strain, and SGY5 grown in 12.5µM BCS show an ‘endogenous and 
physiological’ level of eEF1A protein expression (Figure 5.3.2) and after observation were seen 
to present highly organised actin cytoskeletal architecture, made primarily of actin patches 
and fibres or cables, as indicated by the arrows on the photographs. Growing the same cells 
when the amount of BCS was reduced to 1 and 0.5µM, with around 50% eEF1A expression 
compared to the control strain, demonstrated far fewer fibres, though the actin patches still 
remain.  Once CuSO4 was added, to create the lowest level of eEF1A protein expression at 
around 20%, both actin buds and fibres were disrupted, and no clear actin organisation could 
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Figure 5.3.5 – Reduced 
expression of eEF1A results 
in a disruption of the actin 
organisation in yeast.  Cells 
grown overnight in c-trp in 
the presence of 0, 0.5, 1 or 
12.5µM BCS or 1µM CuSO4 
to exponential phase were 
transferred to YEPD for 4 
hours before fixing and 
staining with rhodamine 
phalloidin, and mounted 
onto a microscope slide for 
viewing.  Cells were 
observed by confocal 
microscopy with a 100x 
objective lens.  White 
arrows point to actin 
fibres/cables.
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5.3.6 Polysome profiles in c-trp and YEPD, with and without 
cycloheximide 
 
The data presented so far demonstrates that a decrease in eEF1A expression results in growth 
defects and changes in actin organisation, both in a dose dependent manner, the most 
extreme phenotypes being observed in the presence of 1µM CuSO4 resulting in the lowest 
level of eEF1A protein expression. It is however unclear whether these reported differences 
are a direct result of reduction in protein synthesis or possibly due to the lowering of other 
sub fraction pools of eEF1A that affect other physiological processes, potentially whilst 
conserving the translational ‘pool’.   
To determine if these down-regulations of eEF1A lead to significant changes in protein 
synthesis, we set out to determine the effect of BCS and CuSO4 addition to polysome profiles, 
however first the protocol needed to be established in the strain used in the media used.  
Polysome profiling is a common method of analysing translational activity of cells and an 
elongation block, which could potentially be caused by reduced levels of eEF1A, could be 
easily indentified due to an accumulation of ribosomes on the mRNA (polysome peaks) as long 
as the experiments are done in the absence of cycloheximide.  As mentioned previously, due 
to the effect of CHX on elongation, it is not ideal to use as a stabilising agent when observing 
potential changes in elongation, especially as these changes have been shown to be 
observable on a polysome profile in some cell types (Rivest et al., 1982).   This causes a 
problem with viewing an elongation block in the sample when extracted in the presence of 
cycloheximide, therefore the polysomes must be extracted without cycloheximide, requiring 
further optimisation.  Most methods already established are also focused on extractions after 
growth in YEPD media, rather than selective media, therefore this provided another hurdle, as 
the ‘gradient’ of expression of eEF1A was only properly observed in c-trp, therefore only c-trp 
could be used.  To ensure the protocol was working sufficiently, polysomes were first 
extracted after growth in YEPD with cycloheximide.  Following on from that, polysomes were 
extracted in c-trp with cycloheximide, and then c-trp without cycloheximide.  It was important 
to test whether polysome profiles could be obtained under each condition to ensure that any 
problems could be detected and solved quickly and easily.  The best examples of these trial 
profiles are shown (Figure 5.3.6). 
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Polysomes were extracted with or without cycloheximide, after growth in YEPD or c-trp, 
separated by density on a sucrose gradient and analysed for absorbance at 254nms.  The 
gradients were run on the gradient profiler to create the polysome profiles showing all 
characteristic features, proving that profiles can be obtained from cells grown in YEPD and in 
c-trp extracted both with and without cycloheximide (Figure 5.3.6).  Characteristic features of 
a normal polysome profile include the 40S and 60S peaks, which represent the individual 
ribosomal subunits, the 80S peak, also known as the monosome peak, which represents the 
intact ribosome, and the polysome peaks, which represent the ribosome that are actively 
translating with the first peak corresponding to mRNA with one monosome translating and the 
second peak with two translating monosomes and so on.  Changes in polysome profiles are 
usually quantified by the polysome/monosome (P/M) ratio, calculated using the areas 
underneath the respective peaks.  Polysome profiles allow changes in the different stages of 
protein translation to be observed, with an initiation block resulting in an increase in the 
monosome peaks with a decrease in polysome peaks causing a decrease in the P/M ratio, and 
an elongation block observed by reduction of the monosome peak and an increase in the 
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Figure 5.3.6 – Polysome profiles can be obtained in both YEPD and c-trp in the presence and 
absence of cycloheximide, with a clear elongation block observed in the strain with a 
translational defect.  For polysomes extracted with CHX, cells were grown to exponential 
phase overnight in YEPD (A) or c-trp (B) before 0.1mg/ml cycloheximide was added for 15 
minutes. Cells were then scraped into lysis buffer containing CHX, isolated, lysed and cellular 
content collected.  200µg of total nucleic acid was loaded onto a sucrose gradient, centrifuged 
at 38,000rpm for 2 hours, and analysed using the Biorad Gradient Profiler.  Polysomes 
extracted in the absence of CHX were prepared in the same way without incubating with CHX, 
and by scraping into lysis buffer without CHX (C).  The characteristic 60S, 80S and polysome 
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5.3.7 SGY5 strain shows an initiation block in the presence of 1µM 
CuSO4 in YEPD medium, but an elongation block in c-trp medium, 
however no difference is seen with varying concentrations of BCS. 
 
Having been able to establish appropriate polysome profiles that allow observation of changes 
in elongation ability both with and without the use of cycloheximide treatment, we sought to 
analyse whether the reduced expression of eEF1A caused by the variation in BCS or CuSO4, 
would lead to changes in polysome profiling that could be detected with our setup.  Cells were 
grown in either YEPD or c-trp with different concentrations of BCS and CuSO4 before, 
polysomes extracted, loaded onto a sucrose gradient and run on the gradient profiler.   
When cells were grown in YEPD and extracted with cycloheximide, the profile obtained for the 
SGY5 strain grown in the presence of 12.5µM BCS, which has similar or higher eEF1A protein 
expression level to the control strain, was comparable to that observed for the control strain, 
with the polysome/monosome (80S peak) ratio (P/M) very similar at 0.827 and 0.720 
respectively.  The profile obtained for the SGY5 strain grown in 1µM CuSO4, however, which 
showed very minimal eEF1A protein expression, showed a reproducible and unexpected 
initiation block, as demonstrated by the P/M ratio changing from 0.827 with 12.5µM BCS to 
0.168 with 1µM CuSO4, compared to 0.720 in the control strain (Figure 5.3.7A).  Cells grown in 
c-trp, and extracted in the presence of cycloheximide with 12.5µM BCS presented a similar 
profile and P/M ratio similar to that of the control strain, 0.121 and 0.163 respectively.  The 
presence of  1µM CuSO4, in synthetic medium,  which showed around 20% eEF1A protein 
expression compared to the control strain, resulted in a severe elongation block observed on 
the profile, with the P/M ratio changing from 0.121 with 12.5µM BCS to 0.865 with 1µCuSO4, 
compared to the control strain at 0.163 (Figure 5.3.7B).  Though cycloheximide can cause an 
elongation block, the block caused by addition of the CuSO4, was large and therefore 
observable in the presence of cycloheximide, however, smaller changes would not be 
observed, therefore to determine whether there were any changes in the profile of SGY5 
grown in the presence of varying concentrations of BCS, the cells were extracted without 
cycloheximide.  It was found that SGY5 cells grown in c-trp in the presence of either 0, 2.5 or 
5µM BCS and extracted in the absence of cycloheximide, showed no difference with P/M 
ratios of 0.061, 0.067 and 0.077 respectively, compared to the control strain with a P/M ratio 
of 0.091 (Figure 5.3.7C), even though the level of eEF1A expression in cells grown in these 
conditions was around 40% compared to the control.  
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Figure 5.3.7 – Reduced expression of eEF1A only caused changes in protein translation at the 
maximum level of protein reduction in the presence of 1µM CuSO4, less drastic changes in 
eEF1A protein level resulted in no change in protein translation.  Cells were grown overnight in 
YEPD with 0 or 12.5µM BCS or 1µM CUSO4 (A) or c-trp with 0, 2.5, 5 or 12.5µM BCS or 1µM 
CuSO4 (B & C) to an OD600 of approximately 0.8.  0.1mg/ml of cycloheximide was added to 
those extracted with CHX for 15 minutes (A & B). Cells were then scraped into lysis buffer 
containing CHX (A & B), or lysis buffer without CHX (C), isolated, lysed and cellular content 
collected.  200µg of total nucleic acid was loaded onto a sucrose gradient, centrifuged at 
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The focus of this chapter aimed to engineer a yeast strain in which the level of eEF1A protein 
expression could be tightly down-regulated in order to determine whether it was possible to 
extend our work to separate the function of eEF1A in protein translation and actin 
remodelling, this time in lower eukaryotes.  This would lend credence to the theory of 
different ‘pools’ of eEF1A for different functions, with the ‘pool’ for translation conserved over 
others due the essential nature of the function to the survival of the cell.   
To study this and in order to have controlled reduced levels of eEF1A, a yeast strain was 
engineered in which the only form of eEF1A expression was regulated through a copper 
repressible promoter (Figure 5.3.1).  The change in eEF1A protein expression with varying 
concentrations of BCS and CuSO4 in c-trp was confirmed by Western blotting (Figure 5.3.2), 
with the cells grown in the presence of 1µM CuSO4 showing the greatest reduction in eEF1A 
protein expression whilst the addition of 12.5µM BCS to the media results in a similar eEF1A 
protein expression to the control strain. Interestingly, regulating the levels of BCS and CuSO4 in 
YEPD did not result in a gradient of eEF1A protein expression, rather more of an ‘all or 
nothing’ response was observed, with a concentration of only 5µM BCS resulting in a large 
decrease in eEF1A protein expression (Figure 5.3.3).  This is likely to be due to YEPD being a 
much more nutrient rich, less restrictive media therefore more extreme conditions are 
required in order to affect the level of protein expression in this media compared to synthetic 
medias such as c-trp. 
Regulating the levels of BCS and CuSO4 led to correlative evidence of eEF1A protein expression 
and cell growth rate although not always providing the best linearity (Figure 6.2.4).  Much 
evidence has shown that cell growth is directly related to actin cytoskeletal organisation, with 
actin patches/buds and cables both having been shown to be involved in cell division in yeast 
(Moseley and Goode, 2006).  Actin patches have been shown to localise to the region at which 
the daughter cell will bud off from the mother cell, and the actin cables have been shown to 
orient along the growth axis (Drubin, 1990).  A change in expression of eEF1A has been shown 
to affect the organisation of the actin cytoskeleton without affecting the rate of total protein 
translation in previous studies (Gross and Kinzy, 2005) as well as in previous chapters (Figures 
3.3.1-5), therefore it seems likely that the reduced growth rate observed in the presence of 
the different concentrations of BCS and CuSO4 in both c-trp and YEPD could be due to the 
disruption of the actin cytoskeleton.   
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In agreement with the suggested possibility that actin disruption could be the cause of the 
observed slow growth phenotype when eEF1A protein is reduced, the overall organisation of 
actin was found to be affected in those cells grown with BCS and CuSO4 (Figure 5.3.5).  With 
intermediate eEF1A protein expression when cells were grown in the presence of 1 or 0.5µM 
BCS which correlates to approximately 50% eEF1A protein expression compared to the control 
strain, a reduction in actin fibres was observed, whilst when the level of eEF1A protein 
expression was reduced to its maximum to around 20% of the control when grown in the 
presence of 1µM CuSO4, both actin buds and actin fibres were disrupted.  As eEF1A is a known 
actin binding protein (Yang et al., 1990, Demma et al., 1990), these results are not surprising 
and could suggest that since and insufficient amount of eEF1A is present in the cell, there is 
much less control of the actin cytoskeleton.   
Though no studies have shown the effect of reduced expression of eEF1A on the actin 
cytoskeleton, overexpression studies have shown that when TEF1 or TEF2 are overexpressed 
in yeast, cell growth rate is reduced and actin cytoskeletal organisation is affected whilst no 
difference in protein translation was observed (Munshi et al., 2000).  Gross and Kinzy, 2005, 
used this overexpression phenotype to observe the effect of eEF1A mutants that were shown 
to affect cytoskeletal organisation without affecting protein translation, and found that the 
mutants affecting the actin cytoskeleton were capable of restoring the slow growth 
phenotype, indicating that the observed phenotype was due to the effect of eEF1A on the 
cytoskeleton.  Based on these studies, as well as the results reported in previous chapters 
which showed a reduced growth rate with a change in actin architecture and no change in 
protein translation caused by a decrease in eEF1A protein expression, it seems sensible to 
suggest that these changes in actin cytoskeletal organisation are likely to be the cause of the 
change in cell growth rate.  Further supporting this is the finding that mutant forms of eEF1β 
can also result in similar effects on the actin cytoskeleton which also confers a slow growth 
phenotype (Pittman et al., 2009), therefore adding further credence to the implication that it 
is the disruption of the actin cytoskeleton that causes the altered growth rate.  This suggests 
that eEF1A may be an important regulator of the actin cytoskeleton in yeast under these 
conditions, and, as the actin cytoskeleton can affect many other cellular functions, this 
reduced expression of eEF1A and its resulting effect on the cytoskeleton could make eEF1A a 
major regulator of many cellular roles.   
The roles of eEF1A in actin binding and protein translation have been suggested to be 
independent based on studies showing changes in actin organisation without any effect on 
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translation by methionine incorporation or polysome profiling (Munshi et al., 2000, Gross and 
Kinzy, 2005), leading to the hypothesis of the different ‘pools’ of eEF1A for different functions.  
Based on the above findings it would be interesting to determine whether changes in 
translation were observed in our yeast cells under the different conditions. 
Attaining polysome profiles of the yeast cells grown in c-trp in the absence of CHX, required 
many steps of optimisation to ensure that all characteristic features of the profile could be 
observed and therefore compared (Figure 5.3.6).  Once the protocol was established, it was 
determined that when cells were grown in the presence of 1µM CuSO4 in YEPD, an initiation 
block was observed (Figure 5.3.7A), however when the cells were grown in the presence of 
1µM CuSO4 in c-trp, an elongation block was observed (Figure 5.3.7B).  The observed 
elongation block in c-trp was expected as, when 1µM CuSO4 was added, the eEF1A protein 
level would have been reduced so drastically that there would not be sufficient protein 
available to allow protein translation to continue at a normal rate.   
The initiation block observed when the cells were grown in 1µM CuSO4 in YEPD was unusual 
as eEF1A is an elongation factor therefore the elongation stage would be expected to be 
affected as observed in c-trp, however, the cells grown under these conditions have been 
shown to have a completely disrupted actin cytoskeleton, and disruption of the actin 
architecture has been shown to affect initiation both as a result expression of mutated eEF1A 
and independently of eEF1A (Gross and Kinzy, 2007).  As several different initiation factors 
have been shown to associate with the cytoskeleton (Howe and Hershey, 1984, Gross and 
Kinzy, 2007), it is possible that the disruption of the cytoskeleton could render the initiation 
factors no longer functional therefore causing the observed initiation block.  Why this is not 
observed in the c-trp samples under the same conditions is unknown, however it is possible 
that the level of cytoskeletal disruption in cells grown in YEPD is greater than that observed in 
c-trp resulting in an initiation block in YEPD and an elongation block in c-trp as there would not 
be sufficient eEF1A to continue the elongation stage. 
Polysome profiles of the SGY5 strain grown in c-trp with 0, 2.5 or 5µM BCS however, showed 
no elongation block when compared to the control strain, showing that although the level of 
eEF1A protein expression is reduced at these concentrations (Figure 5.3.2), the translation 
function of eEF1A is unaffected (Figure 5.3.7C).  This would suggest that under these 
conditions there was sufficient eEF1A protein available for the cell to utilise for protein 
translation, and given the observed changes in actin architecture under these same conditions, 
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supports the theory of there being different ‘pools’ of eEF1A for different functions, with the 
‘pool’ for translation conserved over all other functions. 
The results all taken together provide a picture that suggests that when eEF1A levels are 
reduced by the maximum amount, i.e. when grown in the presence of 1µM CuSO4, actin 
organisation and translation are both affected, as well as having a profound impact on cell 
growth rate.  The change in cell growth rate under these conditions is likely to be caused by 
the effect on both actin organisation and translation, as the integrity of the actin cytoskeleton 
is essential for cell growth, and translation of new proteins is essential to allow the cell to 
divide.  However, when eEF1A levels are reduced to less dramatic levels, i.e. in the absence of 
BCS, the elongation stage of translation is unaffected whilst actin organisation is disrupted 
with fewer actin fibres observed.  At these levels of eEF1A expression, cell growth rate is also 
found to be reduced.  This provides further evidence to support previous studies that have 
suggested that the actin function of eEF1A is independent of its role in protein synthesis 
(Gross and Kinzy, 2005), as well as showing that this disruption of the actin cytoskeleton is 
capable of affecting cell growth rate proving a link between the two processes indicating that 
an intact, undisrupted actin cytoskeleton is essential for normal cell division.  Furthermore, the 
evidence that intermediate levels of eEF1A protein expression allow for a normal translational 
function to the detriment of actin organisation suggests that the theory of different ‘pools’ of 
eEF1A for different functions could be the most likely explanation, and that the ‘pool’ for 
translation is conserved above all others due to its importance to the survival of the cell. 
This potential role of eEF1A in regulating its different functions and affecting the integrity of 
the actin cytoskeleton would have great biological significance, as if there are different ‘pools’ 
of eEF1A conserved for different functions, the level of eEF1A protein expression in the cell 
could regulate the functions of the cell both spatially and chronologically.  The actin 
cytoskeleton is a major regulator of many different functions within the cell and provides the 
structural basis by working as a scaffold for proteins to localise to, thereby allowing 
organisation and compartmentalisation of the cell, therefore by affecting the integrity of the 
actin cytoskeleton, the expression of eEF1A protein can cause changes in many different 
cellular functions.  For example, the disruption of the actin cytoskeleton would affect other 
actin binding proteins.  ABP-1 is an actin binding protein that has been shown to localise to 
actin patches but not to actin cables, and has been suggested to play a role in localised cell 
surface growth of yeast (Drubin, 1990), therefore any disruption of actin patches as observed 
in the 1µM CuSO4 condition would also affect the localisation of ABP-1 and would therefore 
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affect this function of ABP-1.  Similarly tropomyosin has been shown to localise to actin cables 
but not to actin patches, and disruption of the tropomyosin gene results in a slow growth 
phenotype (Liu and Bretscher, 1989), therefore the reduced expression of eEF1A protein 
observed in the intermediate conditions which disrupt actin cables while not affecting actin 
patches would disrupt this function of tropomyosin which could contribute to the observed 
phenotypes.  These are just two examples of actin binding proteins that interact with actin in 
different ways but would not be able to exert their effect if the actin cytoskeleton was 
disrupted as is observed when the level of eEF1A protein is reduced to varying levels.   
This chapter has focussed on the role of eEF1A in translation, actin organisation, and cell 
growth, however, eEF1A has been shown to have other non canonical functions, therefore to 
be able to observe these in this cell system or by similar methods in other cell systems would 
allow further understanding of the regulatory role of eEF1A in cellular functions.  
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6.0 General Discussion and Future Work 
 
6.1 General Discussion 
 
Translation has been shown to be dependent upon a functional well organised actin 
cytoskeleton, and eEF1A provides the perfect link to ensure that the two functions are 
synchronised (Negrutskii and Deutscher, 1991, Gross and Kinzy, 2007).  It is present in large 
excess the other components of the translational machinery (Slobin, 1980), therefore it is very 
easy to view it as a multifunctional protein that can perform several tasks simultaneously.  It is 
a known actin binding protein, which can bundle actin into unique formations which have 
been suggested to be able to exclude other actin binding proteins (Owen et al., 1992), which 
would make it a likely candidate to be one of the main regulators of actin cytoskeletal 
organisation.   
It is therefore our hypothesis that there are different ‘pools’ of eEF1A within the cell for its 
different functions in translation, actin binding, microtubule binding bundling and severing 
(Durso and Cyr, 1994, Shiina et al., 1994, Moore et al., 1998), influencing apoptosis (Billaut-
Mulot et al., 1996, Kato, 1999, Duttaroy et al., 1998, Chen et al., 2000, Ruest, 2002, Talapatra 
et al., 2002, Borradaile et al., 2005) and cell proliferation and cell cycle (Pecorari et al., 2009), 
among others.  This is supported by our findings that the 40% reduction in eEF1A in the 2E2 
cells compared to the control CHO cells results in no change in protein translation, eEF1A’s 
canonical function, however causes significant changes to the actin cytoskeleton, as well as 
the findings that as eEF1A is reduced in yeast cells, actin organisation is affected, whilst 
translation is unaffected, until a point at which eEF1A is reduced by such an extent that both 
the translational functions and the actin organisation are completely disrupted.  eEF1A has 
been shown to bundle actin into square packed bundles which exclude other actin binding 
proteins (Owen et al., 1992).  We suggest that this unique bundling of actin by eEF1A could 
explain the paradoxical observation that when you reduce the level of eEF1A an increase in 
actin bundling is observed as the reduced expression of eEF1A provides the opportunity for 
other actin binding proteins, such as those mentioned previously, to bundle actin into the 
observed actin stress fibres.   
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α-actinin is presented as a likely candidate for the bundling of actin into the observed stress 
fibres in the absence of abundance of eEF1A protein expression, though other ABPs could also 
be involved due to the presence of eEF1A as an side binding actin bundling protein. 
All of these findings point towards eEF1A being a major regulator of the actin cytoskeleton, 
potentially by negatively regulating the activation of proteins or signalling pathways due to its 
abundance within the cell.  Once this abundance is removed by reduced the protein 
expression of eEF1A, the inhibitory effect is removed or reduced therefore allowing processes 
that would normally be prevented to occur.  The evidence supporting this seems reasonably 
strong based on the lack of change in protein synthesis and the drastic change observed in the 
actin cytoskeleton, along with other proteins associated with it.   
It was found that the reduced expression of eEF1A resulted in reduced speed of cell migration 
and decreased cell proliferation, which were both initially thought to be a consequence of the 
disrupted actin cytoskeleton.  In the study of yeast the cell growth rate was closely correlated 
to the level of eEF1A expression which was linked to the organisation of the cytoskeleton.  As 
the level of eEF1A was reduced, the growth rate decreased, and the actin cytoskeleton 
became more disorganised which shows a link between the three areas, however, this link was 
questioned in mammalian cells, when the clonal cell lines failed to rescue the growth 
phenotype.  This lack of rescue is thought to be due to other changes in the cells that have not 
yet been determined, or possibly due to the level of eEF1A expression not being high enough 
to support the rescue of this phenotype or due to the minor differences in hamster and 
human eEF1A.  Further work to create overexpressing clones or clones expressing hamster 
eEF1A would determine which of these is correct, however as the link between eEF1A 
expression and cell growth is fairly well established it would be surprising if the phenotype was 
not eEF1A dependent. 
Interestingly only eEF1A1 was capable of restoring the migration phenotype when both 
eEF1A1 and eEF1A2 were shown to be sufficient to rescue the disruption of the actin 
cytoskeleton, which also calls into question the dependence of the migrational defect on the 
disruption of the actin cytoskeleton.  The rescue of the migration phenotype by eEF1A1 only 
could potentially be a difference in the non canonical functions of eEF1A1 and eEF1A2.  It is 
possible that eEF1A1 could directly regulate cell migration, though by which pathway remains 
to be determined by further studies.  It could be that under normal conditions, the level of 
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eEF1A is sufficient to support actin polymerisation to form the migrational structures, 
filopodia and lamellipodia, however when the protein expression level is reduced by such a 
large amount, this actin polymerisation support is removed and therefore migration speed is 
reduced.  
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6.2 Future Work 
 
Further work would aim to clarify suggestions made based on the results observed so far.  
Further characterisation of the phenotypes already established, for example analysing the 
motility defect in different ways using chemotaxis assays, and progressing to invasion assays, 
would be of great interest, as well as determining the pathways by which the regulation of 
migration by eEF1A occurs.  Analysing the rate of actin polymerisation by eEF1A in the two 
different cell lines would enable us to determine whether it is this function of eEF1A that is 
responsible for the impaired migration phenotype.   
Due to the abundance of secondary functions assigned to eEF1A, it would also be interesting 
to see if these other functions, for example apoptosis, which was appeared to be changed 
when analysing cell cycle, would be affected and which pathway is involved.   
Based on the theory of pools of eEF1A, the CHO-K1 system used would be ideal to try to 
manipulate the level of eEF1A further by using siRNA to reduce the protein expression by even 
greater amounts to see the point at which translation would be affected, as well as observing 
the effects on the other functions, but also to try to restore differing levels of eEF1A1 and 
eEF1A2 to determine at what level of expression certain functions are returned to the cells.  
What would be essential to determine to further understand the observed phenotypes is the 
other actin binding proteins that are involved in this actin stress fibre formation, and whether 
there is any direct interaction of eEF1A with the other actin binding proteins or, as suggested 
by Owen et al, 1992, whether it is simply the way in which eEF1A bundles actin that excludes 
all other actin binding proteins (Owen et al., 1992). 
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Fri Mar 11, 2011 11:21 -0000 
New DNA from 1 to 1389 
Alignment to 




Gaps( ):611  
Unattempted(.):0  
 
                                                                 *                                      *   
     1 a-----------------------t--g---gg-a---a-------------ag----g-----------------------------aaaagactcata 22     
       |                       |  |   || |   |             ||    |                             ||||||||||#|        
     1 ACMSSSRWWAGCWWRCGTTTAACTTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTCGCCACCATGGGAAARRAAAAGACTCACA 100    
    23 tcaacattgtcgtcattggacacgtagattcgggcaagtccaccactactggccatctgatctataaatgcggtggcatcgacaaaagaaccattgaaaa 122    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   101 TCAACATTGTCGTCATTGGACACGTAGATTCGGGCAAGTCCACCACTACTGGCCATCTGATCTATAAATGCGGTGGCATCGACAAAAGAACCATTGAAAA 200    
   123 atttgagaaggaggctgctgagatgggaaagggctccttcaagtatgcctgggtcttggataaactgaaagctgagcgtgaacgtggtatcaccattgat 222    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   201 ATTTGAGAAGGAGGCTGCTGAGATGGGAAAGGGCTCCTTCAAGTATGCCTGGGTCTTGGATAAACTGAAAGCTGAGCGTGAACGTGGTATCACCATTGAT 300    
   223 atctccttgtggaaatttgagaccagcaagtactatgtgactatcattgatgccccaggacacagagactttatcaaaaacatgattacagggacatctc 322    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   301 ATCTCCTTGTGGAAATTTGAGACCAGCAAGTACTATGTGACTATCATTGATGCCCCAGGACACAGAGACTTTATCAAAAACATGATTACAGGGACATCTC 400    
   323 aggctgactgtgctgtcctgattgttgctgctggtgttggtgaatttgaagctggtatctccaagaatgggcagacccgagagcatgcccttctggctta 422    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   401 AGGCTGACTGTGCTGTCCTGATTGTTGCTGCTGGTGTTGGTGAATTTGAAGCTGGTATCTCCAAGAATGGGCAGACCCGAGAGCATGCCCTTCTGGCTTA 500    
   423 cacactgggtgtgaaacaactaattgtcggtgttaacaaaatggattccactgagccaccctacagccagaagagatatgaggaaattgttaaggaagtc 522    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   501 CACACTGGGTGTGAAACAACTAATTGTCGGTGTTAACAAAATGGATTCCACTGAGCCACCCTACAGCCAGAAGAGATATGAGGAAATTGTTAAGGAAGTC 600    
   523 agcacttacattaagaaaattggctacaaccccgacacagtagcatttgtgccaatttctggttggaatggtgacaacatgctggagccaagtgctaaca 622    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   601 AGCACTTACATTAAGAAAATTGGCTACAACCCCGACACAGTAGCATTTGTGCCAATTTCTGGTTGGAATGGTGACAACATGCTGGAGCCAAGTGCTAACA 700    
   623 tgccttggttcaagggatggaaagtcacccgtaaggatggcaatgccagtggaaccacgctgcttgaggctctggactgcatcctaccaccaactcgtcc 722    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   701 TGCCTTGGTTCAAGGGATGGAAAGTCACCCGTAAGGATGGCAATGCCAGTGGAACCACGCTGCTTGAGGCTCTGGACTGCATCCTACCACCAACTCGTCC 800    
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   723 aactgacaagcccttgcgcctgcctctccaggatgtctacaaaattggtggtattggtactgttcctgttggccgagtggagactggtgttctcaaaccc 822    
       |||||||#|||||||||||||||||||#|||||||||||||||||||||||||||||||||||||||||||||||||||||#||||||||||||||||||        
   801 AACTGACMAGCCCTTGCGCCTGCCTCTYCAGGATGTCTACAAAATTGGTGGTATTGGTACTGTTCCTGTTGGCCGAGTGGARACTGGTGTTCTCAAACCC 900    
                 
   823 ggtatggtggtcacctttgctccagtcaacgttacaacggaagtaaaatctgtcgaaatgcaccatgaagctttgagtgaagctcttcctggggacaatg 922    
       ||||||||||#|##|#||||#|||||| |||                                                                             
   901 GGTATGGTGGWCMMCWTTGCYCCAGTC-ACG--------------------------------------------------------------------- 930    
   923 tgggcttcaatgtcaagaatgtgtctgtcaaggatgttcgtcgtggcaacgttgctggtgacagcaaaaatgacccaccaatggaagcagctggcttcac 1022   
                                                                                                                   
   931 ---------------------------------------------------------------------------------------------------- 931    
  1023 tgctcaggtgattatcctgaaccatccaggccaaataagcgccggctatgcccctgtattggattgccacacggctcacattgcatgcaagtttgctgag 1122   
                                                                                                                   
   931 ---------------------------------------------------------------------------------------------------- 931    
  1123 ctgaaggaaaagattgatcgccgttctggtaaaaagctggaagatggccctaaattcttgaagtctggtgatgctgccattgttgatatggttcctggca 1222   
                                                                                                                   
   931 ---------------------------------------------------------------------------------------------------- 931    
  1223 agcccatgtgtgttgagagcttctcagactatccacctttgggtcgctttgctgttcgtgatatgagacagacagttgcggtgggtgtcatcaaagcagt 1322   
                                                                                                                   
   931 ---------------------------------------------------------------------------------------------------- 931    
  1323 ggacaagaaggctgctggagctggcaaggtcaccaagtctgcccagaaagctcagaaggctaaatga 1389   
                                                                      #|#|        
   931 ---------------------------------------------------------------KTWA 934    
        
 
 
Page | 282  
 
8.2 Plasmid Map and Sequence Comparison for eEF1A2 Zeo 
 
Page | 283  
 
Fri Mar 11, 2011 11:24 -0000 
New DNA from 1 to 1392 
Alignment to 




Gaps( ):78  
Unattempted(.):444  
 
                                                                                           *         *      
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ATGGGCAAGGAGAAGACCCACATCA 25     
                                                                                  |||||||||||||||||||||||||        
     1 CMRMMCTWWGCWGCGTTTAACTTAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTCGCCACCATGGGCAAGGAGAAGACCCACATCA 100    
    26 ACATCGTGGTCATCGGCCACGTGGACTCCGGAAAGTCCACCACCACGGGCCACCTCATCTACAAATGCGGAGGTATTGACAAAAGGACCATTGAGAAGTT 125    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   101 ACATCGTGGTCATCGGCCACGTGGACTCCGGAAAGTCCACCACCACGGGCCACCTCATCTACAAATGCGGAGGTATTGACAAAAGGACCATTGAGAAGTT 200    
   126 CGAGAAGGAGGCGGCTGAGATGGGGAAGGGATCCTTCAAGTATGCCTGGGTGCTGGACAAGCTGAAGGCGGAGCGTGAGCGCGGCATCACCATCGACATC 225    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   201 CGAGAAGGAGGCGGCTGAGATGGGGAAGGGATCCTTCAAGTATGCCTGGGTGCTGGACAAGCTGAAGGCGGAGCGTGAGCGCGGCATCACCATCGACATC 300    
   226 TCCCTCTGGAAGTTCGAGACCACCAAGTACTACATCACCATCATCGATGCCCCCGGCCACCGCGACTTCATCAAGAACATGATCACGGGTACATCCCAGG 325    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   301 TCCCTCTGGAAGTTCGAGACCACCAAGTACTACATCACCATCATCGATGCCCCCGGCCACCGCGACTTCATCAAGAACATGATCACGGGTACATCCCAGG 400    
   326 CGGACTGCGCAGTGCTGATCGTGGCGGCGGGCGTGGGCGAGTTCGAGGCGGGCATCTCCAAGAATGGGCAGACGCGGGAGCATGCCCTGCTGGCCTACAC 425    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   401 CGGACTGCGCAGTGCTGATCGTGGCGGCGGGCGTGGGCGAGTTCGAGGCGGGCATCTCCAAGAATGGGCAGACGCGGGAGCATGCCCTGCTGGCCTACAC 500    
   426 GCTGGGTGTGAAGCAGCTCATCGTGGGCGTGAACAAAATGGACTCCACAGAGCCGGCCTACAGCGAGAAGCGCTACGACGAGATCGTCAAGGAAGTCAGC 525    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   501 GCTGGGTGTGAAGCAGCTCATCGTGGGCGTGAACAAAATGGACTCCACAGAGCCGGCCTACAGCGAGAAGCGCTACGACGAGATCGTCAAGGAAGTCAGC 600    
   526 GCCTACATCAAGAAGATCGGCTACAACCCGGCCACCGTGCCCTTTGTGCCCATCTCCGGCTGGCACGGTGACAACATGCTGGAGCCCTCCCCCAACATGC 625    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   601 GCCTACATCAAGAAGATCGGCTACAACCCGGCCACCGTGCCCTTTGTGCCCATCTCCGGCTGGCACGGTGACAACATGCTGGAGCCCTCCCCCAACATGC 700    
   626 CGTGGTTCAAGGGCTGGAAGGTGGAGCGTAAGGAGGGCAACGCAAGCGGCGTGTCCCTGCTGGAGGCCCTGGACACCATCCTGCCCCCCACGCGCCCCAC 725    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   701 CGTGGTTCAAGGGCTGGAAGGTGGAGCGTAAGGAGGGCAACGCAAGCGGCGTGTCCCTGCTGGAGGCCCTGGACACCATCCTGCCCCCCACGCGCCCCAC 800    
Page | 284  
 
   726 GGACAAGCCCCTGCGCCTGCCGCTGCAGGACGTGTACAAGATTGGCGGCATTGGCACGGTGCCCGTGGG-CCGGGTGGAGACCGGCATCCTGCGGCCGGG 824    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||        
   801 GGACAAGCCCCTGCGCCTGCCGCTGCAGGACGTGTACAAGATTGGCGGCATTGGCACGGTGCCCGTGGGGCCGGGTGGAGACCGGCATCCTGCGGCCGGG 900    
 
   825 CATGGTGGTGACCTTTGCGCCAGTGAACATCACCACTGAGGTGAAGTCAGTGGAGATGCACCACGAGGCTCTGAGCGAAGCTCTGCCCGGCGACAACGTC 924    
       #|||||||||||||||||#|#|||||||||||||||||||||||||||||||||#|||||||||#||||||||||||||||||||||#|||||| |||||        
   901 SATGGTGGTGACCTTTGCSCMAGTGAACATCACCACTGAGGTGAAGTCAGTGGASATGCACCACSAGGCTCTGAGCGAAGCTCTGCCSGGCGAC-ACGTC 999    
   925 GGC-TTCAATGTGAAGAACGTGTCGGTGAAGGACATCCGGCGGGGCAACGTGTGTGGGGACAGCAAGTCTGACCCGCCGCAGGAGGCTGCTCAGTTCACC 1023   
       #|| ||||||||||||||||||||............................................................................        
  1000 SGCTTTCAATGTGAAGAACGTGTC---------------------------------------------------------------------------- 1023   
  1024 TCCCAGGTCATCATCCTGAACCACCCGGGGCAGATTAGCGCCGGCTACTCCCCGGTCATCGACTGCCACACAGCCCACATCGCCTGCAAGTTTGCGGAGC 1123   
       ....................................................................................................        
  1024 ---------------------------------------------------------------------------------------------------- 1024   
  1124 TGAAGGAGAAGATTGACCGGCGCTCTGGCAAGAAGCTGGAGGACAACCCCAAGTCCCTGAAGTCTGGAGACGCGGCCATCGTGGAGATGGTGCCGGGAAA 1223   
       ....................................................................................................        
  1024 ---------------RGTGAGGACATCCGGCGGGGCAACKRGTGTGGGGAMCRSCAAGTCTGACCCGSCGCAGGAGGCWKGCTMRTTYMACCTCCCARGT 1108   
  1224 GCCCATGTGTGTGGAGAGCTTCTCCCAGTACCCGCCTCTCGGCCGCTTCGCCGTGCGCGACATGAGGCAGACGGTGGCCGTAGGCGTCATCAAGAACGTG 1323   
       ....................................................................................................        
  1109 CRWCWWCCTGAACCACCCMGGGGYMGATKATCGCCGGCTACSWCCCGGGTMMAYSAMCTGGCACACMGRCCASAWYSGYGGGCAGGTKTGCGAGASYGAA 1208   
  1324 GAGAAGAAGAGCGGCGGCGCCGGCAAGGTCACCAAGTCGGCGCAGAAGGCGCAGAAGGCGGGCAAGTGA 1392   
       ....................................................................|        
  1209 RGGAYACATTGACGGGCASTCTTGGCARAACYGRGRRGAMAACCCCYAGTTCCGTGAATTCKRKGARCA 1277   
 
 
 
 
 
 
